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Abstract
Herpes zoster (shingles) is a disease that approximately 90% of the US population
is at risk of developing. This disease causes intense pain which can affect quality of life
and has a substantial economic burden. A vaccine is available to prevent the disease,
and currently this is the best tool available for combating this disease. However,
the vaccine does not have lifelong durability, and it has less efficacy in older people.
Therefore, it is important to make good decisions on how and when to administer
this vaccine so that we maximize both its benefit and our available resources.
This dissertation uses the techniques of cost-effectiveness analysis, stochastic
dynamic optimization, and value of information analysis to focus on decision making
about how to best use the vaccine. First, cost-effectiveness was completed to show
the value at different ages of vaccination. Stochastic dynamic optimization built upon
the cost-effectiveness models to determine the optimal time to administer the vaccine.
Finally, value of information analysis examined how the optimal policy may change if
perfect information were available on some of the key uncertain parameters.
Results indicate that age 67 is the most cost-effective age to vaccinate men and
women. The optimal policy results from the stochastic dynamic program suggest it
would be best to start vaccinating men and women at age 66 and to stop at 74 (men)
or 77 (women). Results show that there is some value to determining the additional
information on key uncertain model parameters. However, the value we can gain is
unlikely to be worth the investment in the additional research that would be required.
Overall this dissertation shows that the recommended policies in the US of
vaccination at 60 and older could be sub-optimal. Given the results of the models
it may be more optimal to change the recommendation to 65 and older so that the
benefits of the vaccine are conferred at the best times.
xvii
Chapter 1
Introduction
“If you play football for a long time like I did, youre gonna
learn to deal with a lot of pain...but it is nothing like the
pain that shingles causes.”
— Terry Bradshaw, NFL Hall of Fame Quarterback [1]
Terry Bradshaw’s story is just one of many about the herpes zoster virus, commonly
known as shingles. This is a disease that nearly every person in America can develop,
and yet is not well understood by the general population [2]. It is estimated that
more than 1 million new infections occur each year in the US [3]; assigning herpes
zoster (HZ) the highest incidence rate of any neurological disease. In the US, more
will people develop HZ annually than Alzheimers, Huntingtons disease, ALS, and
brain and nervous system cancers, combined [4–7].
To develop HZ one only needs to have had the chickenpox virus or the chick-
enpox vaccine. Because nearly every child will get chickenpox or the vaccination,
approximately 95% of Americans are at risk for developing HZ [2]. To date, age is
the best known risk factor. Categorically, people over age 50 are at the highest risk
of infection; this risk continues to increase with age, as does the risk of additional
complications. For context, there are more than 90 million people older than age 50
living in the US [8]. It is estimated that one third of adults will develop HZ in their
lives and half of adults older than age 85 will experience or have already experienced
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HZ [2].
The most common symptoms of HZ are pain and a blistering rash. While a
typical disease course for HZ is about one month, the pain associated with HZ can
be debilitating, and nearly all patients will experience some pain during the course of
the infection [9]. Patients describe the impact of the pain on daily life:
“For two weeks I sat up in bed because I couldnt lay down...I didnt want
to do anything except sleep and have the pain be over [10].”
“The pain from shingles just made it impossible to even want to move [11].”
Other descriptions of pain include: “sharp,” “stabbing,” “piercing needles in the
skin,” and “burning” [12]. This pain substantially impacts daily functioning, severely
reduces quality of life, and can lead to lost productivity. Thus, despite the short
disease course [13], HZ carries high health burden.
The main complication associated with HZ is postherpetic neuralgia (PHN) which
can present incapacitating pain that can be intense than the pain experienced during
the HZ infection. The pain caused by PHN continues after the HZ rash disappears,
often lasting several months, or years in rarer cases [12]. The risk of PHN increases
with age, a sharp increase occurs after age 60. The pain intensity and duration due
to PHN place an additional and severe burden on patients who experience it. Disease
incidence, pain intensity, and pain duration allow PHN to have a substantial impact
on patients quality of life; making PHN particularly import when discussing HZ, and
its treatment and prevention.
While pain presents a major personal burden to patients, the economic burden
of this disease is also substantial. The majority of people who develop HZ will seek
medical attention and require prescription drugs for the pain and the rash. Including
costs for hospital admissions, outpatient visits, emergency department visits, and
prescription drugs, the average HZ infection costs about $1000 [14]. The average
cost of PHN is estimated at $5000 over a 12 month period [14]. With more than
1 million estimated new HZ infections annually, this equates to well over $1 billion
spent on direct medical costs for HZ and PHN alone. Accounting for costs of other
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complications such as neurological palsies and skin infections, and lost productivity
increase the estimate of the total cost burden. The cost burden is currently unknown.
HZ cannot be cured, and medications have only allowed people to endure the
disease. However, a vaccine was approved for use in 2006 by the US Food and Drug
Administration (FDA) that can be used to prevent the disease and its complications
[15,16] making it an extremely important tool for public health practice, and the best
option to date for reducing the burden of disease. The vaccine is approved for any
person over age 50, and is currently recommended for any person over age 60 [17].
The HZ vaccine has been shown effective at reducing the burden of disease by lowering
the risk of HZ, and perhaps most importantly, “works even better at preventing
the really severe cases likeliest to lead to postherpetic neuralgia” [18]. However, the
initial efficacy and longevity of the vaccine are both age-dependent [15, 16, 19–22].
Therefore, because people are more at risk of infection and disease complications as
they age, and because the vaccine provides different levels of protection based on
when it is administered, understanding how the administration of the vaccine affects
health outcomes and costs and then making good decisions about when to vaccinate
is vital in the attempt to provide the maximum benefit to society by minimizing the
burden of HZ and PHN.
Disease prevention is a core tenet of public health [23–26]. However, no disease can
be prevented effectively without deciding on a strategy, which requires synthesizing
information on the disease, the intervention, and its risks, benefits and costs. Making
good decisions on prevention strategies can save resources, which can be used elsewhere
and allows us to maximize the resources we have. Given the population at risk, the
high cumulative incidence, the impact on quality of life, and the cost, it is evident
that HZ is an important disease to both understand and prevent. However, we
must also decide how to effectively prevent and reduce the burden of this disease to
maximize the use of our resources; this is equally important from the public health
perspective [26]. In this dissertation, I will use the decision analytic techniques of
cost-effectiveness analysis, stochastic dynamic programming and value of information
analysis to provide more understanding of this disease and evaluate strategies for
vaccination which can be utilized to make good decisions on how to minimize the
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burden of HZ and maximize our resources.
1.1 Disease Etiology and Progression
This section provides a brief overview of the key features of the HZ virus and the
disease progression.
Varicella Zoster Virus
Chickenpox is a very common childhood disease [27] caused by the varicella zoster
virus (VZV). The disease is transmitted by direct contact or by air through breathing
or sneezing [28]. VZV is extremely contagious with between 60 – 100% of exposures
leading to infection [28]. Common symptoms of a VZV infection are a pruritic (itchy)
vesicular rash, swelling of the cervical lymph nodes, and fever [29]. The rash typically
forms on the face, trunk, and scalp; a healthy child can expect to experience between
100 – 300 rash lesions during the infection [30]. Fortunately, most VZV infections
will resolve without severe complications.
Figure 1.1: Spinal Nerves [31]
A vaccine was licensed for use in 1995
and since then the incidence of chicken-
pox in the US has reduced by as much
as 90% [28]. Given the high chance of
infection before the vaccine was intro-
duced and the near universal coverage of
the vaccine since 1995, 90-95% of adults
in the US still test positive for serologic
evidence of the virus [28, 32]; this is due
to virus’ behavior. Once introduced into
the body, VZV virus seeks out and ac-
cesses nerve clusters called ganglia. Dur-
ing an infection, the virus can access any
ganglion attached to an afferent neuron (a neuron that sends a signal toward the
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central nervous system) that is also attached to a VZV rash vesicle on the skin surface.
Because the chickenpox rash can develop almost anywhere on the body, the virus
theoretically has access to every ganglion on along the neuraxis (brain and spinal
cord) [29, 33]. However, the dorsal root ganglion in the spinal cord, shown in Figure
1.1, is the most commonly accessed site by VZV. Once inside a ganglion, the virus
enters a latent state. This ability of the virus to establish a latent infection in the
host is a defining feature of the herpes virus (Herpesviridae) family, and a necessary
condition for the herpes zoster virus [27].
Herpes Zoster Activation
Herpes zoster is initiated by the reactivation of the latent VZV inside a single
ganglion [3]. Reactivation of the virus occurs in approximately 25% of all people
who carry the latent VZV [34]. It is the seroprevalence of VZV in adults and high
chance of re-activation that lead to the high annual incidence of HZ in the US and
throughout the world. Unlike other viruses in the Herpesviridae family, the exact
triggering mechanism for VZV reactivation is unknown. The predominating theory
suggests that, due to age, cell-mediated immunity declines below a level sufficient to
keep the virus in its latent state. When this happens the VZV begins to replicate
and spread [32,34,35]. This helps explain why age is the best known risk factor for
an HZ infection.
Herpes Zoster Disease Progression
Once the virus begins to spread, there are three main periods for the HZ infection: 1)
Prodromal (pre-rash); 2) Rash; 3) Post-rash. In the prodromal phase, the virus travels
from the ganglion back toward the skin surface along the sensory nerves causing
necrosis along the way. This is commonly associated with abnormal sensations in the
skin such as tickling, tingling, numbness, itchiness, or burning [12,36]. The prodromal
period usually lasts between 48-72 hours in the area where the sensory nerves are
infected with the virus. This phase terminates when the virus reaches the skin and
the rash phase begins [32, 34].
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Rash Phase
The start of the rash phase is signaled by the formation of a vesicular rash. The most
common places for a rash to form are anywhere between T1 and L2 vertebrae [32] and
near the V1 branch of the trigeminal nerve, shown in Figure 1.2. These dermatomes
(areas of skin supplied by a single spinal or cranial nerve) typically contain the highest
concentration of lesions during a chickenpox infection and are thus the most likely
to be affected during an HZ infection. During the rash phase, the initial vesicular
lesions will develop into pustules, and then crust over. The HZ rash will resolve and
skin will begin to health within two to four weeks after onset. A rash will typically
be contained to a single dermatome, unlike the chicken pox rash which affects many
dermatomes at once.
Figure 1.2: Trigeminal Nerve [31]
Aside from the rash, the main symp-
tom during this phase is pain, and nearly
all patients will experience some pain
during the course of the infection [9].
The pain experienced by patients in the
rash phase has been described as “sharp,”
“stabbing,” and “burning” [12]. This pain
substantially impact daily functioning,
severely reduce quality of life, and can
lead to lost-productivity during the du-
ration of the HZ infection. Thus, de-
spite the short disease course and the
minimal chances for mortality and com-
plications [13], HZ carries high health
burden.
Post-Rash Phase and PHN
Pain that persists after a certain duration of time in the post-rash phase will often be
diagnosed as PHN. Unfortunately, there is no formal medical definition for the length
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of time pain must be present to be considered PHN [37] thus consistent diagnosis
can be challenging due to ambiguity. The two most commonly used definitions for
PHN in the literature are: 1) pain that persists for more than 90 days after the
initial infection (PHN3); 2) pain that persists for more than 30 days after the initial
infection (PHN1) [38].
Regardless of the definition used, PHN is the most common complication of HZ
and is estimated to occur after approximately 10 – 30% of all HZ infections [39,40].
Similar to HZ, the risk of PHN increases with age; with risk increasing sharply
after age 60. There are five distinct types of pain commonly associated with PHN:
1) throbbing pain; 2) stable burning pain; 3) sporadic sharp or shooting pain; 4)
allodynia (burning or shooting pain that is caused by simulating the dermatome in a
way that normally would not cause pain); 5) hyper-pathia (strong pain reaction by
stimulating the dermatome, usually repetitively) [41]. The pain produced by PHN
can be more intense than pain experienced during the HZ infection and can last
several months, or years in rare cases [42]. Disease incidence, pain intensity, and pain
duration allow PHN to have a substantial impact on patients quality of life; making
PHN important to consider when deciding on possible HZ prevention strategies.
1.2 Decision Making
Making good decisions is difficult. This is especially true in health care, as it requires
balancing and integrating risks, benefits, costs, preferences and other evidence to arrive
at a conclusion likely to produce the best outcome [43]. And, unlike many decisions,
making poor decisions in health care can result in serious or fatal consequences. A
principal challenge to making good decisions is that most decisions are made under
conditions of uncertainty [44]. That is, while we know the outcomes of the decision, we
have limited information on the chance of achieving that outcome. Decision analytic
techniques are available that allow for the aggregation of the available information,
the accounting of uncertainty, and the testing of different assumptions. It is these
techniques that help provide clarity and additional information to people or agencies
that make health care decisions or recommendations [43].
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In the US, the Advisory Committee on Immunization Practices (ACIP) is a
group of public health experts supporting the Centers for Disease Control and
Prevention (CDC) that decide on how to recommend the use of vaccines to prevent
and control disease [45]. During the decision process, the ACIP considers the
following aspects in its recommendations: disease epidemiology, disease burden,
vaccine safety, vaccine efficacy, vaccine effectiveness, vaccine implementation, and
economic evaluation [45]. Current recommendations on HZ vaccination from the ACIP
have focused on results from decision analysis and economic evaluation technique of
cost-effectiveness analysis [17].
1.3 Economic Evaluation
Resources are scarce in health care, therefore decisions on what resources (e.g.,
treatment, procedures, medications) to provide can and must be made [46–50].
Economic evaluation is a method that examines the costs and consequences of a
decision or set of decisions to provide information on the allocation of these resources.
This type of evaluation is often best used when questions of efficacy, effectiveness,
and availability have been adequately addressed [47]. In the case of HZ vaccination,
the questions of efficacy and effectiveness (i.e., can it work?; does it work?) were
addressed by the clinical trials for the vaccine [16, 20, 21, 51]. The vaccine is also
readily available to the population. Therefore, the economic evaluation conducted by
the ACIP for the HZ vaccine examines the costs and consequences of two alternatives
(vaccination and no vaccination) to provide information for the recommendations on
how the vaccine should be best allocated.
Cost-benefit Analysis
There are two common methods for health economic evaluation, cost-benefit analysis
(CBA) and cost-effectiveness analysis (CEA) [52–54]. CBA is the most common form
of economic evaluation used outside of the health care sector. Money is one of the
broadest value measures and CBA monetizes both costs and outcomes to determine if
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benefits outweigh costs [55]. That is, CBA values resources used compared to resources
gained or to be gained; if more value is created than lost the treatment or intervention
is considered cost-beneficial. The main advantage to CBA is its cross-compatibility
with other sectors given the common units of measurement. Because more sectors
use CBA than CEA, results from CBAs can be compared together to decide which
interventions or projects create the most value and should be prioritized [46,47].
Cost-effectiveness Analysis
However, monetizing health outcomes is both difficult and controversial. This is a
primary reason why CEA is preferred in health care [48,49,52]. The goal of CEA is
similar nevertheless; costs and outcomes data are aggregated to determine how much
money needs to be spent to achieve the desired level of benefit. However, while costs
are still measured in monetary units, outcomes are measured in quality adjusted life
years (QALYs), which is a metric that accounts for time spent in a certain state of
health and the utility of that health state. A QALY will value each health outcome on
the same scale [56]. The utility scale used for health states is typically bound between
1 and 0, where 1 is assumed to be equal to perfect health and 0 is assumed to be
equal to being dead [46,47]. These costs and outcomes are combined and compared
to a pre-defined threshold of cost-effectiveness. If the result of the CEA produces a
value below this threshold, the intervention is considered cost-effective. If the result
is over this threshold the intervention is considered not cost-effective.
CEA provides the ability for comparison within the health care sector as the use
of the QALY provides a generic outcome measure for health economic evaluation.
Thus studies that use CEA can be compared against one another to determine how
much benefit can be gained given a certain budget. The ACIP used CEA in the
formulation of their most recent recommendation [17]. The knowledge that a vaccine
or treatment is cost-effective provides additional information in a decision making
process and can help set recommendations for its use.
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Limitations of Economic Evaluation
While cost-effectiveness and other forms of economic evaluation are very useful and
can provide insights into decision problems, they do have some limitations. Any
model is only as good as its inputs and assumptions. If poor quality data is used for
the model, or if poor assumptions are made then the outcomes of the model will not
likely be informative or worse, misleading [57]. Therefore, in any model, the structure,
assumptions, and data must be explicitly presented so that the model can be properly
assessed [58]. Additionally, economic evaluation should be seen and used as a tool
to inform decision making. However, the results of the model should not be applied
mechanically without consideration for other important variables (e.g., epidemiology,
equity, safety of the treatment, disease burden, policy implementation, etc.) [48].
That is, while these techniques serve as tools to help influence decision making they
are not incontrovertible. The risk with the direct application of conclusions from
economic evaluations without considerations of other important factors would likely
lead to decisions that would be difficult to alter [48]. Therefore, great care must be
taken with the application of the information. Further, results should be updated as
new information or data becomes available and decision makers must be flexible in
their inclusion of that or any new information into their decision [48].
1.4 Herpes Zoster Cost-effectiveness Literature
To date, there have been 16 CEAs for HZ vaccination; four have been published from
the US perspective [59–62], the remaining 12 are from Canada or Europe [63–74].
The US CEAs present conflicting results; brief overviews are presented in Table 1.1.
Three of the four studies examined vaccination of people greater than age 60, the
other for people between 50 – 59. Three US studies use a $50,000 per QALY threshold
to define if the vaccine is considered cost effective [59–61]. In three US CEAs, the
incremental cost-effectiveness ratio (ICER) exceeded the cost-effectiveness threshold,
thus the vaccine was considered not cost-effective. However, it is important to note
that there is no commonly agreed upon cost-effectiveness threshold in the US. Further,
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recent studies have shown that a threshold of $50,000 would be too low in the US;
research suggests that a US would be between $100,000 and $250,000 [75]. However,
results are stark when comparing US CEAs to more non-US CEAs; 11 of the 12
international studies produced an ICER less than $50,000 per QALY [63,65–74], with
4 producing ICERs less than $30,000 per QALY. Most international studies are newer,
and majority used newer data and more advanced models.
The results of any cost-effectiveness study are dependent on available data and the
assumptions made. A recent systematic review of HZ vaccination CEAs found that, in
a majority of studies, duration of vaccine efficacy and vaccination age had the highest
impact on vaccine cost-effectiveness [76]. Other categories that received a mark of
highest or high impact on the cost-effectiveness results included: PHN costs, PHN
length, vaccine costs, discount rates, pain state split (e.g., mild, moderate, severe),
HZ incidence, and HZ duration [76]. It is important to understand the assumptions
and inputs in any cost-effectiveness study to determine how the final results may be
impacted.
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Study Ages Perspective
Mean
ICER
Results Most Sensitive To
Vaccine
Duration
Limitations
Hornberger
[59]
≥ 60 Societal 118,764
Most cost-
effective for
ages 60 – 64
Age, QALY adjustments (HZ,
PHN), Vaccine (cost, dura-
tion), Time horizon, PHN
(duration), Discount rate
30 years
Data on vaccine
efficacy beyond
three years is
lacking
Pellissier
[60]
≥ 60 Societal 27,325
Cost-
effective for
ages 60 –
64, 65 – 69,
and 70 – 74
PHN (costs), Complications
(costs), Vaccine (duration, ef-
ficacy, PHN efficacy, HZ effi-
cacy), QALY adjustments
Life-long
No vaccine waning.
No description of
time in each state.
Rothberg
[61]
≥ 60 Societal 155,361
Most cost-
effective for
ages 70 – 79
Vaccine (duration, cost, effi-
cacy), PHN (incidence, dura-
tion, utility), HZ (incidence,
severity), Discount rate
10 years
Assumes no reduc-
tion in PHN due to
vaccination beyond
prevention of HZ
Le [62]
50–
59
Societal 351,517
Most cost-
effective for
age 59
Vaccine (cost, efficacy), PHN
(duration)
≈ 10 years
Assumes linear
decline in vaccine.
Uses costs from
previous paper
which are from UK
study in 1990s
Table 1.1: US CEA studies. ICERs reported in 2015 US Dollars ($).
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Assessment of US Cost-effectiveness Analyses
There are notable differences between the US CEAs. Overall, the model constructed
by Rothberg et al [61] was sensitive to characteristics of the vaccine, PHN, and
HZ. Unfortunately there was limited methodology for how the vaccines efficacy and
waning was calculated, and limited information on the time spent in a PHN health
state. The authors assume there is no decrease in PHN incidence beyond the decrease
attributed to reducing HZ incidence with vaccination. That is, they assume that the
vaccine does not impact the severity of the disease for those who still become infected.
Brisson et al [77] suggest that just accounting for the additional reduction of PHN
can reduce the cost per QALY by as much as 40%. Rothberg et al also assume that
an individual either spends less than 12 months with PHN, or several years with
PHN. And, there is no account for PHN severity as only one PHN utility score is
given. This CEA helps to illustrate the potential importance of PHN and the impact
that assumptions about this condition could have on results of the CEA.
Le and Rothberg [62] provide the newest estimate for the cost-effectiveness in the
US. They do make use of the new vaccine waning data as well. However, there are
some complications with their paper. First, they assume the vaccine wanes using a
strictly linear rate. While this assumption may have been more plausible for older
studies, current data suggests that the vaccine has a step decline in the efficacy during
the first year which would not be captured in the linear model [20, 78]. Second, PHN
cost data is from a 1994 study from the UK, which was also used in their previous
CEA [61]. The cost of one of the most important parameters (PHN) in many HZ
CEA models, in this paper, is 20 years old and from a country where the health care
financing structure is very different than in the US. Finally, some epidemiological
model inputs (e.g., probability of PHN) are defined by age groups. It was unclear if
the authors implemented these probabilities directly into the model as a discontinuity,
or they attempted to do some types of fitting for the data. This CEA is the first
in the US to examine the impact of the vaccine for people ages 50 – 59. It is an
important paper for this reason, but leaves room for improvement on determining
the value of vaccination for this group.
13
Hornberger and Robertus [59] make assumptions about PHN, and vaccine efficacy
that may impact the CEA results. First, the authors assume that PHN does not
result unless pain has been persistent for 182 days from the start of the rash phase.
This definition of PHN may underestimate the proportion of people who actually
experience PHN. Prior to developing PHN, people in persistent pain for 6 months are
assumed to have the utility value of HZ, which was much higher than PHN. If people
develop PHN, there is no severity distinction as there is only one PHN utility value
given. Therefore, by using a definition that may underrepresent the incidence of PHN
and giving people more utility for longer, this paper may underestimate the QALYs
gained by vaccination which can impact the cost-effectiveness results. The authors
also admit to having limited data on vaccine efficacy beyond the initial 2005 clinical
trial results [59]. The assume an upper limit of 30 years vaccine efficacy based on
unreferenced VZV vaccine waning models. This assumption could be problematic as
VZV vaccination is a) a different vaccine and b) is typically given during childhood
when there is less risk of immunity loss thus longer vaccine duration may be more
reasonable. These assumptions are extremely important to this paper as the vaccine
was only considered cost-effective if it was assumed to last for the upper limit of 30
years and given to people 70 years old or younger.
Pellissier et al present the best methods of any US CEA for describing how the
vaccine efficacy and waning was calculated, however, they do not assume any vaccine
waning in the base case analysis [60]. However, the authors only had limited data on
the vaccines waning and efficacy at the time of publication. Their model also does
not examine the length of time spent with HZ, PHN, or other complications within
the model itself. All costs and QALYs in the model were pre-determined and entered
into a model where every state is assumed transient. The authors do distinguish
between the severity of HZ infections, but not the severity of PHN cases. PHN costs
had the highest impact on the results in the probabilistic sensitivity analysis and
the second highest impact on results in the one-way sensitivity analysis (vaccine cost
was highest). Vaccine efficacy against PHN also had an important impact on the
sensitivity analysis. Cost of PHN is likely to vary both by severity [79] and time
spent with PHN. Vaccine efficacy will have an important impact on control the costs
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of PHN. This paper again shows the ability of vaccine efficacy and PHN to affect the
results of the CEA.
1.5 Research Gaps and Opportunities
Based on the assessment of the US CEAs and economic evaluations, it is evident
that all make assumptions that impact the results; with efficacy and waning effect of
the vaccine, and the characteristics (time, cost, severity) of PHN being two potential
crucial drivers of results. With regard to assumptions made about the vaccines effect
on HZ and PHN, it is important to note that three of US studies are among the
oldest CEAs available [59–61]. The most recent of these three being published by
Pellissier et al [60] approximately 18 months after approval of the vaccine by the
FDA. Since then, new data on short-term and long-term vaccine efficacy [20,21,78]
has been published. This data is vital to better establishing both the age-specific
initial vaccine efficacy, and also how the vaccine wanes over time. Further, work done
by Bilcke et al [19] and van Hoek et al [72] provide methods for using published data
to create efficacy and waning estimates for the vaccines protection against HZ and
PHN. Incorporating these data and methods into current health economic models
will allow for a more accurate prediction of the value of the vaccine and can aid with
future recommendations.
In addition to new data on short-term and long-term vaccine efficacy, research has
also been published on vaccine efficacy for people ages 50-59 [51]. Currently, there
are three non-US CEAs [68,71,74] that have included a 50-59 age group. Vaccination
of this group was considered cost-effective. While this group was included in the most
recent US CEA, the vaccine was not found to be cost-effective for this age group [62].
There have been new publications on the costs and decrements in quality of life from
HZ and PHN [14,80–87]. Further, HZ is unique among vaccine preventable diseases
in that much of its total burden is in the form of intangible costs (i.e., pain and
suffering) that is borne exclusively by individuals. There is now data available that
helps to characterize these intangible costs [88, 89] associated with HZ and PHN.
Recent CEAs from Europe [65,68,76] have modeled HZ and PHN in ways that better
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capture the severity of the condition and can be adapted to account for the impact
of time with PHN. Including these additional costs and quality of life data as well
adapting the model structure to better account for the impact of HZ and PHN will
allow for the creation of a more comprehensive estimate of the cost-effectiveness and
the burden of disease. Further, this will be the first US specific evaluation of the HZ
vaccine to include both broad age groups (i.e., ACIP recommendations (60 and older)
and FDA approval (50 and older)) in the same analysis.
The question of an optimal age for HZ vaccination remains largely unanswered.
One CEA study from Belgium explored impact of vaccination at single ages from
60-85; vaccination at age 60 was the most cost-effective [64]. No other study to date
has examined the impact of vaccinating at individual years. Further, one complication
with some decision models is the ability to only compare one decision at a time (e.g.,
vaccinate or not at some age). These types of evaluations typically do not account
for the decision to defer vaccination or the prior risk of disease. Accounting for these
things can help to determine the optimal policy of deciding when people should
get vaccinated rather than determining if the vaccine is cost-effective at some age.
Finally, no study to date has examined the value of information on model parameters
for HZ or the vaccine. Based on the literature, it is evident that certain sets of
parameters greatly affect the outcomes of the models. Minimizing the uncertainty of
these parameters could help improve recommendations, or help prioritize research
about the vaccine.
1.6 Contribution to Literature
This dissertation will add to the existing literature in three ways. First, I will provide
a new estimate of the cost-effectiveness for the HZ vaccine from the US perspective.
This estimate will incorporate new information on the vaccines waning and efficacy
over time. It will also utilize new data on disease costs, and utility lost to better
account for the total burden of disease. Finally, it will be the first US study to include
a 50-59 age group alongside the 60 and older group. As a result, this research should
provide the best estimate of the cost-effectiveness to date. Second, I will examine the
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question for the optimal timing of vaccination against HZ. Providing a prediction
of the optimal age for the vaccine will be useful in setting policy recommendations
and be important to minimizing the burden of disease. I will also investigate the
importance of the booster vaccine in making this decision about the optimal age to
vaccinate, as having the option for a booster vaccine may change recommendations
and further help reduce the burden. Finally, I will provide an estimate of the value of
additional information and research for parameters that affect the results and impact
possibly policy recommendations. Understanding the value of added research will be
important for future research prioritization.
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Overview of Chapters
Chapter 2
Cost-effectiveness Analysis of Herpes Zoster Vaccination
The objective of this chapter is to determine the cost-effectiveness of the HZ vaccine
at every age between 50 and 100. This chapter will use a cohort state-transition
model to estimate the cost-effectiveness.
Chapter 3
Optimal Timing of HZ Vaccination: One vs Two Dose Administration
The objective of this chapter is to determine the optimal age for administering the
HZ vaccine to people between ages 50 and 100. This chapter will use a discrete
time Markov decision process to determine if people should get vaccinated or defer
vaccination at every starting at 50 years old.
Chapter 4
Value of Information Analysis
The objective of this chapter is to determine the value or perfect information on two
key vaccine parameters. This chapter uses three different modeling techniques to
estimate the value of this information. A comparison of method efficiency is also
provided.
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Chapter 2
Cost-Effectiveness of Herpes
Zoster Vaccination
2.1 Introduction
The objective of this chapter is to determine the cost-effectiveness of the HZ vaccine
using a decision analytic model. Only one US CEA has used the most current
estimates for vaccine efficacy and waning [62]. In general, studies from the US have
also made simplifying assumptions about the impact of PHN which may influence the
cost-effectiveness of the vaccine given the ability of PHN to have a severe influence on
quality of life. Providing a new estimate of the cost-effectiveness of the HZ vaccine by
accounting for the waning and efficacy of the vaccine as well as the impact of PHN
will be important for setting future recommendations on vaccination.
The Utility of Simulation Models
Simulation models provide a useful platform to better predict outcomes and costs,
and to explore multiple long-term pathways of illness for conditions with uncertain
prognoses. To construct a decision analytic model, the best available evidence must
be aggregated and synthesized from all available sources (e.g., clinical trials, meta-
analyses, cohort studies, etc.) [43]. This chapter will utilize a specific subclass of a
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decision analytic simulation called a Markov-like state-transition model to estimate
the cost-effectiveness of the HZ vaccine.
State-transition models are commonly used for clinical decision making and
decision analytic research when a clinical situation of interest can be deconstructed into
conditions or states that describe the health of a patient (e.g., disease free, sick, etc.)
and the movement between those different states can be properly characterized. These
movements, or transitions (e.g., disease free to sick) are governed by probabilities that
occur over explicitly defined time cycles (e.g., the one year probability of transitioning
from disease free to sick) [90]. Compared to decision tree models, state-transition
models are useful when the timing of an event may change (e.g., incidence increases
with age), or if an event may be recurrent [43].
Each state-transition model is constructed by including a set of mutually exclusive
and collectively exhaustive health states that define the disease course, and a set of
transition probabilities that define movement between states. State-transition models
are composed of two or more component models: the natural history model and
the intervention model(s). The natural history model simulates the course of the
disease assuming no intervention. The intervention model(s) will follow the same
disease progression, but the transition probabilities between states will change to
reflect the effects of the intervention(s) under consideration [91]. A cohort model
was used for this chapter. Cohort models simulate the progression of a medical
condition or intervention for a group of people. Because the group is examined as
a whole, the model reports the mean effect of the condition or intervention for the
specific group or population being studied (e.g., 50 year women who receive a vaccine).
Examining the mean effect is a benefit of the cohort model and makes these models
easier to interpret, build, and modify. The disadvantage of the cohort model is that
the model must abide by the “memoryless” Markovian assumption. This means that
the history of previous health states is not accounted for; rather the only health state
that affects the transition is the health state the cohort was last in. As a result of
this assumption, clinical history (such as time spent in a health state) can be difficult
to add to cohort models without including many more model states to account for
the variety of different clinical scenarios.
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2.2 Methods
Model Structure
To determine the cost-effectiveness of the HZ vaccine a cohort model was constructed
to calculate costs and QALYs to formulate incremental cost-effectiveness ratios
(ICERs). Model construction and simulation was completed using TreeAge Pro 2016,
R1.0. TreeAge is a decision modeling software that provides a graphical user interface
for creating basic decision trees, cohort state-transition models, and other types of
decision models. To construct the model, established modeling guidelines for general
simulation setup, comparison of alternative system configurations, incorporated
complexity, and model transparency were followed [58,90,92–94].
The model calculated the cost-effectiveness of current zoster vaccine for ages 50 –
100. Figure 2.1 provides an overview of the model. Model health states are defined by
ovals and transitions are defined by arcs or lines between health states. Transitions
between disease free to HZ, and HZ to PHN are regulated by the vaccine; these
transitions are indicated in the Figure 2.1 by yellow circles. The cohort starts in
either the natural history model or the intervention model in the disease free health
state. The time period between transitions (cycle time) for this model was set to 1
month (30 days). From the initial disease free health state, after each cycle there
is a chance of staying disease free or developing HZ. The probability of developing
HZ was dependent on age of the cohort and, if vaccinated, the initial efficacy and
waning rate of the vaccine; vaccine characteristics are further discussed in Vaccine
Parametrization and Appendix A.4 on page 185. Once HZ occurs, it was initially
characterized as no pain, mild pain, moderate pain, or severe pain. This classification
is defined by the Zoster Brief Pain Inventory (ZBPI). The ZBPI is an adapted 11-point
Likert scale (0–10) used to quantify four types of pain (worst, least, average, now) [95].
The cut points in the ZBPI scale that characterize these four HZ pain states (no,
mild, moderate, severe) are presented in Table 2.1. Further complications can arise
due to HZ, however, only those who experience some HZ pain have the chance to
experience further complications.
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HZ – No Pain
Other 
Complications
PHN Severe
PHN Mild
PHN Moderate
Disease Free Disease Free with HZ History
Death
HZ – Mild Pain
HZ – Severe 
Pain
HZ – Moderate 
Pain
Figure 2.1: State transition model. Yellow circles indicate where the vaccine can have an
effect.
The main complication of HZ is PHN. For this model, PHN is defined as any
pain persisting for more than 90 days after the initial infection (PHN3). This is
one of the two most commonly used definitions of PHN [37]. One benefit of this
model structure is the ability to test changes in PHN status over time conditional
upon the initial characterization of PHN. Characterization of PHN states is a feature
included in recent cost-effectiveness models from Europe [63,65,68,70], but has not
been examined in US models. This structure is shown on the right portion of Figure
2.1. If PHN develops, it is initially characterized as mild, moderate, or severe. This
characterization is also defined by the ZBPI; scales are presented in Table 2.1. Current
literature suggests that the older an individual is, the more likely he/she will develop
PHN and the more severe the episode will be [70]. Once in a PHN health state
transitions can occur to move to the next best PHN state at the end of each cycle.
The length of time spent in PHN was based on data from the average length of time
spent in different PHN states [79]. The assumption for this model is that all people
must transition through all better states of PHN before reaching the disease free with
HZ history state. Utilizing this ladder-like progression allows for better estimates of
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Health States Description
Disease Free People start model here, “No HZ”
HZ – No pain HZ with ZBPI score = 0
HZ – Mild Pain HZ with ZBPI score = 1 – 3
HZ – Moderate Pain HZ with ZBPI score = 4 – 6
HZ – Severe Pain HZ with ZBPI score = 7 – 10
PHN – Mild Pain PHN with ZBPI score = 1 – 3
PHN – Moderate Pain PHN with ZBPI score = 4 – 6
PHN – Severe Pain PHN with ZBPI score = 7 – 10
Ocular Complications
Any complication involving the eye that due to an
HZ infection
Neurological Complications
Any complication involving the nervous system
due to an HZ infection
Cosmetic Complications
Any outward or visible damage caused by HZ after
the rash has disappeared
Disease Free with HZ History
Health state for when people have gone through
the course of their infection
Table 2.1: Model states
disutility associated with PHN.
People can also develop non-pain complications. Ocular complications are the
most common of the non-pain complications. These complications arise when a case
of HZ directly affects the eye. In the majority of cases, symptoms resolve quickly and
leave no long-standing issues. In this model we assume that all ocular complications
resolve within an average time of 3 months [14] and that no long-standing issues occur.
This assumption was made because there were minimal data on the epidemiology
(incidence and duration) and disutilities associated with long-standing issues due to
zoster-related ocular complications. Other non-pain complications can also occur.
These other non-pain complications include: neurologic complications – symptoms
include Ramsay Hunt Syndrome (facial paralysis and hearing loss) – and cosmetic
complications – symptoms include conditions like scarring, or bacterial superinfection
of rash lesions [35,96]
The probability of developing these other non-pain complications (neurologic and
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cosmetic) in the base case analysis was set to 0. This assumption was made because
the probability of developing these conditions is low, and there were limited data
available on the duration and disutility associated with these health states. Therefore,
it was predicted that due to the low probability of occurrence, these states would have
a minimal impact on the cost-effectiveness. This assumption tested by including these
complications in scenario analysis. From the non-pain complications or the PHN
health state, the patient will then transfer to the disease free health state. This model
allowed for disease recurrence. No recurrence of PHN or non-pain complications was
allowed. The death state could be reached from any health state in the model at any
cycle.
Model Inputs & Data
Evidence-based estimates for the parameter inputs were required for the model.
Parameters were defined using best available data, and evidence synthesis techniques
were used to combine data from published studies. The model required three general
categories of specific parameters: transition probabilities, costs, and health outcome
values.
• Transition probabilities represent the chance of movement between model states.
If data were available, parameters were adjusted for age and gender.
• Costs included direct medical costs, and lost productivity costs. All direct
medical costs were adjusted to 2015 dollars using medical care component of
the Consumer Price Index (CPI). Lost productivity was applied to all people
regardless of employment status.
• Health outcome values reflect the health-related quality of life associated with
the included short-term and long-term health states. The inclusion of quality
adjustment values for each state of health in the simulation model allowed for
the calculation of quality-adjusted life years.
Data were collected from the societal perspective, the most common for decision
analysis and recommended by the US Panel on Cost-effectiveness [46]. The societal
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perspective accounts for costs and outcomes beyond the health system; this perspective
is more inclusive and allows the vaccine to be evaluated on a more comprehensive
level. A scenario analysis was included that examines the analysis from the health
care perspective.
To collect data, a systematic literature review was conducted for each category
of model input required. These reviews assessed the published data relating to
the vaccine efficacy, epidemiology, costs, and QALYs associated with HZ and its
complications. Search terms for each review were selected based on their use in
similar systematic reviews. More information on the systematic literature review is
available in Appendix A.6 on page 205. All literature reviews focused on peer-reviewed
published literature relating to HZ in the US. Peer-reviewed articles relating to HZ
outside the US was considered for disease epidemiology and quality of life (depending
on data quality and transferability). All cost data were limited to studies within the
US due to transferability issues and differences in health care systems [97]. Data
collected from the literature reviews were used to generate transition probabilities,
costs, and health outcomes for the model. Inputs were adjusted accordingly to account
for demographic factors, including age and gender. Model inputs generated from
the systematic reviews are presented in Tables 2.2 – 2.4. Model inputs were also
converted from discrete values to distributions to allow for probabilistic sensitivity
analyses (PSA) to be conducted; Table 2.5 provides the distributions of the PSA –
further discussed in Sensitivity Analysis.
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Variable Base Value Lower Value Upper Value Reference
All-cause mortality Age Dependent [98]
HZ mortality 5.10e-7 4.30e-7 5.60e-7 [99]
HZ recurrence
Ages 50 – 69 0.0010 0 0.0020 [100]
Ages 70+ 0.0027 0 0.0054 [100]
HZ incidence*
Male – (asymp, xmid, scale)
(13.935,
773.204,
184.470)
(11.148,
773.204,
184.470)
(17.418,
773.204,
184.470)
[101–103]
Female – (asymp, xmid, scale)
(19.227,
824.028,
199.408)
(15.382,
824.028,
199.408)
(24.033,
824.028,
199.408)
[101–103]
Probability of Any Pain | HZ 0.95 0.73 1.00 [15,84]
Probability of Mild Pain | Any Pain HZ 0.12 0.06 0.43 [15,84]
Probability of Moderate Pain | Moderate
or Severe Pain HZ
0.44 0.20 0.56 [15,84]
Risk of PHN** – (b1, b2)
(1.772e-07,
2.013)
(8.86e-08,
2.013)
(3.544e-07,
2.013)
[42,79,104–108]
Probability of Moderate or Severe PHN
Ages 50 – 59 0.46 0.36 0.56 [79], Assumption
Ages 60 – 69 0.56 0.46 0.66 [79], Assumption
Ages 70 – 79 0.61 0.51 0.71 [79], Assumption
Ages 80 – 85 0.65 0.55 0.75 [79], Assumption
Ages 85+ 0.68 0.58 0.78 [79], Assumption
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Variable Base Value Lower Value Upper Value Reference
Probability of Moderate PHN | Moderate
or Severe PHN
0.50 0.30 0.80 Assumption
Duration of Mild PHN 6.7 6.1 7.4 [79]
Duration of Moderate PHN 10.0 9.4 10.7 [79]
Duration of Severe PHN 12.5 11.1 14.1 [79]
Probability of Ocular Complications
Ages 50 – 59 0.03 0.01 0.05 [108], Assumption
Ages 60 – 69 0.04 0.02 0.06 [108], Assumption
Ages 70 – 79 0.05 0.03 0.07 [108], Assumption
Ages 80+ 0.07 0.05 0.09 [108], Assumption
Duration of Ocular Complications 3.0 1.0 6.0 [14], Assumption
Probability of Neurological Complications 0 0.02 0.05 [108]
Duration of Neurological Complications 6.0 1.0 12.0 [14]
Probability of Cosmetic Complications 0 0.02 0.05 [108]
Duration of Cosmetic Complications 6.0 1.0 12.0 [14]
Vaccine Efficacy – Initial*** Age Dependent -0.15 +0.10 [15,22,51]
Vaccine Efficacy – Waning**** Age Dependent 0.70 1.30 [15,22,51]
Table 2.2: Model inputs – epidemiology. *Logistic function used for HZ incidence: asymp
1+e(
xmid−age
scale )
. **Power Function used for PHN risk:
b1 × ageb2 . ***Absolute change made to initial vaccine efficacy. ****Relative change of made to vaccine waning.
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Variable Base Value Lower Value Upper Value Reference
Costs
HZ 957 867 1051 [14]
PHN 5831 4055 7936 [14]
Ocular Complications 4163 2986 5543 [14]
Neurological Complications 9872 5520 15253 [14]
Skin Complications 9873 3036 19883 [14]
Vaccine 173.97 150 250 [109–112]
Vaccine – Administration 31.38 30.03 32.73 [110–113]
Vaccine – Severe Adverse
Reaction *
0.18 0.11 0.25 [114,115]
Productivity Lost
No Pain HZ 5 3 6 [63,116]
Mild HZ 6 4 8 [63,116,117]
Moderate HZ 22 15 30 [63,116,117]
Severe HZ 61 39 82 [63,116,117]
Mild Pain PHN 4 3 5 [63]
Moderate Pain PHN 30 20 41 [63]
Severe Pain PHN 81 53 110 [63]
Table 2.3: Model inputs – economic. Cost values are presented in 2015 US Dollars ($). Hours of
productivity lost are converted into 2015 US dollars ($) by multiplying by the mean hourly wage of
$25.20 [118] – Additional detail provided in Appendix. * Detail on cost of severe adverse event cost
calculation is available in the Appendix.
Variable Base Value Lower Value Upper Value Reference
No Pain HZ 0.150 0.100 0.200 Assumption
Mild HZ 0.200 0.133 0.267 [88]
Moderate HZ 0.300 0.200 0.400 [88]
Severe HZ 0.450 0.300 0.600 Assumption
Mild Pain PHN 0.310 0.211 0.433 [88]
Moderate Pain PHN 0.550 0.389 0.731 [88]
Severe Pain PHN 0.770 0.498 0.992 [88]
Ocular Complications 0.240 0.178 0.311 [88]
Cosmetic Complications 0.350 0.200 0.500 Assumption
Neurologic Complications 0.350 0.200 0.500 Assumption
Vaccine – Common Adverse
Reaction
0.001 0.0005 0.002 [15,22]
Vaccine – Severe Adverse
Reaction
2.13e-05 6.41e-06 4.57e-05 [115,119]
Table 2.4: Model inputs – disutilities. Disutilities subtracted from age-dependent baseline QOL
[120] – Additional detail provided in Appendix.
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Category Distribution
Probability – HZ* – asymp lnN (0, 0.099)
Probability – Any Pain | HZ β(10.17, 0.82)
Probability – Mild Pain | Any Pain HZ β(1.22, 8.95)
Probability – Moderate Pain | Moderate or Severe Pain HZ β(13.212, 17.871)
Probability – PHN* – b1 lnN (0, 0.295)
Probability – Moderate or Severe PHN** N (0, 0.05)
Probability – Moderate PHN | Moderate or Severe PHN lnN (−0.693, 0.199)
Duration – Mild PHN lnN (1.902, 0.05)
Duration – Moderate PHN lnN (2.30, 0.05)
Duration – Severe PHN lnN (2.52, 0.07)
Probability – Ocular Complications** N (0, 0.01)
Duration – Ocular Complications lnN (1.098, 0.223)
Vaccine – Initial Efficacy (η)** N (0, 0.035)
Vaccine – Waning Rate (ζ)* N (1, 0.12)
Cost – HZ Γ(414.598, 1/2.308)
Cost – PHN Γ(34.691, 1/168.084)
Cost – Ocular Complications Γ(40.767, 1/102.114)
Cost – Vaccine Γ(23.33, 1/7.5)
Cost – Vaccine Administration Γ(2196.6, 70)
Cost – Vaccine Severe Reactions Γ(18, 100)
Hours Productivity Lost – No Pain HZ* † N (1, 0.13)
Hours Productivity Lost – Mild HZ* † 6/5
Hours Productivity Lost – Moderate HZ* † 22/5
Hours Productivity Lost – Severe HZ* † 61/5
Hours Productivity Lost – Mild PHN* ‡ N (1, 0.13)
Hours Productivity Lost – Moderate PHN* ‡ 30/4
Hours Productivity Lost – Severe PHN* ‡ 81/4
Disutility – No Pain HZ †† β(24.75, 140.25)
Disutility – Mild HZ †† 20/15
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Category Distribution
Disutility – Moderate HZ †† 30/15
Disutility – Severe HZ †† 45/15
Disutility – Mild PHN ‡‡ 32/77
Disutility – Moderate PHN ‡‡ 55/77
Disutility – Severe PHN ‡‡ β(8.85, 2.65)
Disutility – Ocular Complications β(38, 120)
Disutility – Common Vaccine Complications β(6, 6000)
Disutility – Severe Vaccine Complications β(2.13, 100000)
Table 2.5: Parameter distributions for probabilistic sensitivity analysis. * – A scaling
factor for the parameter was sampled and multiplied by the base value for that parameter.
** – A parameter was sampled and added to base case parameter value. † – Hours of
productivity lost for HZ are correlated with no pain HZ state, all other HZ health states
are multiplied by factors listed in the table. ‡ – Hours of productivity lost for PHN are
correlated with mild PHN state, all other PHN health states are multiplied by factors listed
in the table. †† – Disutility for HZ states are correlated with no pain HZ state, all other HZ
health states are multiplied by factors listed in the table. ‡‡ – Disutility for PHN states are
correlated with severe PHN state, all other PHN health states are multiplied by factors
listed in the table.
Vaccine Parameterization
This section describes how the vaccine was parameterized in the model. The protection
of the vaccine against HZ (efficacy) was comprised of two parts. First, the initial
vaccine efficacy (β0jHZ ). This was defined as the efficacy from the time of the
vaccination through the first year (t = [0, 1)); j is the age of vaccination, t is measured
in years. This initial efficacy changes by age [22]. Second, the waning of the vaccine
(V Ei). Vaccine waning was assumed to occur from the time of the vaccination through
the time when the vaccine provided no further protection, (t = [0, X]), where X is
a some random number of years in the future. For this model, I assume that the
components (initial efficacy and waning) are combined using the form of a linear
30
Age 0 1 2 3 4 5 6 7 8 9
5 0.781 0.781 0.781 0.781 0.781 0.781 0.781 0.781 0.781 0.780
6 0.779 0.776 0.771 0.765 0.757 0.746 0.733 0.718 0.701 0.681
7 0.659 0.635 0.610 0.584 0.557 0.529 0.501 0.472 0.442 0.414
8 0.384 0.355 0.327 0.298 0.269 0.240 0.211 0.182 0.153 0.124
9 0.095 0.066 0.037 0.008 0 0 0 0 0 0
10 0
Table 2.6: β0jHZ fitted values
equation (y = mt+ b) to create the age-specific efficacy and waning of the vaccine
(V Eij). That is, the initial protection was assumed to be the intercept (b), the waning
was assumed to be the slope (m), t was the number of years vaccinated from [0, X],
and y was the protection of the vaccine against HZ. Note, this does not assume
that the components (initial efficacy and waning) are strictly linear; rather these
components were estimated separately and then combined using this equation form.
The minimum value for vaccine efficacy was 0%. That is, I assume that the vaccine
will not ever increase the incidence of HZ. Data on the initial vaccine efficacy and
waning came from from clinical trial and observational data [20–22,51,78] and were
combined using statistical methods similar to those used in other studies [19,60]. For
all analyses, I assume that V Eij changes through the combination of two restricted
cubic spline (RCS) models. These models were selected using best fit statistics. The
outcomes of the two RCS models are presented in Table 2.6 – 2.7. The general form of
the vaccine efficacy equation is shown by Equation 2.1, where i is the number of years
vaccinated from [0, X], j is the age of vaccination from [50, 100], η is the adjustor
for the initial efficacy in sensitivity analysis (base value = 0), and ζ is the adjustor
for waning efficacy in sensitivity analysis (base value = 1). The base results of this
equation are shown in Figure 2.2. More detail on how data were fit and combined is
available in Appendix A.4 on page 185.
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β1 β2 β3 β4 β5
-0.20834831 0.031716085 -0.065752089 0.034499987 -0.000463984
Table 2.7: V Ei fitted values
V EijHZ = max(0, β0jHZ + η)
+ β1ζi
+ β2ζ max(i, 0)
3
+ β3ζ max(i− 1, 0)3
+ β4ζ max(i− 2, 0)3
+ β5ζ max(i− 7, 0)3
(2.1)
There is some data that suggests that the vaccine provides additional protection
against PHN beyond the reduction in HZ incidence [22]. Data were used to provide an
estimate of the initial additional protection benefit of the vaccine against PHN, where
additional protection is defined as any reduction beyond what can be attributed to a
reduction in HZ incidence. Using a synthetic data set created from available data [22]
I constructed seven possible models for this initial protection benefit against PHN
(β0jPHN ) from t = [0, 1). I selected the model presented in Table 2.8 to represent the
base case. This selection was based on understanding of the disease, the vaccine, and
discussions with zoster vaccine experts at the US Centers for Disease Control and
Prevention (CDC). There is unfortunately no data on how the additional protection
benefit wanes with time. Therefore, I made the assumption that the additional
protection benefit against PHN lasts only as long as the protection against HZ
incidence. That is, if the vaccine is assumed to provide X years of protection against
HZ, then the individual is assumed to also receive the same number of years of extra
protection against PHN. I also make the assumption that the additional protection
wanes at the same rate as the vaccines protection against PHN; this was accomplished
using Equation 2.2. I finally assume that the vaccine provides a minimum of 0%
extra protection against PHN. At 0% additional protection, an individual who was
vaccinated would have the same likelihood of acquiring PHN given HZ as someone
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accinat
ion
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70
80
90
100
Years Vaccinated
0
5
10
15
Efficacy
0.0
0.2
0.4
0.6
0.8
1.0
Figure 2.2: Age-specific vaccine waning model against HZ
without the vaccine. The base case additional protection benefit assuming the initial
additional protection as shown in Table 2.8 and the waning rate as defined by Equation
2.2 is shown in Figure 2.3.
V EijPHN =
β0jPHN ×
V EijHZ
β0jHZ
if β0jHZ > 0
0 if β0jHZ = 0
(2.2)
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Age 0 1 2 3 4 5 6 7 8 9
5 0.040 0.57 0.075 0.093 0.110 0.128 0.146 0.164 0.182 0.199
6 0.217 0.234 0.252 0.270 0.288 0.305 0.323 0.341 0.359 0.376
7 0.394 0.412 0.429 0.447 0.465 0.465 0.465 0.465 0.465 0.465
8 0.465 0.465 0.465 0.465 0.465 0.465 0.465 0.465 0.465 0.465
9 0.465 0.465 0.465 0.465 0.465 0.465 0.465 0.465 0.465 0.465
10 0.465
Table 2.8: β0jPHN fitted values
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Figure 2.3: Age-specific vaccine waning model of additional protection against PHN
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Analysis Plan
Model results were generated using TreeAge software. Results were then exported
and imported into R (v.3.2.3) – an open-source data analytic software. Data were
cleaned, analyzed, and figures were generated. TreeAge is capable of data analysis
and visualization however, there are more options for data analysis and visualization
using R and its many packages.
For the analysis, I compared the results of the two mutually exclusive options for
this model: vaccination and no vaccination. The costs and effectiveness (measured in
QALYs) from each component model were calculated and entered into Equation 2.3 to
create incremental cost-effectiveness ratios (ICERs). The ICER provides information
on the additional cost per unit of benefit between an option and the next less expensive
alternative.
ICER =
∆Costs
∆Effectiveness
(2.3)
To determine if an intervention is cost-effective, it must be compared to a cost-
effectiveness threshold. This threshold represents the maximum willingness to pay
(WTP) for a single unit of benefit (one QALY). The base case analysis assumes a
WTP of $100,000 / QALY. However, because there is no standard WTP/QALY in
the US [75] I also evaluated model outcomes using against additional WTP values.
The base case analysis examined the cost-effectiveness of the HZ vaccine under the
assumption that there is zero probability of neurological and cosmetic complications
(i.e., only PHN and ocular complications were allowed to follow an episode of HZ).
Cohort model were independently simulated for each age and gender from 50 – 100
using a lifetime time horizon, to determine the cost-effectiveness of the vaccine at
that age. For each model, I assumed no prior history or risk of HZ. The probability
of death was set to 100% at age 100. Age-dependent probabilities in the model were
altered to reflect the age of the cohort being simulated.
I added additional payoff variables to the model to determine intermediate (epi-
demiological) outcomes. Intermediate outcomes for the model included: number of
HZ cases prevented with vaccination; the number of PHN cases prevented with vacci-
nation; and the number of ocular complications prevented with vaccination. For all
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intermediate outcomes, a cohort model was simulated to give the lifetime probability
of developing HZ, PHN or ocular complications with and without vaccination. I
multiplied these final probabilities by 10,000 (i.e., assuming a cohort size of 10,000
men or women) to determine the number of cases of HZ, PHN or ocular complications
for a cohort of 10,000 men or women. The difference in the number of cases between
the vaccination and no vaccination arms of the model were the number of cases
prevented given vaccination.
Sensitivity Analysis
Several sensitivity analyses, a method that examines how responsive outcomes are
to changes in parameter inputs and model assumptions, were completed. First, I
conducted a one-way sensitivity analysis by varying each of the model parameters
independently at the ends of their ranges (shown in Tables 2.2 – 2.4) to examine the
effect on outcomes and create a tornado diagram. This identified the model parameters
that the cost-effectiveness results were most sensitive to. For any parameters that the
model was very sensitive to I conducted additional two-way analyses to determine how
interactions between these parameters would change the cost-effectiveness results.
I also performed first order Monte Carlo probabilistic sensitivity analysis with the
model to estimate the ICERs given the uncertainty of multiple model parameters
simultaneously. To accomplish this, I converted model inputs from discrete values
to distributions. For cost inputs, I utilized a gamma (Γ) distribution. For hours of
productivity lost, I correlated hours within each overall health state (i.e., HZ or PHN)
with one another. No pain HZ and mild PHN were used to correlate all other pain
states for HZ and PHN, respectively. This was done so that the possibility of a more
severe case of HZ, for example, would not produce fewer hours of productivity loss
than a less severe case (additional detail is provided in Table 2.5). For disutilities,
I assumed a beta (β) distribution. For disutilities, I also correlated within each
overall health state to avoid the situation where a more severe form of disease would
have a smaller disutility than a less severe form. For HZ disutilities, all pain states
were correlated with mild HZ. For PHN disutilities, all pain states were correlated
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with severe PHN; this was done to avoid having a disutility value greater than
1.0. For probabilities that were adjusted by additive means a normal distribution,
(mean = 0), was used (e.g., η for initial vaccine efficacy). For probabilities that
were adjusted by multiplicative means, a log normal distribution, (mean = 1), was
used (e.g., ζ for vaccine waning). The results from the PSA were used to generate
cost-effectiveness acceptability curves (CEACs) to determine the probability that the
vaccine was cost-effective at different WTPs. All sensitivity analyses were conducted
using recommended procedures and guidelines [94].
Scenario Analysis
I also conducted several scenario analyses. I first examined the cost-effectiveness
given a non-zero probability of neurologic and cosmetic complications in the base
case model. Then I tested the cost-effectiveness of the HZ vaccine using a third
order polynomial function to predict V EijHZ ; see section A.4 for further detail on
this combination. The third-order polynomial model was the second best model
behind the RCS model based on best fit statistics. Finally, I tested the remaining six
models for the additional protection against PHN. I assumed that all of these models
waned at the same rate as the vaccines protection against HZ. I then performed an
additional analysis where I held the waning of the vaccines protection against HZ
constant and altered the waning of the protection against PHN independently. This
was done to gain further insight into the possible effects of protection against PHN.
Model Validation
I performed several validation checks on the model. First, I set all baseline QOL
to 1.0, removed the disutilities associated with the health states, and removed the
discount rate. I then performed simulations with different age groups and compared
the results of the model to the CDC life tables [98]. This procedure provided a check
that the cohorts in the model were dying at the expected rate as the removal of
QOL and discounting provides an estimation of remaining life-expectancy. Next, I
removed the costs and disutilities associated with the vaccine from the base case
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Age Life Expectancy – Model Life Expectancy – CDC [98]
50 32.75 33.3
60 24.03 24.5
70 16.11 16.4
80 9.41 9.6
90 4.5 4.7
100 0.08* 2.3
Table 2.9: Model validation – life expectancy check – Women. *People at age 100 in the
model only live 1 month
model. Under these circumstances the vaccine was predicted to dominate the choice
of no vaccination for every age from 50 – 93 and be indifferent between 94 – 100
(the vaccine is assumed to have no benefit after age 93, see Figure 2.2). Finally, to
ensure that the vaccine equations were entered into the model correctly, I selected
different ages and numbers of years vaccinated and performed the calculations on
what the probability of an event should be by hand. I then changed the TreeAge
model to reflect the scenarios I was testing and used the evaluator tool to ensure that
the probabilities calculated by the model matched the probabilities I had calculated.
2.3 Results
Model Validation
The results from the model validation are presented in Tables 2.9 – 2.11. Table 2.9
shows the comparison of life expectancy in the model to the CDC life table [98].
There are small differences in the life expectancy between the CDC life tables and
the results produced by the model. The biggest difference is at age 100, where the
CDC life tables predict a life expectancy of 2.3 years and the model estimates life
expectancy of 0.08 years (1 month). The main difference between these two estimates
is that in the model the probability of death was set to 100% at age 100. Table
2.10 shows the comparison between V EijHZ as calculated by hand (using data from
Tables 2.6 – 2.7 and Equation 2.1) compared to the values calculated by TreeAge.
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Scenario V EijHZ – Calculated V EijHZ – From TreeAge
j: 50, i: 0 0.7814 0.7814
j: 55, i: 10 0.1322 0.1322
j: 60, i: 4 0.4762 0.4762
j: 65, i: 7 0.2769 0.2769
j: 70, i: 2 0.4304 0.4304
j: 75, i: 8 0.0000 0.0000
j: 80, i: 3 0.1245 0.1245
j: 85, i: 5 0.0000 0.0000
j: 90, i: 0 0.0950 0.0950
Table 2.10: Model validation – vaccine efficacy check
All hand calculated values match the values produced by TreeAge indicating that the
vaccine efficacy was implemented into the model correctly. Finally, Table 2.11 shows
data from an analysis where the costs and disutilities associated with the vaccine
were removed. As predicted, the option to vaccinate dominated the do not vaccinate
option for every age between 50 – 93 (where the vaccine had some benefit) and the
model was indifferent between the options from ages 94 – 100 as the vaccine confers
no benefit but also presents no risk or cost to the recipient.
Age Option Cost Effect Inc Cost Inc Eff Inc Analysis
50 Vaccine 349.19 15.94 0 0
50 No Vaccine 391.41 15.94 42.22 -1.20E-2 (Dominates)
55 Vaccine 352.26 14.35 0 0
55 No Vaccine 406.09 14.34 53.82 -1.54E-2 (Dominates)
60 Vaccine 344.29 12.66 0 0
60 No Vaccine 411.39 12.66 67.09 -1.95E-2 (Dominates)
65 Vaccine 330.04 10.92 0 0
65 No Vaccine 405.54 10.92 75.49 -2.28E-2 (Dominates)
70 Vaccine 315.94 9.15 0 0
70 No Vaccine 386.36 9.15 70.42 -2.29E-2 (Dominates)
75 Vaccine 299.77 7.40 0 0
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Age Option Cost Effect Inc Cost Inc Eff Inc Analysis
75 No Vaccine 352.92 7.40 53.14 -1.92E-2 (Dominates)
80 Vaccine 275.77 5.72 0 0
80 No Vaccine 306.28 5.72 30.50 -1.25E-2 (Dominates)
85 Vaccine 239.37 4.17 0 0
85 No Vaccine 249.56 4.17 10.18 -4.88E-3 (Dominates)
90 Vaccine 187.85 2.88 0 0
90 No Vaccine 190.23 2.87 2.37 -1.34E-3 (Dominates)
93 Vaccine 154.85 2.22 0 0
93 No Vaccine 154.88 2.22 3.12E-2 -1.18E-5 (Dominates)
94 Vaccine 142.48 2.00 0 0
94 No Vaccine 142.48 2.00 0 0 (Indifferent)
99 Vaccine 43.02 0.61 0 0
99 No Vaccine 43.02 0.61 0 0 (Indifferent)
100 Vaccine 0 5.65E-2 0 0
100 No Vaccine 0 5.65E-2 0 0 (Indifferent)
Table 2.11: CEA model validation – model check. Costs in 2015 US dollars ($). Effect in
QALYs. Inc: Incremental. ICER: Incremental cost-effectiveness ratio. Dominates: Denotes
if vaccination strategy dominates no vaccination strategy.
Base Case Analysis
This section highlights the cost-effectiveness results of the base case analysis. The
base case model produces a mean incremental cost-effectiveness ratio (ICER) of
$137,843 when adjusted for the population and gender balance of the US for age
50-85 [8]. Ages over 85 were removed from this mean to not skew the ICER. The
ICER for the current US policy (i.e., 60 and older) is $135,036, adjusting for the
population and gender composition of the US for people 60 and older. Figure 2.4
shows the results of the base case analysis. For men and women, vaccination at age
67 produces the lowest ICER with values of $96,278 and $69,961, respectively. For
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Figure 2.4: ICER by age for men and women. Dots indicate the ICER at age of vaccination.
White dot indicates the age with lowest ICER.
women, the vaccine produces an ICER less than $100,000/QALY for ages 59 – 74. For
men, the vaccine produces an ICER less than $100,000/QALY for ages 64 – 69. After
age 80 for women and men there is a rapid increase in the ICER. The the y-axis on
Figure 2.4 only shows values up to $1,000,000. After ages 86 and 85 for women and
men, respectively, the ICER reaches values of greater than $1,000,000/QALY, until
age 91 when it becomes dominated. The vaccine is more cost-effective for females at
every age.
Table 2.12 provides data on intermediate outcomes for the base case analysis
for women. The table for men is available in the end of chapter appendix on page
67. Vaccination of 10,000 women at age 50 prevents 180 cases of HZ, 11 cases of
PHN, and 5 ocular complications. Using US census projections for the population,
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vaccination of every 50 year old would prevent 40,758 cases of HZ in women, 35,475,
in men, 76,233 total. Vaccination at ages 64 or 65 prevents the most cases of HZ per
10,000 people (288). Vaccination at ages 69 – 72 prevents the most cases of PHN
(49). Using the US population estimates, vaccination of all women at age 67 produces
the highest number of PHN cases prevented, 8,489 over their lifetime. This is also
the age with the lowest ICER for women. The results of the intermediate outcomes
were validated against studies that reported data similarly. Because I parameterized
the vaccine in a different way compared to all other cost-effectiveness analyses, I was
only able to use data from no vaccination strategies for validation. In total, four
studies [59,62,67,69] reported intermediate outcomes data that could be compared.
Data generated by this study fell within the reported range from these four studies.
Age ∆ HZ ∆ PHN ∆ OC $ – VX Q – VX $ – no VX Q – no VX
50 180 11 5 554.73 15.949 391.42 15.948
51 189 12 6 556.11 15.636 394.95 15.635
52 197 14 6 557.14 15.320 398.22 15.319
53 206 16 7 557.79 15.001 401.18 15.000
54 215 18 7 558.01 14.678 403.82 14.677
55 224 20 8 557.79 14.351 406.09 14.350
56 233 22 8 557.10 14.020 407.98 14.018
57 242 24 9 555.92 13.685 409.46 13.683
58 252 27 9 554.25 13.346 410.53 13.345
59 261 29 10 552.18 13.005 411.17 13.003
60 269 32 10 549.83 12.662 411.39 12.660
61 276 34 11 547.24 12.317 411.18 12.315
62 282 37 11 544.47 11.971 410.52 11.969
63 286 39 12 541.57 11.623 409.38 11.621
64 288 42 12 538.58 11.274 407.73 11.272
65 288 44 12 535.58 10.923 405.54 10.921
66 285 46 13 532.63 10.570 402.82 10.568
67 280 47 13 529.79 10.218 399.56 10.216
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Age ∆ HZ ∆ PHN ∆ OC $ – VX Q – VX $ – no VX Q – no VX
68 272 48 12 527.03 9.865 395.76 9.863
69 262 49 12 524.28 9.512 391.37 9.510
70 249 49 12 521.47 9.158 386.37 9.157
71 235 49 11 518.55 8.805 380.76 8.803
72 219 49 11 515.49 8.452 374.60 8.450
73 203 48 10 512.25 8.101 367.90 8.099
74 186 47 9 508.78 7.753 360.68 7.751
75 168 45 9 505.31 7.407 352.93 7.405
76 150 42 8 501.44 7.063 344.61 7.061
77 133 40 7 497.11 6.721 335.74 6.720
78 116 37 6 492.30 6.383 326.35 6.382
79 99 33 5 487.02 6.050 316.52 6.049
80 84 30 5 481.30 5.723 306.28 5.722
81 69 26 4 475.10 5.401 295.62 5.400
82 55 23 3 468.35 5.084 284.52 5.084
83 43 19 2 461.08 4.774 273.06 4.773
84 32 15 2 453.33 4.472 261.40 4.472
85 23 12 1 444.91 4.180 249.56 4.179
86 16 9 1 435.39 3.896 237.58 3.896
87 12 7 1 425.12 3.625 225.63 3.625
88 9 6 1 414.63 3.365 213.75 3.365
89 6 5 0 404.04 3.117 201.95 3.117
90 4 3 0 393.39 2.880 190.23 2.880
91 2 2 0 382.66 2.653 178.55 2.653
92 1 1 0 371.76 2.434 166.82 2.434
93 0 0 0 360.38 2.221 154.89 2.221
Table 2.12: Intermediate model outcomes – Women. ∆: The number of cases prevented
due to vaccination. OC: Ocular complications. $: Costs, in 2015 US dollars. Q: QALYs.
VX: Vaccine option. no VX: No vaccine option.
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Sensitivity Analysis
One-way Sensitivity Analysis
p(death | HZ)
Cost − PHN Wages
QOL − No pain HZ
Cost − Ocular Complications
QOL − Vaccine Severe Reaction
Time − Mild PHN
Cost − HZ
QOL − Ocular Complications
p(HZ recurr)
p(Ocular Complications)
Cost − PHN
QOL − Severe PHN
Time − Moderate PHN
Time − Ocular Complications
QOL − Moderate PHN
Cost − HZ Wages
p(Moderate pain | HZ)
p(Moderate PHN)
Time − Severe PHN
p(Mild pain | HZ)
QOL − Moderate HZ
QOL − Vaccine Common Reaction
p(Moderate or Severe PHN)
Vaccine Efficacy − PHN Intercept
QOL − Mild HZ
QOL − Severe HZ
Discount Rate
QOL − Mild PHN
p(Any pain|HZ)
p(HZ)
p(PHN)
Cost − Vaccine
Vaccine Efficacy − Waning
Vaccine Efficacy − Intercept
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Figure 2.5: Tornado diagram for base case analysis. Ages
50 – 85.
A tornado diagram for all
model input is shown in Fig-
ure 2.5. This indicates the
model is most sensitive to the
initial efficacy of the vaccine,
the waning of the vaccine, the
cost of the vaccine, the prob-
ability of PHN, the probabil-
ity of HZ, and the probability
of any pain given HZ. Figures
2.6 and 2.7 show the results
of the one-way sensitivity anal-
ysis of the probability of HZ
and PHN for men, respectively.
These analyses show that the
probability of HZ does not im-
pact the age that produces the
lowest ICER. That is, for all
probabilities of HZ, age 67 has
the lowest ICER. The curves in
Figure 2.6 suggest that chang-
ing the probability of HZ has
the most effect on younger ages. This can be seen on the left where there is more
space between the curves than at any other point. Unlike the impact of HZ, changing
the probability of PHN does impact the age with the lowest ICER. At the bounds
of the lowest probability, the age that produces the lowest ICER for vaccination is
66. At the highest probability of PHN, the age the produces the lowest ICER is
68. Changing the probability of PHN affects both earlier and later ages. With a
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higher probability of PHN the curve is much flatter and produces ICERs less than
$100,000/QALY from ages 56 – 77. With a low probability of PHN, there are no
ICERs less than $100,000/QALY.
Two-way Sensitivity Analysis
Figures 2.8 – 2.10 provide the two-way sensitivity analyses on the three parameters
that have the biggest impact on the cost-effectiveness: initial vaccine efficacy, vaccine
waning, vaccination cost (including administration fees). All two-way sensitivity
analyses in this section are for women age 67. This group was selected because it
was the most cost-effective age and gender combination. Further figures for multiple
ages are presented in the appendix for this chapter beginning on page 66. Figure 2.8
shows that the base case ICER is less than $75,000 and under most circumstances
the ICER will be less than $100,000 for age 67. If the waning ‘speed’ is increased
by 20% (i.e., ζ = 1.2) the ICER will be greater than $100,000 if the initial efficacy
remains constant. If the initial efficacy is increased by 10% (i.e., η = 0.10) and there
is no change in the waning, the ICER will be ≤ $50,000.
The interaction between vaccination cost and initial vaccine efficacy is shown in
Figure 2.9. Assuming a 10% increase in the initial efficacy of the vaccine the ICER
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Figure 2.6: Sensitivity analysis of p(HZ)
by age – Men. Top line: asymp = 11.148.
Middle line: asymp = 13.935. Bottom
line: asymp = 17.418
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Figure 2.7: Sensitivity analysis of
p(PHN) by age – Men. Top line: b1 =
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Bottom line: b1 = 3.544e− 07
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Figure 2.8: Sensitivity analysis of vaccine efficacy vs. vaccine waning – women. Black dot
= base case. Contours represent ICER values of vaccination vs. no vaccination.
will be less than $50,000/QALY. Under most circumstances the vaccine produces an
ICER less than $100,000. Figure 2.10 shows the interaction between vaccine waning
and vaccine cost. A 20% reduction in the waning ‘speed’ (i.e., ζ = 0.80) and no
change in the cost of vaccination will produce an ICER less than $50,000. At the
base case vaccination cost, $205 (including administration fees), the ICER would only
be greater than $100,000 if the vaccine waned more than 30% faster than predicted.
If vaccination costs more than $250, the ICER would also be greater than $100,000.
Figures 2.11 – 2.14 show two-way sensitivity results from some of the other key
parameters. Figure 2.11 shows the analysis between the probability of HZ and the
probability of PHN (given HZ). This analysis suggests that under most conditions
the ICER for the vaccine is less than $100,000. Only if the incidence of HZ drops
below 9.5/1000 people and the risk of PHN given HZ drops below 11% is the ICER
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Figure 2.9: Sensitivity analysis of vaccine efficacy vs. vaccination cost – women. Black
dot = base case. Contours represent ICER values of vaccination vs. no vaccination.
greater than $100,000. Figure 2.12 shows the interaction between the probability of
HZ and the probability of pain (given HZ). In the base case analysis the probability of
pain with HZ was 95%. In the majority of circumstances the ICER is below $100,000
unless the probability of pain falls below 70% and the incidence of HZ falls below
9/1000.
Figure 2.13 shows the results of the sensitivity analysis between the probability
of HZ and cost of vaccination. If vaccination costs only $175, the ICER can be less
that $50,000 if the annual incidence of HZ is greater than 11/1000. At this same
probability of infection, vaccination can cost more than $250 and still produce an
ICER less than $100,000. Figure 2.14 shows the results of the sensitivity analysis
between the probability of PHN given HZ and the cost of vaccination. Under most
conditions, the ICER is less than $100,000. If there is a low probability of PHN
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Figure 2.10: Sensitivity analysis of vaccine waning vs. vaccination cost – Women. Black
dot = base case. Contours represent ICER values of vaccination vs. no vaccination.
and vaccination is more expensive by approximately $25.00 the ICER greater is
than $100,000. With a high chance of PHN and a decrease in vaccination cost to
approximately $150, the ICER for vaccination at age 67 can be lower than $25,000.
Additional figures for all two-way sensitivity analyses are available in section 2.A.
Probabilistic Sensitivity Analysis
Figures 2.15 – 2.16 provide the results from the probabilistic sensitivity analysis for
women and men, respectively. For women, there is at least a 40% probability that the
vaccine is cost-effective at a WTP of $100,000 for ages 56 – 76. The vaccine has at
least a 60% chance of being cost-effective at a WTP of $100,000 for ages 60 – 73. At
the lowest permitted vaccination age (50), the vaccine has a ≥ 60% chance of being
cost-effective if the WTP is approximately $200,000. Assuming a WTP of $200,000
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Figure 2.11: p(HZ) vs. p(PHN) –
Women. Black dot = base case. Contours
represent ICER values of vaccination vs.
no vaccination.
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Figure 2.12: p(HZ) vs. p(HZ – any
pain) – Women. Black dot = base case.
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Figure 2.13: p(HZ) vs. vaccination cost
– Women. Black dot = base case. Con-
tours represent ICER values of vaccina-
tion vs. no vaccination.
Age: 67
0.10 0.15 0.20 0.25
15
0
20
0
25
0
p(PHN | HZ)
Co
st 
of
 V
ac
cin
e 
($
)
C
os
t o
f V
ac
ci
na
tio
n 
($
)
Figure 2.14: p(PHN) vs. vaccination
cost – Women. Black dot = base case.
Contours represent ICER values of vacci-
nation vs. no vaccination.
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Figure 2.15: Cost-effectiveness acceptability contour – Women. Lines represent probability
that vaccination is cost-effective compared to no vaccination.
the vaccine has at least a 90% probability of being cost-effective for ages 56 – 75.
Under this WTP, it has a 99% chance of being cost-effective for ages 64 – 69.
For men, the vaccine does not have as high a probability of being cost-effective. For
a WTP of $100,000, the vaccine has at least a 40% probability of being cost-effective
for ages 60 – 73. Assuming a WTP of $200,000, the vaccine has at least a 20%
probability of being cost-effective for age 50 – 81. For ages 57 – 74, this probability
increases to 80% with a WTP of $200,000. The WTP needs to be greater than
$200,000 for any age to have a 99% chance of being cost-effective. At a WTP of
approximately $250,000, the vaccine has a 99% probability of being cost-effective for
ages 60 – 71.
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Figure 2.16: Cost-effectiveness acceptability contour contour – Men. Lines represent
probability that vaccination is cost-effective compared to no vaccination.
Scenario Analysis
Additional PHN Protection
This section provides the results from the scenario analyses on additional PHN
protection. Figures 2.18 and 2.19 show the results from the different options for initial
additional protection against PHN; these options are further described on page 205.
Figure 2.17 provides a reference guide for the figures in this section. Only figures for
women are provided; figures for men are provided in the end of chapter appendix
on page 75. Figure 2.18 shows that for every option of initial additional protection
against PHN, with the exception of the no additional protection option, the results
after age 81 are the same. If there is no additional protection against PHN, the
vaccine is less cost-effective at every age with the ICER becoming much greater at
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earlier ages. Figure 2.19 provides a zoomed in version of Figure 2.18 between the
ages of 60 – 75. The largest difference in range between the ICERs, excluding the
no additional protection option is approximately $20,000 at age 70. The minimum
ICER for all curves occurs between 65 – 70. The results of this scenario analysis
indicate that the choice of the initial additional protection benefit does impact the
cost-effectiveness of the vaccine, however, it does not greatly change the age with the
lowest ICER.
Figures 2.18 – 2.19 provide insight to the issue of the initial additional protection
benefit against PHN. However, the results from these figures also assume that the
additional protection benefit wanes at the same rate as the protection against HZ.
Figure 2.20 shows the results of a two-way analysis where each of the seven initial
additional protection options was tested with altering the waning speed of the
additional protection benefit (while holding the waning speed of the HZ vaccine
constant (i.e., ζ = 1)). Results show that regardless of how slow or fast the additional
protection wanes, the lowest ICERs still fall between 60 – 75 (using $100,000 or less
as the reference). The speed of the additional protection does reduce the ICER for
older ages. However, the largest differences are achieved for people older than 85 and
even assuming a 40% reduction in the waning speed, the ICERs produced are still
greater than $250,000.
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Figure 2.17: Initial additional protection against PHN – reference guide
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Figure 2.18: Scenario analysis – PHN
intercept – Women
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Figure 2.19: Scenario analysis – PHN
intercept – Women – zoomed
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Figure 2.20: Scenario analysis – additional PHN protection efficacy vs waning – Women. Contours represent ICER
values of vaccination vs. no vaccination
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Figure 2.21: Scenario analysis – Other complications – Women. White dots = base case.
Red dots = base case including complications.
Other Complications
Including other complications (neurological and cosmetic) into the model improved
the cost-effectiveness of the vaccine. Figure 2.21 shows the results for women when
other complications were included. Comparing these scenarios, the vaccine is always
more cost-effective when the other complications are included. The ICER for women
is approximately $20,000 less at age 50, $15,000 less at age 67, and $17,000 less at
age 75. Additional figures on the sensitivity of these complications are included in
the end of chapter appendix. Figures 2.37 – 2.42 on page 76 show that adjusting the
probability of other complications had the biggest impact on the cost-effectiveness.
Changing the disutilities associated with these complications has a larger impact of
the cost-effectiveness than changing the cost of the complications.
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Figure 2.22: Scenario analysis – polynomial waning
Polynomial Vaccine Waning
Figures 2.22 – 2.23 contain the results of the scenario analysis where the polynomial
waning function was tested. The base case restricted spline function is also plotted
for comparison. Figure 2.22 shows that there is a minimal difference between the two
functions at every age. The polynomial function produces the lowest ICER at age
68. Figure 2.23 shows the differences between the ICERs from ages 50 – 80. The
zoomed-in figure shows that there is more of a difference between the two function
choices on the left side of their respective minimums with the RCS function producing
lower ICERs from 50 – 68. After age 68, the ICERs begin to converge and remain
close from ages 69 – 80. These plots show that there is a minimal difference in the
results depending on the choice of waning function.
No Productivity Loss
Figures 2.24 – 2.25 show the results of the scenario analysis were productivity loss
was excluded from the analysis. This scenario represents the health care perspective.
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Figure 2.23: Scenario analysis – polynomial waning – zoomed
Without lost productivity being included as a cost the vaccine is less cost-effective at
every age as evidenced by comparing the base case values (in red). Age 67 remains
the most cost-effective age to vaccinate and the pattern for men and women remain
the same with the vaccine being more cost-effective at every age.
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Figure 2.24: Scenario analysis – pro-
ductivity loss – Women
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Figure 2.25: Scenario analysis – pro-
ductivity loss – Men
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Community Rated Disutilities
Figures 2.26 – 2.27 provide the results of the scenario analysis where community
ratings were used for the disutility values. Table 2.13 shows differences in the values.
Using community ratings, disutility values for HZ are much higher and the values for
PHN are much lower. This results in the vaccine being more cost-effective at younger
ages for both men and women. This result can be see by the difference between the
two lines in Figure 2.26 and 2.27. With community ratings the most cost-effective age
for vaccination drops to age 65 for both men and women (as indicated by the white
dot). After age 70, the two lines in the graph cross which indicates that when using
community rating the vaccine is less cost-effective at older ages than in the base case.
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Figure 2.26: Scenario analysis – Com-
munity ratings – Women
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Figure 2.27: Scenario analysis – Com-
munity ratings – Men
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Variable Base Case Community Rating Reference
HZ – No Pain 0.15 0.30 [88]
HZ – No Pain 0.20 0.50 [88]
HZ – No Pain 0.30 0.70 [88]
HZ – No Pain 0.45 0.90 [88]
PHN – No Pain 0.31 0.18 [88]
PHN – No Pain 0.55 0.18 [88]
PHN – No Pain 0.77 0.22 [88]
Table 2.13: Community disutility ratings
2.4 Discussion
In this chapter, I examine the cost-effectiveness of the current herpes zoster vaccine
for every age between 50 and 100 for women and men. The vaccine is always more
cost-effective for women than men in the ages where the vaccine is not dominated.
This is likely due to women being more susceptible to developing HZ and having
a longer life expectancy. For both men and women, age 67 produces the lowest
ICER. One-way and two-way sensitivity analysis show that the cost-effectiveness is
most sensitive to the initial efficacy of the vaccine, the speed the vaccine wanes, and
the cost of the vaccine. Probabilistic sensitivity analysis confirms that vaccinating
between the ages of 65 – 70 has the highest chance to be cost-effective assuming a
WTP of $100,000.
Vaccine
The vaccine data and its parameterization were two strengths of this research. This
was the first US cost-effectiveness analysis to use the new long-term zoster vaccine trial
data [20] for an age group over 50 [62]. It was the first study to use new observational
data from a large managed-care cohort on the vaccine’s waning pattern [78]. Using
this data to parameterize the age-specific waning and initial efficacy of the vaccine
was accomplished with the aid of zoster vaccine experts at the CDC. For example,
their input ensured that the steep decline in efficacy over the first year of vaccination
was featured; this decline has not been accounted for in other US studies. Feedback
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from the CDC was crucial as it enabled the parameterization of the vaccine to be
the best that it could be. However, there is still uncertainty about the vaccine
parameters. This was shown in the two-way sensitivity analysis; the initial efficacy
and the waning of the vaccine have a large potential impact on the on the results.
Given this impact further research may be needed to better predict vaccines efficacy
and waning. Techniques like value of information analysis will be important to
determine the potential value of this added research.
One limitation of this paper is the effect of the vaccine on pain. There is some
evidence that the vaccine reduces the burden of PHN [15] which I have accounted
for through the additional protection benefit. But there is also some evidence that
those who were vaccinated and develop HZ may develop a less severe case of HZ
than unvaccinated individuals [15]. However, these data were not translatable into
probabilities for the model. The sensitivity analysis shows that the HZ pain states
do have some impact on the ICER. Being able to accurately account for difference in
HZ pain states for vaccinated vs non-vaccinated individuals would likely to further
reduce the ICERs.
The scenario analysis between the two different waning functions showed minimal
differences in the ICERs at every age. The minimum ICER was found at age 67 using
the base case restricted cubic spline model and 68 using the third order polynomial
model. It is interesting to note that the age that produced the lowest ICER was only
different by one year when there was a difference of approximately two years in the
durability of the vaccine; this can be seen in Figures A.10 and A.11 on page 200.
PHN and Vaccination
From the beginning of this research, I assumed that the vaccine’s additional protection
against PHN would be a key driver of the results. However, this was not found.
Rather it was the impact of the vaccine against HZ that had the most effect. Seven
options for the vaccines initial additional protection and waning (independent of
the vaccines waning against HZ) were tested in scenario analysis. The selection of
the initial additional protection against PHN (shown in Figures 2.18 and 2.36) was
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shown to make some difference to the ICER, however, the base case selection was
near the middle of the extremes for the majority of the ages. Further, when the
waning of this additional protection was tested independently of waning against HZ
(shown in Figure 2.20) I show that the ages where the vaccine is most cost-effective
remains between ages 60 – 75. Panel G in Figure 2.20 shows the benefit of assuming
a 45% additional protection benefit for all ages; even adding this benefit to the earlier
ages (e.g., 50 – 60) and slowing the waning ‘speed’ against PHN independent of the
waning speed against HZ did not greatly change the age range where the vaccine was
most cost-effective. Therefore, while being able to correctly determine the additional
protection is important for being able to get an exact estimate of the cost effectiveness,
the additional protection against PHN did not have as great of an impact on the
results as just protection against HZ or the probability of PHN.
Impact of PHN
The impact of the probability of PHN on the ICER was shown in both the one-way
and two-way sensitivity analyses. Of all of the non-vaccine epidemiological parameters,
this had the greatest impact on the results. One of the strengths of this analysis
was the characterization of the PHN states and the use of the ladder-like progression
through PHN. This model structure was adapted from recent zoster vaccine models
from Europe [63,65,68,70], and provides a better way to characterize the disutility
associated with PHN as a whole. The disutility of mild PHN had the largest impact
of all PHN related disutilities, most likely because all people with PHN must pass
through this state before reaching a disease free health state. It is interesting to note
that it was the probability of PHN that had the biggest impact on the results, while
all individual components of the PHN had only smaller impacts. Using a concept
from “systems thinking” it could be that these model components work together to
make their impact greater than the sum of their parts [121]. I see this laddering
structure as an important piece to the model. However, for future model simplicity
I think it would be reasonable to build a ladder-like PHN sub-model to generate a
age-specific PHN disutility values that could then be used for a general PHN health
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state.
While the ladder like structure was a strength in its ability to emulate the true
disease progression it does have limitations. First, this structure does assume that
all people must pass through all better states of PHN before reaching a disease free
health state. This assumption was based on available data and while it was the
best assumption that could be made given these data, it may not perfectly reflect
the underlying disease process. That is, it may be possible for cases of severe or
moderate PHN to resolve without the patient experiencing mild PHN. This is an area
for future research. In addition, using this structure was a disadvantage from the
cost perspective. The best available data were used for costs in this model, however,
US specific cost data were not available by PHN state. Papers from Europe [70,79]
have shown that higher costs are associated with worse PHN states. However, due
to complications with transferring costs from other countries and health systems
where the financing structure may be very different, costs from these papers were
not included in the model [97]. The cost of PHN in this model was varied widely in
sensitivity analysis and was shown to have little impact on the ICER. Nonetheless,
for a more accurate representation of the costs associated with PHN conditions, this
is also an area for future research.
Comparisons with other US models
Four previous CEAs have been published for the HZ vaccine in the US [59–62]. Three
of these CEAs were published in 2007 or earlier [59–61]; this was near the time when
HZ vaccine data were first released as part of the shingles prevention study (SPS).
Because the SPS only included people ages 60 and older, the earliest CEAs only
includes groups ages 60 and older. When comparing against the other US studies,
this research shares the most in common with the 2007 study by Pellissier et al [60].
For characterizing the disease, they also used differing levels of HZ pain using the
ZBPI. However, they did not use differing levels of PHN. They also fit vaccine data
from the SPS in a similar manner to this paper; using an initial age based efficacy
and waning. However, their waning function did not account for the severe drop in
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efficacy through the first year, rather it was a linear function. This research shares a
common fit pattern of the age specific initial efficacy as both assume a concave shape
for similar fitted values. Results from Pellissier et al suggest a minimal change in
the ICER between ages 60 – 80. The ICERs produced by my models are the most
consistent between ages 60 – 75.
Hornberger and Robertus [59] published a CEA that shows that the only time
the vaccine can produce an ICER less than $100,000 is when the vaccine is less than
$200, the recipient is less than 70 years old and the vaccine effectiveness lasts more
than 30 years. Current information [20,78] suggests that the vaccine is not likely to
last 30 years. Based on my fits of the vaccine data with more current information, at
a best case scenario (+0.10% initial efficacy and 30% slower waning at age 50) the
vaccine would only last 20 years. The authors also admit to having limited data on
vaccine efficacy beyond the initial 2005 clinical trial results [59]. The authors also
assume that PHN does not result unless pain has been persistent for 182 days from
the start of the rash phase. This definition of PHN may underestimate the proportion
of people who actually experience PHN, and allow people to have higher utility for
longer periods of time. Thus, Hornberger and Robertus [59] may underestimate the
QALYs gained by vaccination which could negatively impact the cost-effectiveness
results.
The model constructed by Rothberg et al [61] was sensitive to characteristics of
the vaccine, PHN, and HZ. Unfortunately there was limited methodology for how
the vaccine’s efficacy and waning was calculated. The authors assume there is no
decrease in PHN incidence beyond the decrease attributed to reducing HZ incidence
with vaccination (i.e., they do not assume an additional protection benefit). Brisson
et al [77] suggest that just accounting for the additional reduction of PHN can reduce
the cost per QALY by as much as 40%. Rothberg et al also assume that an individual
either spends less than 12 months with PHN, or several years with PHN. And, there
is no accounting for PHN severity as only one PHN utility score is given. The paper
by Le and Rothberg [62] provides the newest estimate for the cost-effectiveness in the
US and is an update of the Rothberg et al CEA [61]. Le and Rothberg do make use
of newer vaccine waning data. However, they assume that the vaccine wanes using a
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strictly linear rate. Second, cost data on PHN is from their previous CEA model [61].
The CEA model by Rothberg et al [61] used cost data from a 1994 cost study from
the UK. The cost of PHN is one of the most important parameters in many HZ CEA
models. Using cost data that is more than 20 years old and from a country where the
health care costs are known to be cheaper than in the US [122, 123] would likely lead
to misleading results. Even if these costs had been recent, it is not common practice
to transfer costs [97] across health systems due to structure and financing differences.
Other Limitations
One limitation of this paper was the exclusion of cosmetic and neurological complica-
tions from the base case analysis. These were included in scenario analysis and their
inclusion did lower ICER for every age. However, the results from these scenario
analyses are best to not be over-interpreted. There is still only a small body of
evidence about these other complications (compared to evidence for complications
like PHN). Additional data would be needed, specifically about the disutility and the
time spent in this health state before each should be included in the base case analysis.
As a result of the possible impact of these parameters, the base case analysis should
be seen as a the upper bound for the cost-effectiveness of the HZ vaccine. Another
limitation was truncating the model at age 100; this assumption may underestimate
the benefit of the vaccine. Despite the probability of death due to HZ being very low,
vaccinated individuals would be less likely to experience this event as they would
be less likely to experience HZ. Therefore, there is likely to be a bias against the
vaccination strategy due to the assumption of a truncated life expectancy as the
difference is QALYs would likely be slightly greater than what is reported in this
study.
Conclusions
This study was the first in the US to include the 50 – 59 age group alongside the 60+
age group. With the aid of collaborators at the CDC, the vaccine parameterization
should be the most realistic representation of how the vaccine behaves. The complex
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modeling structure shows the impact on health utility that can be attributed to
PHN. Using a threshold of $100,000 this research shows that the vaccine would
be cost-effective for women between the ages of 59 – 74 and 64 – 69 for men.
There are some policy implications that can be examined from the results. The
current recommendation from the ACIP is open-ended (i.e., 60 and above without a
stopping age). Results of the CEA as shown by Figure 2.4 and the cost-effectiveness
acceptability contours (Figures 2.15 – 2.16) show that the vaccine is not likely to be
considered cost-effective using a threshold between $100,000 – $150,000 for people
older than age 80. Further using this same threshold it is unlikely to be cost-effective
for people younger than 60 (at the very earliest age 55). Therefore, the results of
this research indicate that the open-ended recommendation may be recommending
vaccination over too wide of a range, and that there may be benefit to reducing that
age range.
These results give an indication of the most cost-effective range for vaccination for
men and women, but do not address the question of the optimal policy. Each ICER
assumes that the cohort does not assume a prior risk of HZ. Because this is a disease
that most are at risk for, it will be important to examine the decision to vaccinate or
defer when aiding future recommendations. Further, additional work may be needed
to determine the true values of vaccines waning and efficacy as both had a substantial
impact on the results. However, techniques like value of information should first be
used. While this research does provide an update to the cost-effectiveness of the
vaccine, further work should be done provide the best possible information to decision
makers for developing future recommendations.
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2.A Additional Figures and Tables
Age ∆ HZ ∆ PHN ∆ OC $ – VX Q – VX $ – no VX Q – no VX
50 162 11 5 466.69 15.597 297.60 15.596
51 169 12 5 467.10 15.272 299.84 15.272
52 176 14 6 467.22 14.945 301.85 14.944
53 183 15 6 467.03 14.617 303.63 14.616
54 190 17 6 466.54 14.286 305.15 14.285
55 198 18 7 465.71 13.954 306.41 13.953
56 206 20 7 464.56 13.620 307.39 13.619
57 213 22 8 463.06 13.286 308.09 13.285
58 221 24 8 461.19 12.950 308.48 12.949
59 228 26 9 459.02 12.613 308.53 12.611
60 235 28 9 456.61 12.272 308.19 12.270
61 240 31 10 453.98 11.928 307.45 11.927
62 245 33 10 451.19 11.581 306.29 11.580
63 247 35 10 448.28 11.232 304.68 11.230
64 248 36 11 445.32 10.880 302.64 10.878
65 247 38 11 442.38 10.527 300.17 10.525
66 243 39 11 439.52 10.173 297.28 10.172
67 238 40 11 436.81 9.821 293.99 9.820
68 230 41 11 434.19 9.469 290.28 9.468
69 220 41 10 431.62 9.118 286.13 9.116
70 209 41 10 429.04 8.766 281.52 8.765
71 196 41 9 426.39 8.415 276.45 8.414
72 183 40 9 423.64 8.064 270.93 8.063
73 168 39 8 420.76 7.715 265.02 7.714
74 153 38 8 417.71 7.370 258.73 7.368
75 138 36 7 414.75 7.028 252.11 7.027
76 123 34 6 411.53 6.691 245.16 6.690
77 108 32 6 408.00 6.357 237.84 6.356
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Age ∆ HZ ∆ PHN ∆ OC $ – VX Q – VX $ – no VX Q – no VX
78 94 29 5 404.19 6.028 230.24 6.027
79 80 26 4 400.07 5.705 222.38 5.705
80 68 24 4 395.670 5.389 214.30 5.388
81 56 21 3 391.00 5.081 206.05 5.080
82 44 18 2 386.10 4.781 197.67 4.780
83 34 15 2 380.87 4.489 189.14 4.488
84 26 12 1 375.21 4.202 180.38 4.201
85 18 9 1 369.35 3.930 171.84 3.930
86 13 7 1 362.87 3.671 163.41 3.671
87 10 6 1 355.91 3.424 155.11 3.424
88 7 5 0 348.87 3.189 146.97 3.189
89 5 4 0 341.84 2.966 138.99 2.966
90 3 3 0 334.84 2.754 131.15 2.754
91 2 2 0 327.85 2.552 123.42 2.552
92 1 1 0 320.80 2.357 115.73 2.357
93 0 0 0 313.47 2.168 107.96 2.168
Table 2.14: Intermediate model outcomes – Men. ∆: Number of cases prevented due to
vaccination.
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Figure 2.28: Vaccine Efficacy vs. Vaccine Waning Panel – Women. Contours represent ICER values of vaccination
vs. no vaccination.
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Figure 2.29: Vaccine Efficacy vs. Vaccination Cost Panel – Women. Contours represent ICER values of vaccination
vs. no vaccination.
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Figure 2.30: Vaccine Waning vs. Vaccination Cost Panel – Women. Contours represent ICER values of vaccination
vs. no vaccination.
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Figure 2.31: p(HZ) vs. p(PHN) Panel – Women. Contours represent ICER values of vaccination vs. no vaccination.
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Figure 2.32: p(HZ) vs. p(HZ – Any Pain) Panel – Women. Contours represent ICER values of vaccination vs. no
vaccination.
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Figure 2.33: p(HZ) vs. Vaccination Cost Panel – Women. Contours represent ICER values of vaccination vs. no
vaccination.
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Figure 2.34: p(PHN) vs. Vaccination Cost Panel – Women. Contours represent ICER values of vaccination vs. no
vaccination.
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Figure 2.35: Scenario Analysis – PHN Intercept – Men
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Figure 2.36: Scenario Analysis – PHN Intercept – Men – Zoomed
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Figure 2.37: Scenario analysis – other
complications – Women – probability.
White dots - base case analysis. Top
red line: p(comps) = lowest, Middle red
line: p(comps) = mean. Bottom red line:
p(comps) = highest.
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Figure 2.38: Scenario analysis – other
complications – Men – probability. White
dots - base case analysis. Top red
line: p(comps) = lowest, Middle red
line: p(comps) = mean. Bottom red line:
p(comps) = highest.
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Figure 2.39: Scenario analysis – other
complications – Women – costs. White
dots - base case analysis. Top red line:
cost = lowest, Middle red line: cost =
mean. Bottom red line: cost = highest.
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Figure 2.40: Scenario analysis – other
complications – Men – costs. White dots
- base case analysis. Top red line: cost
= lowest, Middle red line: cost = mean.
Bottom red line: cost = highest.
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Figure 2.41: Scenario analysis – other
complications – Women – QOL. White
dots - base case analysis. Top red line:
lost QOL = lowest, Middle red line: lost
QOL = mean. Bottom red line: lost QOL
= highest.
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Figure 2.42: Scenario analysis – other
complications – Men – QOL. White dots
- base case analysis. Top red line: lost
QOL = lowest, Middle red line: lost QOL
= mean. Bottom red line: lost QOL =
highest.
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Chapter 3
Markov Decision Processes:
One & Two Dose Administration
3.1 Introduction
The question of an optimal policy for the age of administering the herpes zoster
vaccine remains largely unanswered. Cost-effectiveness analyses have given some
indication of the most cost-effective age group (e.g., people ages 65 – 70) but results
vary across studies [59–61]. The optimal policy is of particular importance given that
vaccine efficacy and duration can change greatly depending on the age at vaccination.
Thus even marginal changes in the age of administration could affect the long term
outcomes and produce sub-optimal results if not administered at the correct time.
The objective of this chapter is to estimate the optimal timing of the vaccination
against HZ by answering the following two questions:
1. Conditional upon only one dose being available, at what ages is it optimal to
receive the HZ vaccine?
2. Conditional upon an individual having received the initial vaccine at any
previous age X, where X falls in the range of [50, 99], is it ever optimal for that
individual to receive a second dose of the vaccine?
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Utility and Background on Markov Decision Processes
This chapter will build on the results from Chapter 2 and utilize a different type of
decision analytic simulation model. In a state-transition model, only one decision
can be evaluated in each model iteration [124]. State-transition models can provide
information on a current decision but it is difficult to account for future decision
options, and outcomes. And, while these models are common, they can be less valuable
if there are many decisions required for a certain treatment, or if the same decision
needs to be evaluated at different time points. Therefore, using state-transition
models in those situations may lead to sub-optimal performance [125].
The Markov decision process (MDP) model, however, is a class of decision model
that allows for the consideration of multiple or sequential decisions over time. MDP
models are over 60 years old and come from the field of stochastic, dynamic opti-
mization [126, 127]. They have only recently been applied to optimal allocation of
medication or treatment policy problems in health care [128–133]. The MDP method
optimizes a dynamic policy over a particular decision objective. For example, the
method could determine the age of vaccination that maximizes the quality of life
gained or minimizes the costs incurred [128]. Thus, the MDP model could be used
to determine the optimal vaccination age that could help to minimize the burden of
disease.
Five sets of information are required for every MDP [125]:
1. Decision epochs
2. System states
3. Available actions
4. Rewards dependent on state and action taken
5. Probabilities dependent on state and action taken
Decision epochs are time points in the model when a decision on an action is made.
The time between epochs is called a period and these periods are analogous to cycles
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in state-transition models [124]. System states are the set of mutually exclusive and
collectively exhaustive states that define the outcomes in the model. Similar to a
state-transition model, transition probabilities are used to defined the movement
between the possible states of the model. Actions are the decisions that are made at
each decision epoch. Rewards (monetary or other) are assigned for the actions taken
at some epoch. When an action is selected the decision maker receives the award and
the “system evolves to a possibly different state at the next decision epoch” [125].
3.2 Methods
Two separate MDP models: 1) One Dose MDP; 2) Two Dose MDP, were created
to answer the the questions for this chapter. Each model and its methods will be
discussed in turn.
One Dose Model
Structure
An overview of the one dose MDP model is shown in Figure 3.1. In this model a
cohort is assumed to start at age 49, and an initial decision on vaccination is made
when reaching the first decision epoch at age 50 (t = 0). The MDP model has two
states: 1) Vaccinate (v); 2) Wait (defer vaccination) (w). Decisions are made at
annual decision epochs from age 50 (t = 0), to age 100 (t = 50). In choosing vaccinate,
the cohort gains immediate rewards for being vaccinated at that age. If the decision is
to wait, the cohort remains unvaccinated for 1 period (1 year), and faces the choice to
vaccinate or defer again at the next decision epoch. Data for the MDP model comes
from cohort state-transiton models similar to the models used in the cost-effectiveness
analysis in Chapter 2.
The cohort state-transition models (STMs) were constructed in R (v.3.2.3) to give
the lifetime costs and QALYs for a cohort who either receives the vaccine or develops
HZ at any age between 50 and 100. These costs and QALYs are the immediate
rewards that are associated with the states and actions of the MDP. Figure 3.1 is
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Figure 3.1: One dose MDP model
further deconstructed in Figure 3.2; this figure shows where the STM outputs are
implemented within the MDP. Any red triangle in Figures 3.1 and 3.2 implies a
terminal state; it is in these states where STM outputs are assigned. If one chooses to
vaccinate (v), then immediate rewards are collected. These rewards are the lifetime
costs and QALYs associated with vaccinating at that age. The vaccination STM,
shown in the top half of Figure 3.2, has four states: 1) disease free, 2) herpes zoster,
3) disease free 2, 4) death. In this model, the cohort starts as disease free and has the
chance to transition to HZ or death at the end of each model cycle. Cycle time for all
STMs was set to 1 year to match the period length of the MDP. HZ is an all-inclusive
health state that provides a cumulative estimate of the QALYs and costs with a case
of HZ, which may include PHN or ocular complications. A further description of this
STM is available in Appendix B.1 on page 208.
If the decision is wait (w), then the cohort is assumed to stay disease free for the
current model period, and has the chance of transition into HZ, death, or back to
disease free at the start of the next period (shown in the bottom half of Figure 3.2).
The lifetime costs and QALYs associated from developing HZ in the next period were
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derived from a HZ STM where a cohort starts in a HZ health state rather than a
disease free health state. Similar to the vaccine STM, this HZ health state provides a
cumulative estimate of the HZ, which can include PHN or ocular complications. The
reward for death in all models is assumed to be 0.
Figure 3.2: One dose MDP model breakdown. DF: Disease Free; HZ: Herpes Zoster,
DF-2: Disease Free 2; D: Death.
The one dose MDP model is governed by the optimal value function, shown by
Equation 3.1. In this equation Vt(st) is the optimal value function for the model at
time t (t = 1, ..., T ) in state s. The action set a at time t includes only two actions
that correspond to the states in the model: {v, w}. Rt(v) is the immediate rewards
gained from vaccinating at time t as determined by the vaccine STM. Rt(w) is the
immediate QALY reward gained for spending one cycle in a disease free state at time
t. Rt(w) is summed with the discounted lifetime rewards associated with dying, p(D),
or transitioning to HZ, p(HZ), in the next cycle (t + 1). Vt+1(st+1) is the optimal
value function at t+ 1. Vt+1(st+1) is initially set by the boundary condition of the
model, VT (sT ), at age 100. At age 100 (t = 50), Vt+1(st+1) = 0 and the probability of
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death, p(D), is 100%. Therefore, VT (sT ) is the optimal value function at the boundary
of the model and is the maximum between the immediate rewards for vaccinating and
not vaccinating at age 100; shown by Equation 3.2. The optimal value function at the
boundary is substituted for Vt+1(st+1) at age 99 (t = 49) and once this condition is
set, the model runs recursively from age 99 to age 50, updating Vt+1(st+1) each year.
Discounting in the model (shown by λ) was set to 3% (0.97)). Further information
on the STMs and the data used to generate them is available in the appendix on
page 208.
Vt(st) = max
at∈{v,w}
{
Rt(v), Rt(w) + λ
(
p(D|st, w)Rt+1(D)
+ p(HZ|st, w)Rt+1(HZ)
+ p(DF |st, w)Vt+1(st+1)
)} (3.1)
For all st and t = 1, ..., T − 1
VT (sT ) = max
aT∈{v,w}
{RT (v), RT (w)} (3.2)
Analysis Plan
The MDP was built using R (v.3.2.3). First, the STMs outputs were loaded into
the R environment. The MDP was constructed by programming Equation 3.1 using
the base language. Care was taken to ensure that there was continuity between the
structures of the MDP and the STM (i.e., that transitions were occurring at the
same time and that rewards were being assigned in the same way). To run the model
recursively, a loop was created that started the MDP at the boundary condition and
worked backwards through each age from 100 to 50 selecting the optimal decision at
each decision epoch. This method is known as backwards induction [125].
Table 3.1 provides the data used to generate the base case results of the one dose
MDP model. The data in this table is representative of women only; data for men
82
is given in at the end of the chapter appendix on page 115. Transition probabilities
for this model were taken from the data used for the cost-effectiveness analysis in
Chapter 2. The probability of death comes from the CDC life tables [98]; the model
assumes no death from zoster cases. The probability of developing HZ was determined
by using the logistic equation and its parameters presented in Table 2.2 on page 27.
The rewards for vaccination and HZ (Rt(v), Rt(HZ)), in Table 3.1 are expressed as
net monetary benefits (NMB). The STMs provided both lifetime costs and QALYs
and Equation 3.3 was used to convert those values into NMB, under an assumed
willingness-to-pay (WTP) of $100,000. The immediate reward for waiting (Rt(w))
was the baseline QOL for the cohort multiplied by the WTP [120].
NMB = WTP ×QALY − Cost (3.3)
Age Rt(v) Rt(w) Rt(HZ) p(HZ) p(D) p(DF )
50 1, 608, 177 82, 900 1, 571, 554 0.005 0.003 0.992
51 1, 577, 634 82, 600 1, 540, 585 0.005 0.004 0.992
52 1, 546, 759 82, 300 1, 509, 260 0.005 0.004 0.991
53 1, 515, 540 82, 000 1, 477, 528 0.005 0.004 0.991
54 1, 483, 918 81, 700 1, 445, 387 0.006 0.004 0.990
55 1, 451, 892 81, 400 1, 412, 821 0.006 0.005 0.990
56 1, 419, 445 81, 100 1, 379, 851 0.006 0.005 0.989
57 1, 386, 599 80, 800 1, 346, 547 0.006 0.005 0.988
58 1, 353, 414 80, 500 1, 312, 944 0.007 0.006 0.988
59 1, 319, 944 80, 200 1, 279, 128 0.007 0.006 0.987
60 1, 286, 263 79, 900 1, 245, 139 0.007 0.007 0.986
61 1, 252, 415 79, 600 1, 210, 993 0.007 0.008 0.985
62 1, 218, 411 79, 300 1, 176, 683 0.008 0.008 0.984
63 1, 184, 248 79, 000 1, 142, 186 0.008 0.009 0.983
64 1, 149, 893 78, 700 1, 107, 483 0.008 0.010 0.982
65 1, 115, 344 78, 400 1, 072, 663 0.009 0.011 0.981
66 1, 080, 679 78, 100 1, 037, 793 0.009 0.012 0.979
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Age Rt(v) Rt(w) Rt(HZ) p(HZ) p(D) p(DF )
67 1, 045, 967 77, 800 1, 002, 892 0.009 0.013 0.978
68 1, 011, 226 77, 500 967, 927 0.009 0.014 0.976
69 976, 425 77, 200 932, 899 0.010 0.015 0.975
70 941, 563 76, 900 897, 834 0.010 0.017 0.973
71 906, 659 76, 600 862, 836 0.010 0.018 0.971
72 871, 834 76, 300 828, 008 0.011 0.020 0.969
73 837, 181 76, 000 793, 421 0.011 0.022 0.967
74 802, 774 75, 700 759, 051 0.011 0.025 0.964
75 768, 585 75, 400 724, 866 0.011 0.027 0.962
76 734, 587 75, 100 690, 934 0.012 0.030 0.959
77 700, 836 74, 800 657, 307 0.012 0.033 0.955
78 667, 405 74, 500 624, 153 0.012 0.036 0.951
79 634, 449 74, 200 591, 550 0.013 0.040 0.947
80 602, 051 73, 900 559, 470 0.013 0.045 0.942
81 570, 178 73, 600 527, 872 0.013 0.050 0.937
82 538, 795 73, 300 496, 903 0.013 0.055 0.932
83 508, 036 73, 000 466, 827 0.014 0.062 0.925
84 478, 184 72, 700 437, 626 0.014 0.069 0.917
85 449, 214 72, 400 409, 361 0.014 0.077 0.909
86 421, 188 72, 100 382, 276 0.014 0.087 0.899
87 394, 347 71, 800 356, 389 0.014 0.098 0.888
88 368, 715 71, 500 331, 691 0.015 0.109 0.876
89 344, 269 71, 200 308, 123 0.015 0.122 0.863
90 320, 964 70, 900 285, 616 0.015 0.136 0.849
91 298, 725 70, 600 264, 044 0.015 0.151 0.833
92 277, 425 70, 300 243, 207 0.015 0.168 0.817
93 256, 864 70, 000 222, 802 0.016 0.185 0.799
94 236, 748 69, 700 202, 369 0.016 0.204 0.781
95 216, 615 69, 400 181, 200 0.016 0.223 0.761
96 195, 752 69, 100 158, 133 0.016 0.244 0.740
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Age Rt(v) Rt(w) Rt(HZ) p(HZ) p(D) p(DF )
97 173, 021 68, 800 131, 305 0.016 0.265 0.719
98 146, 563 68, 500 97, 570 0.016 0.287 0.697
99 113, 255 68, 200 51, 479 0.017 0.309 0.675
100 67, 686 67, 900 0 0 1 0
Table 3.1: One vaccine MDP input parameters – Women. WTP = $100,000.
Optimal Value Curve
To examine the impact of WTP on the optimal policy, an optimal value curve analysis
was conducted [134]. As WTP changes the optimal policy will also change; the
optimal value curve is used to show changes in expected costs and expected QALYs
as WTP changes. To generate this curve the following procedure was used:
1. Load raw cost and QALY data from the STMs needed for the MDP
2. Set WTP to 0
3. Use WTP to convert raw costs and QALYs to NMB for immediate MDP rewards
4. Run MDP
5. Save optimal policy
6. Increase WTP
7. If maximum WTP reached then stop; otherwise return to Step 3
This loop was completed for each WTP from $0 to $2,000,000 by $2,000 increments,
and each MDP provided an optimal policy for its corresponding WTP. Next another
procedural loop was conducted to determine only the costs and QALYs associated
with each optimal policy for each WTP. Each iteration of following loop produced
one set of costs and QALYs (a cost,QALY set) associated with the optimal policy at
a particular WTP.
1. Load MDP structure with raw costs and QALYs as rewards for actions (not
NMB)
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2. Load WTP
3. Load optimal policy associated with WTP
4. Run MDP where decisions are fixed based on loaded optimal policy
5. Record costs associated with optimal policy
6. Run MDP where decisions are fixed based on loaded optimal policy
7. Record QALYs associated with optimal policy
8. Save costs, QALYs, WTP, and optimal policy (one cost,QALY set)
9. Update WTP
10. Return to Step 3
This second loop was completed for all WTPs run in the first loop. This provided
a set of cost and QALY data that could be plotted. The data collected from these
loops provide information that can be used to visualize the changes in costs and
QALYs gained as WTP changes.
Sensitivity Analysis
I conducted two sets of sensitivity analyses, a method that examines how responsive
outcomes are to changes in parameter inputs and model assumptions, were completed.
First, I conducted a one-way sensitivity analysis by varying each of the model
parameters independently at the ends of their ranges to examine the effect on
outcomes. This identified the model parameters that the results were most sensitive
to. Inputs for the one-way sensitivity analysis are presented in Table 3.2.
I also performed second order Monte Carlo probabilistic sensitivity analysis
(PSA) to estimate the optimal policy given uncertainty of multiple model parameters
simultaneously. To accomplish this, I converted model inputs from discrete values to
distributions. For cost inputs, I utilized a gamma (Γ) distribution. For disutilities, I
assumed a beta (β) distribution. I then performed Monte Carlo simulations on the
STMs and used those results to perform independent MDP simulations to determine
the optimal policy. I used seeding to ensure the same variables were being used in
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Variable Base Lower Upper STM MDP
Vaccine – Initial Efficacy 0.00 -0.10 0.10 ×
Vaccine – Waning Rate 1.00 0.70 1.30 ×
p(HZ) – asymp – Women 19.277 15.382 24.033 × ×
p(HZ) – asymp – Men 13.935 11.148 17.418 × ×
p(PHN |HZ) – b1 1.772E-7 8.86E-8 3.544E-7 ×
p(OC|HZ) 0.00 -0.02 0.02 ×
Cost – HZ (without compli-
cations)
1934 1559 2287 ×
Cost – HZ with PHN † ×
Cost – HZ with OC 4163 2896 5543 ×
Cost – Vaccine 205.53 180.14 282.98 ×
Disutility – HZ (without
complication)
0.03 0.019 0.0415 ×
Disutility – HZ with PHN † ×
Disutility – HZ with OC 0.09 0.065 0.129 ×
Disutility – Vaccine Compli-
cations
8.397E-5 4.16E-5 1.68E-4 ×
Table 3.2: Inputs for one-way sensitivity analysis. OC: ocular complications. † – Age
dependent variables, tables with all data available on page 214. × in the table indicates
what model (STM or MDP) the variable is contained within.
each STM and MDP in the same iterations (e.g., STM and MDP PSA iteration one
share the same probability of HZ – prior to adjustment for vaccination). More detail
is available in the Appendix on page 212.
The results of the PSA were used to generate two pieces of information. First
results of the PSA were used to estimate the probability that vaccination was optimal
at any age. To accomplish this, individual MDP models were run for each Monte
Carlo iteration performed (e.g., 1000 Monte Carlo runs = 1000 MDP models). Once
all 1000 MDPs were run, an R code was developed that searched all 1000 policies and
determined which policies recommended vaccination at any age. The total number
of policies where vaccination was recommended was divided by the total number of
Monte Carlo iterations to determine this probability. Second, the same 1000 policies
produced by the MDPs were searched by age to determine the chance that a certain
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age would be selected into the optimal policy (from 0 - 100%). The total number of
times an age was selected into an optimal policy was divided by the total number of
Monte Carlo iterations (1000).
Variable Distribution
Vaccine – Initial Efficacy* N (0, 0.035)
Vaccine – Waning Rate** N (1, 0.12)
Probability – HZ** – asymp lnN (0, 0.099)
Probability – PHN** – b1 lnN (0, 0.295)
Probability – Ocular Complications* N (0, 0.01)
Cost – HZ Γ(106.14, 1/18.02)
Cost – PHN †
Cost – Ocular Complications Γ(41.96, 1/99.20)
Cost – Vaccine Γ(23.33, 1/7.5)
Cost – Vaccine Administration Γ(2196.6, 70)
Cost – Vaccine Severe Reactions Γ(18, 100)
Disutility – HZ β(24.39, 804.59)
Disutility – PHN †
Disutility – Ocular Complications β(16.4, 254.81)
Disutility – Common Vaccine Complications β(6, 6000)× (30/365)
Disutility – Severe Vaccine Complications β(2.13, 100000)× (30/365)
Table 3.3: Parameter distributions for PSA. * – A parameter was sampled and added
to base case parameter value. ** – A scaling factor for the parameter was sampled and
multiplied by the base value for that parameter. † – Age dependent distributions, table of
distributions available on page 218
Two Dose Model
There is currently no booster vaccine available for HZ. However, one study has
investigated the immunogenicity of a second dose of the HZ vaccine [135]. Given
that the vaccine is available for purchase and a first dose could have been given at a
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sub-optimal time in the past, it is important to consider if and when a person should
get a second dose. To answer this question I make the following assumptions for the
base case analysis. First, the second dose of the vaccine is not a booster vaccine.
Rather it is the administration of the original vaccine a second time. Therefore, it is
assumed to have the same risks and costs as the first dose. Second, I assume that the
second dose does not provide any additional benefit from remaining efficacy from the
first vaccine. For example, if a person is originally vaccinated at age 50, his/her first
dose is projected to last 12 years. If he/she was vaccinated with a second dose at age
57, there would be no added benefit from the extra five years of efficacy remaining
with the first dose. I relax this assumption in scenario analysis.
Structure
An overview of the two dose model is shown in Figure 3.3. This model is evaluated
in two pieces, each piece has two states: 1) Vaccinate/Vaccinate Again (v or va);
2) Wait (w). The model that covers the second dose decision was the first to be
evaluated, this is shown by the vertical arms in Figure 3.3 that begin with jv, where j
is an age from [50, 99]. Each of these arms is a MDP sub-model (second dose model)
that is evaluated independently. In these two dose models, it is assumed that the
cohort receives in first dose at age j. After this initial dose, each subsequent year the
choice must be made to either vaccinate again va, or wait. These second dose models
are governed by optimal value function in Equation 3.4. The notable differences
between Equations 3.1 and 3.4 are the the probability and reward for HZ. In the
second dose model, p(HZ|s, w, vj) is adjusted by the age when the initial vaccine
j was given and then adjusted by its waning function, shown by vj. Rt+1(HZ|vj)
is calculated from an R STM model that simulated the lifetime QALYs and costs
for people who developed HZ at some age Y given they had been vaccinated at age
j. This is further discussed in Appendix B.1. To evaluate the two dose MDP, 50
independent MDPs were run that evaluated all possible combinations of st and vj,
each conditional upon the initial age of the first dose j. Each of these MDPs started
at the boundary condition where age = 100, and worked recursively to the age of the
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first dose j.
Vt(st|vj) = max
at∈{va,w}
{
Rt(va), Rt(w) + λ
(
p(D|st, w)Rt+1(D)
+ p(HZ|st, w, vj)Rt+1(HZ|vj)
+ p(DF |st, w)Vt+1(st+1)
)} (3.4)
For all j, st and t = 1, ..., T − 1
VT (sT |vj) = max
aT∈{va,w}
{RT (va), RT (w)} (3.5)
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Figure 3.3: Two dose MDP model. White boxes indicate the age of initial vaccination.
Vertical arms from the white boxes are the second dose MDP models.
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Figure 3.4: Two dose MDP model – second
step
Evaluation of the two dose models
provided an update for the initial esti-
mates of the lifetime QALYs and costs;
shown in Figure 3.4 by blue squares. Us-
ing these new estimates of the lifetime
QALYs and costs conditional upon a sec-
ond vaccination being available at some
time in the future, Equation 3.1 was used
to evaluate the model shown in Figure
3.4. This provided an estimate of the
optimal policy of evaluating two doses
versus one dose.
Sensitivity Analysis
Sensitivity analysis was also performed in the two dose models. First, parameters of
interest from the one dose model were adjusted to the ends of their ranges to examine
the impact on the results. This helped identify if there were any parameters that
also greatly impacted the two dose model. I then performed first order Monte Carlo
PSA with the model to estimate the optimal policy given the uncertainty of multiple
model parameters simultaneously. For this analysis, I utilized the same procedure
as for the one dose model. In brief, I ran PSA on the STM models used as inputs
for the two dose MDP. I then adjusted shared parameters in the MDP by the same
values and ran a separate MDP for each set of PSA results from the STMs. More
detail is available in the Appendix on page 212.
The results of the PSA were used to generate two pieces of information. The 1000
policies per age of initial vaccination were searched by age to determine the chance
that a certain age would be selected into the optimal policy for the second dose (from
0 - 100%). The total number of times an age was selected into an optimal policy
was divided by the total number of Monte Carlo iterations (1000). I performed this
analysis of PSA data for the model structures in Figure 3.3 and 3.4. This analysis for
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Figure 3.3 provided the probability that an age for the second dose would be selected
into an optimal policy conditional upon the age when the first dose was received.
The analysis using the structure in 3.4 provided the probability for the initial age of
vaccination to be selected into a policy where two doses would be optimal compared
to one.
Scenario Analysis
One benefit of modeling studies is the ability to test scenarios that may be too
difficult to test with clinical trials or observational studies. For the two dose model,
I ran two scenario analyses to examine research questions that have not been well
researched using other methods. First, as previously discussed, there is no indication
that a second dose of vaccine provides additional benefits [135]. To examine the
difference that a possible boost in efficacy could create I tested two scenarios. In
these scenarios the initial efficacy of the second dose was increased by a fixed amount.
In the first case, I assume that the initial efficacy was increased by two percentage
points above its expected value at some age (e.g., V Eij +0.02). In the second analysis,
I increased the initial efficacy by five percentage points above its expected value (e.g.,
V Eij + 0.05).
For the other scenario analysis, I examined the policy regarding a new HZ vaccine.
A new vaccine in development and early data suggests that it will have a much higher
initial efficacy than the current vaccine [136]. No data are currently available on
the waning of this vaccine. Given the new vaccine may be a large improvement over
the current vaccine, I sought to determine at what age a person should receive this
new vaccine, given that he/she may have had the current vaccine at some previous
age. To do this, I made the following assumptions. First, the vaccine has an initial
efficacy of 97% across all age groups [136]. Second, the new vaccine will wane at
the same rate as the current vaccine. Third, the new vaccine does not provide any
additional protection against PHN. Forth, as no price has been set, I assume that
the new vaccine will cost the same at the current vaccine. Finally, I assume the new
vaccine as the same safety profile as the current vaccine (i.e., the same QALY loss).
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Vaccine Parameterization – All Models
In all (non-scenario) analyses the initial efficacy and waning of the vaccines protection
against HZ and PHN were assumed to to be the same as for the cost-effectiveness
model in Chapter 2. The protection of the vaccine was comprised of two parts.
First, the initial efficacy of the vaccine (β0jHZ ). This was defined as the efficacy
from the time of the vaccination through the first year (t = [0, 1)); j is the age of
vaccination and t is measured in years. Second, the waning of the vaccine. Vaccine
waning was assumed to occur from the time of the vaccination through the time
when the vaccine provided no further protection benefit, (t = [0, X]), where X is
some number of years in the future. These component pieces were combined using
the form of a linear equation (y = mt + b) to create the age specific efficacy and
waning of the vaccine (V Eij). That is, the initial efficacy was assumed to be the
intercept (b), the waning was assumed to be the slope (m), t was the number of years
vaccinated (t = [0, X]), and y was the protection of the vaccine against HZ. These
components are not strictly linear, rather they were fit using restricted cubic spline
functions (RCS) and then combined using this equation form. The minimum value
for vaccine efficacy was 0%; that is, the vaccine could not have a negative effect. Data
on the initial vaccine efficacies and waning over time came from from clinical trial and
observational data [20–22,51,78] and were combined using statistical methods [19].
More detail on how this data was fit and combined is available in Appendix A.4 on
page 185. Equation 3.6 shows the equation used to model vaccine efficacy and waning,
where i is the number of years vaccinated and j is the age of vaccination.
V EijHZ = β0jHZ + β1i
+ β2 max(i, 0)
3
+ β3 max(i− 1, 0)3
+ β4 max(i− 2, 0)3
+ β5 max(i− 7, 0)3
(3.6)
This model also assumed the same base case initial protection against PHN as the
cost-effectiveness analysis. There is some evidence that the vaccine provides additional
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protection against PHN beyond the reduction in HZ incidence [22]. This data was
used to provide an estimate of the initial additional protection benefit of the vaccine
against PHN, where additional protection is defined as any reduction beyond what
can be attributed to a reduction in HZ incidence. However, available data only covers
the initial additional protection against PHN (β0jPHN ) from t = [0, 1) and there is
unfortunately no data on how this additional protection benefit wanes with time.
Therefore, the assumption was made that the additional protection benefit against
PHN lasts only as long as the protection against HZ incidence. I also assume that the
the additional protection wanes at the same rate as the vaccines protection against
HZ; this was accomplished using Equation 3.7. I finally assume that the vaccine
provides a minimum of 0% extra protection against PHN. At 0% additional protection,
an individual who was vaccinated would have a same likelihood of acquiring PHN
given a HZ infection as someone without the vaccine.
V EijPHN =
β0jPHN ×
V EijHZ
β0jHZ
if β0jHZ > 0
0 if β0jHZ = 0
(3.7)
Model Validation
Validation of the models was done in two steps. The STMs were first validated to
ensure they were producing the correct data. Next the MDP was validated to ensure it
was using the data correctly. To validate the STMs I first set all baseline QOL to 1.0,
removed the disutilities associated with the health states, and removed the discount
rate. I then performed simulations with different age groups and compared the results
of the model to the CDC life tables [98]. This procedure provided a check that the
cohorts in the model were dying at or close to the expected rate as the removal of
QOL and discounting provides an estimation of remaining life-expectancy. Next, I ran
a cost-effectiveness simulation between the arms of the STM models to further test
the results. To do this, I removed the costs and disutilities associated with the vaccine
from the base case model. I also changed the starting state of the HZ STM to ensure
that every person started as disease free. Under these circumstances the vaccine was
95
predicted to dominate the choice of no vaccination for every age from 50 – 93 and be
indifferent between 94 – 100 (the vaccine is assumed to have no benefit after age 93,
as shown in Figure 2.2.) Finally, to ensure that the vaccine equations were entered
into the model correctly, I selected different ages and numbers of years vaccinated
and manually performed the calculations on what the probability of an HZ or PHN
should be. I then changed the VX STM in R to reflect these scenarios, to ensure that
the probabilities calculated by the model matched the probabilities I had calculated.
Data from STMs was then implemented into the MDP structure. To validate the
MDP model, I first removed the cost and disutility associated with vaccination. I
then changed the initial efficacy function from the restricted cubic spline model to a
linear model that predicted 100% efficacy at age 50 and 0% efficacy at age 100 (thus,
2% absolute decrements per year). Under this scenario, there was was no cost or
QALY penalty associated with getting vaccinated, and the vaccination (in terms of
efficacy) would be less optimal (in terms of initial efficacy and durability) each year.
Therefore, it was predicted that the model should always select the vaccinate option
as vaccination will always have benefit (expect at age 100), it will be free of cost
and QALY penalties, and each earlier age would confer more benefit than the next
later age (i.e., there would be no reason to delay vaccination). I also utilized print
statements within the code to ensure that the equations were running correctly and
using the correct probabilities. Finally, to verify the results, I built a MDP model
using Microsoft excel and data from Table 3.1 to calculate the policy manually; I
then compared those results to the MDP simulation built in R.
3.3 Results
Model Validation
The results from the model validation are presented in Tables 3.4 – 3.6. Table 3.4
shows the comparison of life expectancy in the model (calculated by setting the
background health utility to 1.0 for all ages and removing the discount rate). There is
a difference in the life expectancy between the CDC life tables and the life expectancy
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Age Life Expectancy – Model Life Expectancy – CDC [98]
55 28.80 28.80
65 20.42 20.30
75 13.06 12.90
85 7.17 6.90
95 3.31 3.30
100 1* 2.3
Table 3.4: Model validation – life expectancy check – Women. *People at age 100 in the
model are set to only live 1 year
produced by the model. The biggest difference is at age 100, where the CDC life
tables predict a life expectancy of 2.3 years and the model estimates life expectancy
of 1 year. The main difference between these two estimates is that in the STM the
probability of death was set to 100% at age 100. Table 3.5 shows the comparison
between V EijHZ as calculated by hand compared to the values calculated within the
R STMs. For consistency, I used the same scenarios as the cost-effectiveness model
in Chapter 2. All hand calculated values match the values produced by R indicating
that the vaccine efficacy was implemented into the model correctly. Finally, Table
3.6 shows data from an analysis where the costs and disutilities associated with the
vaccine were removed. As predicted, the option to vaccinate dominated the do not
vaccinate option for every age between 50 – 93 (where the vaccine had some benefit)
as demonstrated by the negative ICERs (due to less cost with more effect). When the
model was indifferent between the options from ages 94 – 100 as the vaccine confers
no benefit but also presents no risk or cost to the recipient. Figure 3.5 shows the
results of the MDP validation. Here, as predicted, the model selected vaccination
as the optimal choice at every age. This indicated the the code for the model was
making the correct choices based on the input data it received.
One Dose Model
The results from the base case analysis for women are presented in Figure 3.6.
Assuming a WTP of $100,000, the model recommends vaccination between the ages of
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Scenario V EijHZ – Calculated V EijHZ – From R
j: 50, i: 0 0.7814 0.7814
j: 55, i: 10 0.1322 0.1322
j: 60, i: 4 0.4762 0.4762
j: 65, i: 7 0.2769 0.2769
j: 70, i: 2 0.4304 0.4304
j: 75, i: 8 0.0000 0.0000
j: 80, i: 3 0.1245 0.1245
j: 85, i: 5 0.0000 0.0000
j: 90, i: 0 0.0950 0.0950
Table 3.5: Model validation – vaccine efficacy check
Age VX Q VX C NV Q NV C I.C I.Q I.Analysis
50 16.09 340.22 16.09 384.75 -44.53 0.001 (Dominates)
55 14.52 344.82 14.52 401.65 -56.83 0.001 (Dominates)
60 12.87 338.88 12.87 409.80 -70.91 0.002 (Dominates)
65 11.16 327.20 11.16 407.46 -80.26 0.002 (Dominates)
70 9.42 316.64 9.42 392.55 -75.91 0.002 (Dominates)
75 7.69 305.20 7.69 363.90 -58.69 0.002 (Dominates)
80 6.03 286.51 6.02 322.00 -35.49 0.001 (Dominates)
85 4.50 256.47 4.50 269.74 -13.27 0.0005 (Dominates)
90 3.21 210.00 3.21 214.18 -4.18 0.0001 (Dominates)
94 2.37 167.84 2.37 167.84 0 0 (Indifferent)
100 0.68 0 0.68 0 0 0 (Indifferent)
Table 3.6: CEA validation results. VX: Vaccine arm, NV: No Vaccine arm, C: costs, Q:
QALYs, I.C: Incremental costs, I.Q: Incremental QALYs, I.Analysis: Incremental analysis,
denotes if vaccination strategy dominates no vaccination strategy.
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Figure 3.5: Optimal policy – validation
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Figure 3.6: Optimal policy – one dose
model – Women
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Figure 3.7: Optimal policy – one dose
model – Men
66 – 77. Taking the perspective of a 50 year old woman (the age at the first decision
epoch), following the optimal policy would mean vaccinating at age 66 and would
produce a net monetary benefit of approximately $1.6 million. The results of the
optimal policy for men are presented in Figure 3.7. Assuming a WTP of $100,000,
the model recommends vaccination between the ages of 66 – 74.
Figure 3.8 presents the results from the optimal value curve for women. This
analysis takes the perspective of a 50 year old woman. Assuming a WTP of $0, it
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Figure 3.8: Optimal value curve – Women. WTP / QALY is written above curve points.
would never be optimal to vaccinate any women and the expected lifetime discounted
costs of that policy would be approximately $375 per person; no additional QALYs
would be gained. As the WTP increases to $56,000 age 67 would be the first age
where vaccination is recommended. Following this policy would lead to an increase of
approximately 10 QALYS for 10,000 50 year olds and an expected lifetime cost of
$440 per person. As the WTP increases, the optimal policy changes to recommend
vaccination at earlier ages as shown by Figure 3.8. This pattern plateaus at age
62 under a WTP of $1,028,000. The figure shows that vaccination at earlier ages
(e.g., 60 or 61) produces higher costs and lower QALYs, thus these policies are
dominated. Using the base parameter values, for women, age 62 is the youngest age
where vaccination would ever be recommended. The optimal value curve for men is
shown in Figure 3.17 in the end of chapter appendix on page 116. This curve shows
a similar pattern to the optimal curve for women. For men, the WTP is higher for
initiating vaccination at newer ages. The lowest WTP is $72,000 for vaccination at
age 67. The other main difference is that age 61 is the lowest age recommended for
vaccinating men at a WTP of $1,470,000.
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Sensitivity Analysis
Figure 3.9 shows the results from the one-way sensitivity analysis for women. Overall,
the model was robust to changes in most parameters. At a WTP of $100,000 the
earliest age where vaccination would be recommended is 64; this assumes that the
vaccine is waning at the slowest possible rate (30% slower). Based on deviation
from the base case (either direction), vaccine efficacy, vaccine waning, vaccine cost,
disutility of PHN, and p(PHN |HZ) had the most effect on the policy. For women,
the latest initial age for vaccination is 67, this occurs if the vaccine is expensive,
the initial efficacy of the vaccine is lower (-10%), or the vaccine is waning at the
fastest possible rate (30% faster). Figure 3.18 on page 117 shows the results of the
one-way sensitivity analysis for men. The model for men is most sensitive to, based
on deviation from the base case (either direction), vaccine efficacy, vaccine waning,
vaccine cost, disutility of PHN, p(PHN |HZ), and p(HZ). At the fastest waning
rate, the lowest initial efficacy, the highest vaccine cost, and the lowest probability of
PHN given HZ, the optimal policy does not recommend vaccinating men at any age.
The results from the probabilistic sensitivity analysis are shown in Figures 3.10 –
3.11. Figure 3.10 shows the probability (for men and women) of vaccination being
recommended at any age. For men, the PSA shows that in approximately 23% of
simulations, the optimal policy would not include vaccination at any age at a WTP
of $100,000. For women, this probability drops to approximately 9%.
Results from Figure 3.11 are to be interpreted as the probability from 0 – 100% of
any one age being selected into the optimal policy for women. Figure 3.11 shows the
results assuming WTP was fixed at $100,000. At this WTP the model suggests that
ages 63 – 85 have some probability of being selected into the model. Ages 67 – 71
have more than an 85% chance of being selected; age 68 has the highest probability
of any ages of being selected into an optimal policy. Figures for men can be found
in the appendix at the end of the chapter appendix on page 118. For men, the age
range extends from 62 – 84; age 68 also has the highest probability of being selected.
However, none of the ages in the range has over an 75% chance of being selected.
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Figure 3.9: One-way sensitivity analysis results – Women. Blue line indicates the base
case age range. WTP = $100,000/QALY
Two Dose Model
The results from the base case analysis for the two dose model are presented in Figure
3.12. This figure provides the results for women only; the figure for men can be found
at the end of chapter appendix on page 119. For women, results show that receiving
a second dose is optimal if an individual was initially vaccinated between the ages
of 50 – 67. Using base case parameter estimates it is never optimal to administer
the booster vaccine until the original vaccine has been exhausted completely. For
men, receiving the second dose would only be optimal if the individual was originally
vaccinated between the ages of 50 – 63.
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Figure 3.11: Probabilistic sensitivity analysis – Women – WTP: $100,000
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Figure 3.13 shows the policy for women when considering if it is ever optimal to
have a two dose policy compared to a one dose policy. Results suggest that it would
be optimal for women between the ages of 62 – 67 to receive two doses of the HZ
vaccine. If the first dose was administered between 62 – 67, then, using Figure 3.12 it
would be optimal to receive the second dose at between the ages 72 – 76 (depending
on the age of the first dose). Figure 3.21 on page 120 shows the policy for men when
considering if it would ever be optimal to receive two doses of the vaccine. Results
suggest that, under base case assumptions, it would never be optimal to recommend
a two dose policy for men.
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Figure 3.12: Optimal policy – two dose model – Women
Sensitivity Analyses
Results from the one-way sensitivity analysis are presented in the end of chapter
appendix on pages 121 – 123. The one-way sensitivity analysis shows that the second
dose is also responsive to some of the key parameters in the one-way sensitivity
analysis from the one dose model. The response of the second dose follows the same
pattern as the one dose model. If the vaccine if more efficacious, wanes slower, or
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Figure 3.13: Optimal policy – two dose model, second step – Women
the probability of PHN is higher, the second dose is recommended over a wider
range. If evaluated using the model structure from Figure 3.4, it becomes optimal
to recommend the two dose compared to one dose policy over a wider age range.
Conversely, if the vaccine has worst parameters (i.e., faster waning or lower efficacy)
or the probability of PHN is lower, then the policy space for a second dose is reduced,
and a two dose policy is never optimal compared to a one dose policy.
Figure 3.14 shows a heat map of the probability of an age of the second dose
being selected into the optimal policy conditional upon the initial age of the first dose.
This figure is specific to women only. Based on Figure 3.14, ages 67 – 73 have the
highest probability of being recommended for an optimal policy for the second dose
with a probability of between 80 – 89%. The range of ages for the second dose for
women extends from 64 – 84, depending on the age of the initial dose. Ages 81 – 84
never have more than a 19% chance of being selected into an optimal policy. Figure
3.34 on page 124 shows the PSA results for men. Similar to the one dose PSA, there
is less chance for the second dose to be optimal at any age. For men, ages 67 – 70
have the greatest chance of being selected into an optimal policy with a probability
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Figure 3.14: Probabilistic sensitivity analysis – two dose model – Women
of between 70 – 79%. The range of ages for a second dose for men extends from 64 –
83. Ages 81 – 83, regardless of the age of the initial vaccine have less than a 10%
chance of being selected into an optimal policy.
Figure 3.15 shows the probability, for women, of a single age being selected into
an optimal two dose policy. The ages on this plot are when the first dose would be
given. Therefore, for women, ages 54 – 70 all have some probability of being selected
into a policy where it would be optimal to vaccinate with two doses. Age 62 has the
highest probability of any of the ages to be selected into a policy, with approximately
a 55% chance. Ages 61 – 65 all have over a 40% chance of being selected into an
optimal policy. The same figure for men is presented on page 124. For men, ages 55 –
69 have some chance of being selected into an optimal two dose policy. Age 62 has
the highest chance at approximately 32%. Ages 61 – 64 have a 25% or greater chance
for being selected into a policy that would recommend two doses versus one.
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Figure 3.15: Probabilistic sensitivity analysis – two dose model, second step – Women
Scenario Analyses
The results for the scenario analysis assuming a higher initial efficacy for the second
dose are available in Figures 3.36 – 3.39 on page 125. Compared to the base case
figures, the scenario analysis shows that if you assume a two percentage point increase
in initial efficacy for the second dose, the second dose is recommended at more ages
compared to the base case analysis. Increasing the initial efficacy by five percentage
points above base case further increases the policy space. When examining the
optimality of a two dose vs. one dose policy, increasing the initial efficacy results
in the two dose policy being optimal over a wider age range. Figure 3.16 shows the
results of the scenario analysis of determining the age that the new vaccine should
be given as a second dose conditional upon the current vaccine being given at some
previous age as a first dose. The earliest recommended age for a second dose with
the new vaccine is 69; this is four years after the earliest recommended age of the
second dose when using the current vaccine. For any women who were vaccinated at
age 80 or older with the current vaccine, it would be optimal to vaccinate with the
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Figure 3.16: Scenario analysis – two dose model, new vaccine – Women
new dose the following year. The policy space for receiving a second dose with the
new vaccine is much larger than the policy space for receiving a second dose of the
current vaccine.
3.4 Discussion
This research determined the optimal policy for the HZ vaccine for women and men.
As it is difficult to use state-transition models to account for multiple decisions or
sequential decisions over time, a MDP model was utilized to decide when to vaccinate
women and men. The model made decisions at annual decision epochs for a cohort
starting at age 49. This research also examined the opportunity of receiving a second
dose of the herpes zoster vaccine given that the original dose may have been given at
some time in the past.
In the base case analysis, results suggest that age 66 is the first age recommended
for vaccination. For women, there are more ages where vaccination is recommended
compared to men, (66 – 77) and (66 – 74) respectively. Some possible explanations
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for the differences are life expectancy and disease incidence. Women have a longer
life expectancy than men [98]. Therefore, recommending vaccination at later ages
for women could be because more women are likely to be alive in those later years.
Women also have an increased risk of disease compared to men (see Figure A.1 on
page 178). Thus, more women are likely to be alive and those who are alive are more
likely to get the disease than their male counterparts.
When examining the one-way sensitivity analysis there are no scenarios when
the vaccine is not recommended at some age for women. Conversely, there are four
situations in the one-way sensitivity analysis where no vaccination is the optimal
policy for men (fastest waning speed, lowest initial efficacy, lowest probability of
PHN, highest vaccine cost). The probabilistic sensitivity analysis also shows that
there are more scenarios where the vaccine would not be optimal for men compared
to women (see Figure 3.10). From the one dose model it is evident that the vaccine is
more likely to be beneficial under more circumstances for women than for men. This
finding is consistent with the results of the cost-effectiveness analysis in Chapter 2.
Two Dose Model
The results from the two dose model match the same trend presented by the one dose
model. In the base case analysis the objective was to determine if and when a person
should receive a second dose conditional upon having received the initial dose at some
time in the past. The results for women show that it would be optimal to receive the
second dose over a wider range of ages compared to men. When the data from this
question was used to determine if there were policies where it was optimal to ever
receive two doses compared to one; there were ages where it was optimal for women
to receive two doses (62 – 67). However, under the base case assumptions, it was only
ever optimal for men to receive one dose even when a second dose was available.
The PSA for the two dose models provides some further insight into the two dose
recommendation for men versus women. In comparing the two heat maps for the
determining the probability of an age for a second dose being recommended given
vaccination at some first age (Figures 3.14 and 3.34), women are much more likely to
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have a second dose recommended over more ages. For example, if the initial dose of
the HZ vaccine was given at age 50, for women ages 67 – 73 have a 80 – 89% chance of
being selected as part of an optimal policy for the second dose. For men, ages 67 – 70
were the most likely to be selected with a probability of 70 – 79%. Similar to the one
dose model, the PSA suggests that that second dose is more likely to be recommended,
and more likely to be recommended over a wider age range for women than men.
When examining the PSA for the two dose policy compared to the one dose policy,
the results show that the two dose policy would be optimal for women approximately
50% of the time. For men it would only be optimal 30% of the time (See Figures 3.15
and 3.35). Because women are more likely to live longer than men [98], they are more
at risk for the disease, and are more likely to develop complications (due to increased
life expectancy and increased probability of complications with age), it makes sense
that it would be more likely to recommend a second dose for women so that they are
covered during the periods when they are most at risk.
The results of this research also highlight the importance of modeling studies.
There has only been one clinical study that has examined the impact of receiving a
second dose [135]. Levin et al examined the impact of the second dose 10 years after
receiving the first dose. Their study did include the comparison of patients who were
receiving an initial dose, however the metric of efficacy was cellular response to the
vaccine. While cellular responses have been shown to be able to predict efficacy in the
zoster vaccine [137], clinical trial or long-term observational data on the protective
effect of a second dose is not available. Levin et al [135] did not show a significant
difference in the cellular response between those who were receiving the second dose
10 years after the initial dose and those who were receiving the vaccine for the first
time. Their study was also restrictive to a sample of people age 70 and older. In this
research, we show that assuming the second dose of the vaccine confers no additional
protection (as the results presented by Levin et al [135] suggest) that the second
dose could still be optimal to receive for women. Further, this research examines the
results assuming the option to get a second dose at any time after the first dose. In
their paper, Levin et al [135] call for further research to be done on the multiple dose
question to determine the benefits of the receiving the second dose. If the objective
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of future studies is to determine the potential benefit of the second dose, we have
shown, using a modeling study, that even if the second dose confers no additional
benefit there is still a 50% chance for women and a 30% for men that receiving two
doses of the vaccine would be optimal. If further studies found that the second dose
produced more benefit, the range of ages for the second dose would likely increase, as
shown by the scenario analysis.
Limitations
This study does have limitations. The MDP and its state-transition models were
run in annual epochs and cycles. This was in part done for simplicity but also to
reflect what could be actual policies. The cost-effectiveness in Chapter 2 was run in
monthly cycles and shorter cycles should give a better estimate of the durability of
the vaccine. That is, if the vaccine were to last seven years and one month in a model
that uses monthly cycles, it would last a full eight years in a model that uses annual
cycles. Therefore, the waning models used in this research may slightly overestimate
the benefit of the vaccine. However, any additional benefit gained by the choice of
annual cycles should never be greater than 11 months. Further, this additional benefit
should be minimal (estimated at less than 2%). The choice of annual cycles does more
accurately reflect the policy space for the vaccine. If the MDP were run in monthly
epochs, the model could have suggested that it would be optimal to vaccinate at 65
years and 8 months (for example). While this may more optimal than vaccinating
at 66 years of age, it would be unlikely to reflect an actual policy. The STMs also
uses a collapsed health state for HZ; all potential complications occur within this
HZ health state. The results from the CEA in Chapter 2 used a more complicated
model, but results show that the model was robust to small changes in within the
PHN state. For simplicity, the structure was collapsed for this paper. While this may
have impacted the results, sensitivity analysis showed that the MDP was only slightly
impacted by the changes in costs and utilities of PHN. Similar to the the CEA, the
probability of PHN had one of the biggest impacts on the results. Therefore, while
the collapsed health state may not provide as accurate of results, it did provide a
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similar pattern of results and make model construction much simpler, which aided in
ability to perform PSA on both the one and two dose models. The uncertainty in the
parameters is also a limitation of this research. However, the PSA and the sensitivity
analyses help to address these concerns and show what parameters the model is most
sensitive and robust to. The PSA is of particular importance as it helps to narrow
show the likely range of the optimal policy for both men and women.
Policy Implications
The results from this model have important policy implications. In the CEA presented
in Chapter 2, I found that the vaccine is unlikely to be cost-effective (at a WTP of
$100,000) for people below age 60 and greater than age 80. In this analysis, the MDP
model narrows that range while simultaneously accounting for the risk of deferring
vaccination. The MDP shows (based on Figures 3.6 – 3.7) that the optimal range
is 66 – 77 for women and 66 – 74 for men. This analysis agrees with the CEA that
the vaccine is likely to provide more benefit to women, however it also shows that
delaying the start of vaccination until the mid-to-late 60s is more optimal even if
the vaccine is considered cost-effective for women in their early 60s (as shown by the
CEA). The Monte Carlo simulations for the MDP further support the decision to wait
until the mid-to-late 60s to vaccinate. This is evidenced by age 65 being included in
less than 50% of all optimal policies for women, with ages 64 and 63 being included
in less than 15% of all optimal policies; results for men share a similar pattern. Given
the results of this analysis, putting a cap on the recommendations at (or near) age 80
moving the starting age to (or near) 66 would provide a more optimal vaccination
policy than the current policy. It is also evident that a second dose of the current
vaccine may be valuable to consider for women, especially for those women who may
have received their first dose at a sub-optimal time. Finally, while the new vaccine
has not come to market yet, the two-dose MDP shows that it will likely be optimal
for women and men to receive this new vaccine as a second dose even if the current
vaccine has already been given.
The MDP is important as it provides policy-makers with an optimal policy (i.e.,
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a clear start and stop age). It is important to note that STMs could be setup to
determine the most optimal age of vaccination by comparing all possible vaccination
ages against one another for a cohort starting at age 50 (i.e., 50 different options).
However to determine the optimal policy (not just the optimal age) using STMs
would require 250 different simulations (in theory) as there are 50 decision epochs in
this model, each with two actions. When expanding the problem to include a second
dose it becomes apparent that an STM is likely not a reasonable solution. Therefore,
the MDP and the CEA should be seen as complements to one another. The CEA
can provide insight as to the possible range for a policy and the MDP can provide a
means to optimize that range in an efficient manner.
Conclusions
This paper shows that the vaccine is likely to be optimal over a wider range for
women than men, similar to the cost-effectiveness analysis of Chapter 2. Based on a
search of the literature, this is the first paper, to my knowledge, that uses a MDP
structure to evaluate the question of multiple vaccine doses. Further, this paper adds a
probabilistic sensitivity analysis for both the one and two dose questions, accomplished
in part due a simple model structure. This is uncommon due to complications with
probabilistic sensitivity analysis with MDPs [138]. Results indicate that there is likely
to be a stopping time for both men and women. Current ACIP recommendations
are open-ended (i.e., there is no stopping age); this research is potentially valuable
for future recommendations given that it shows a narrower range where the vaccine
is most likely to be optimal. Finally, similar to the cost-effectiveness, the vaccine
parameters (efficacy and waning) had the biggest impact on the optimal policy. Future
research on these parameters may be necessary to make the best recommendations
possible.
113
3.A Additional Figures and Tables
Age Rt(v) Rt(w) Rt(HZ) p(HZ) p(D) p(DF )
50 1, 576, 803 85, 900 1, 538, 623 0.004 0.005 0.991
51 1, 545, 038 85, 700 1, 506, 499 0.004 0.006 0.990
52 1, 513, 013 85, 400 1, 474, 199 0.004 0.006 0.990
53 1, 480, 824 85, 200 1, 441, 664 0.004 0.007 0.989
54 1, 448, 404 84, 900 1, 409, 012 0.005 0.007 0.988
55 1, 415, 870 84, 700 1, 376, 180 0.005 0.008 0.987
56 1, 383, 160 84, 400 1, 343, 281 0.005 0.008 0.986
57 1, 350, 387 84, 200 1, 310, 184 0.005 0.009 0.986
58 1, 317, 412 83, 900 1, 276, 912 0.006 0.010 0.985
59 1, 284, 274 83, 700 1, 243, 292 0.006 0.010 0.984
60 1, 250, 792 83, 400 1, 209, 395 0.006 0.011 0.983
61 1, 217, 037 83, 200 1, 175, 120 0.006 0.012 0.982
62 1, 182, 907 82, 900 1, 140, 599 0.006 0.013 0.981
63 1, 148, 534 82, 700 1, 105, 793 0.007 0.013 0.980
64 1, 113, 872 82, 400 1, 070, 890 0.007 0.015 0.979
65 1, 079, 123 82, 200 1, 035, 905 0.007 0.016 0.977
66 1, 044, 295 81, 900 1, 001, 037 0.007 0.017 0.975
67 1, 009, 586 81, 700 966, 165 0.008 0.019 0.974
68 974, 876 81, 400 931, 337 0.008 0.020 0.972
69 940, 212 81, 200 896, 451 0.008 0.022 0.970
70 905, 492 80, 900 861, 623 0.008 0.024 0.968
71 870, 827 80, 700 826, 770 0.008 0.026 0.966
72 836, 146 80, 400 792, 150 0.009 0.028 0.963
73 801, 703 80, 200 757, 759 0.009 0.031 0.960
74 767, 492 79, 900 723, 835 0.009 0.034 0.957
75 733, 749 79, 700 690, 233 0.009 0.037 0.954
76 700, 333 79, 400 656, 992 0.009 0.041 0.950
77 667, 272 79, 200 624, 234 0.010 0.045 0.946
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Age Rt(v) Rt(w) Rt(HZ) p(HZ) p(D) p(DF )
78 634, 708 78, 900 592, 095 0.010 0.049 0.941
79 602, 766 78, 700 560, 559 0.010 0.054 0.936
80 571, 431 78, 400 529, 821 0.010 0.060 0.930
81 540, 898 78, 200 499, 867 0.010 0.067 0.923
82 511, 154 77, 900 470, 697 0.011 0.073 0.916
83 482, 188 77, 700 442, 038 0.011 0.081 0.909
84 453, 747 77, 400 414, 942 0.011 0.091 0.898
85 426, 874 77, 200 389, 027 0.011 0.101 0.888
86 401, 189 76, 900 364, 402 0.011 0.112 0.876
87 376, 796 76, 700 340, 946 0.011 0.125 0.864
88 353, 583 76, 400 318, 744 0.011 0.138 0.851
89 331, 618 76, 200 297, 609 0.012 0.152 0.836
90 310, 733 75, 900 277, 566 0.012 0.167 0.821
91 290, 942 75, 700 258, 366 0.012 0.183 0.805
92 271, 998 75, 400 239, 912 0.012 0.201 0.787
93 253, 805 75, 200 221, 774 0.012 0.219 0.769
94 235, 937 74, 900 203, 583 0.012 0.237 0.750
95 218, 025 74, 700 184, 469 0.012 0.257 0.731
96 199, 193 74, 400 163, 282 0.012 0.277 0.711
97 178, 314 74, 200 137, 819 0.012 0.298 0.690
98 153, 187 73, 900 104, 577 0.013 0.318 0.669
99 120, 325 73, 700 56, 979 0.013 0.339 0.648
100 73, 186 73, 400 0 0 1 0
Table 3.7: One vaccine MDP input parameters – Men. WTP = $100,000.
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Figure 3.17: Optimal value curve – Men
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Figure 3.18: One-way sensitivity analysis – Men
117
010
20
30
40
50
60
70
80
90
100
50 60 70 80 90 100
Age
Pr
ob
ab
ilit
y 
Se
le
ct
ed
 (%
)
Figure 3.19: Probabilisitic sensitivity analysis – Men
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Figure 3.20: Optimal policy – two dose model – Men
119
0400
800
1200
1600
50 55 60 65 70 75 80 85 90 95 100
Age
Ne
t M
on
et
ar
y B
en
ef
it (
$K
)
Decision
One Vaccine
Wait
Dose
Figure 3.21: Optimal policy – two dose model, second step – Men
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Figure 3.22: Sensitivity analysis – two
dose model – initial efficacy, higher,
women
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Figure 3.23: Sensitivity analysis – two
dose model – initial efficacy, lower, women
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Figure 3.24: Sensitivity analysis – two
dose model, second step – initial efficacy,
higher, women
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Figure 3.25: Sensitivity analysis – two
dose model, second step – initial efficacy,
lower, women
121
50
55
60
65
70
75
80
85
90
95
100
50 55 60 65 70 75 80 85 90 95 100
Age of Second Dose
Ag
e 
Va
cc
ina
te
d
Decision
Second Dose
Wait
A
ge
 o
f F
irs
t D
os
e
Figure 3.26: Sensitivity analysis –
two dose model – waning speed, slower,
women
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Figure 3.27: Sensitivity analysis – two
dose model – waning speed, faster, women
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Figure 3.28: Sensitivity analysis – two
dose model, second step – waning speed,
slower, women
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Figure 3.29: Sensitivity analysis – two
dose model, second step – waning speed,
faster, women
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Figure 3.30: Sensitivity analysis – two
dose model – p(PHN|HZ), upper, women
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Figure 3.31: Sensitivity analysis – two
dose model – p(PHN|HZ), lower, women
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Figure 3.32: Sensitivity analysis – two
dose model, second step – p(PHN|HZ),
upper, women
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Figure 3.33: Sensitivity analysis – two
dose model, second step – p(PHN|HZ),
lower, women
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Figure 3.34: Probabilisitic sensitivity analysis – two dose model – Men
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Figure 3.35: Probabilisitic sensitivity analysis – two dose model, second step – Men
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Figure 3.36: Scenario analysis – two
dose model – + 2 percentage points
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Figure 3.37: Scenario analysis – two
dose model, second step – + 2 percentage
points
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Figure 3.38: Scenario analysis – two
dose model – + 5 percentage points
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Figure 3.39: Scenario analysis – two
dose model, second step – + 5 percentage
points
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Chapter 4
Value of Information Analysis:
Vaccine Waning & Efficacy
4.1 Introduction
The objective of this chapter is to determine the value of information on the initial
efficacy and waning characteristics of the herpes zoster vaccine. As shown by the
previous two chapters, the waning speed of the vaccine and its initial efficacy can
substantially impact the cost-effectiveness and the optimal policy. For example, in
men, having a lower vaccine efficacy or a vaccine that wanes more quickly produces a
policy that does not recommend vaccination at any age assuming all other parameters
are held at base case values. Because these parameters can have this impact on
vaccine recommendations it may be valuable to gather additional information to
determine how recommendations may change. However, before any additional research
is undertaken, it is important to estimate the value of the information that could be
gained.
Background and Utility of Value of Information Analysis
The underlying objective of health economic evaluation is to make decisions that
maximize the health gains from available resources [46–50,55]. To make the most of
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the available resources in health care, good decisions must be made, and to make good
decisions two questions which must be answered [139]. First, should a technology (e.g.,
treatment, medication, device) be recommended? Second, is there further evidence
needed to support the decision? Answering the first question is often accomplished
with the aid of modeling exercises such as using a state-transition model to predict
the cost-effectiveness (similar to Chapter 2, more common), or using an MDP to
determine the optimal policy (similar to Chapter 3, less common). If there is sufficient
evidence that a technology should be recommended, for example showing a high
probability of cost-effectiveness, that provides valuable information to decision makers.
However, decisions based on current information are dependent on the quality of
that information [139]. Further, due to uncertainty, there is always a chance that
a “wrong” decision will be made based on the current information. Therefore, if
there is uncertainty in the model or model parameters, that uncertainty could impact
the recommendation and additional research may be needed. Should this occur, the
technology could either be recommended with a request for additional research, or
not recommended until the additional research is completed. The HZ vaccine fits into
the first of these two categories as it has been widely adopted around the world but
further work may be needed to improve recommendations. This has been a general
objective of this dissertation thus far. However, because resources are scarce, the
potential value that could be gained should be quantified so as to not waste resources
in the pursuit of information that may be little value to decision makers. This is
the objective of value of information (VOI) analysis; to assess the potential value
of additional research to help set priorities and ensure that resources are efficiently
allocated. VOI analysis comes from foundations in Bayesian and statistical decision
theory. These techniques have and have been applied successfully to health care in
recent years for a number of different technologies [140–143] and have been used in
setting research priorities [139].
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4.2 Methods
To complete a value of information analysis three steps must be completed. First,
a decision model must be constructed. Decision models were created for Chapter
2 and 3 as part of this dissertation. Second, the decision model must be subjected
to a probabilistic analysis. This was also accomplished in Chapters 2 and 3 in
doing probabilistic sensitivity analysis (PSA). Finally, a sampling algorithm must be
applied to the probabilistic form of the model to determine the value of the unknown
information.
Expected Value of Partially Perfect Information
It is most common to determine the expected value of perfect information (EVPI)
first. EVPI selects the optimal decision under the assumption of perfect information
on all model parameters. To perform an EVPI analysis, Equation 4.1 is needed. The
EVPI is the difference in expected payoff assuming perfect information compared to
the payoff under current information (uncertainty). In Equation 4.1, θ is the set of
all unknown parameters in the model. Given these unknowns, the optimal decision
that can be made is the age of vaccination j that produces the highest average
net monetary benefit (NMB) (where j ∈ {⊗, 50, ..., J}; where ⊗ designates never
vaccinate). This is shown on the right side of Equation 4.1 by maxj EθNMB(j, θ).
EV PI = Eθ[max
j
NMB(j, θ)]−max
j
Eθ[NMB(j, θ)] (4.1)
With perfect information, θ would be known; as a result the future outcomes of
the model would be certain and the age of vaccination j that produces the maximum
net benefit could be selected each time with each new set of θ parameters. This
selection would be given by maxj NMB(j, θ) [139]. However, as θ is unknown the
values of simulations under perfect information must be averaged over all values of θ.
This is shown on the left side of Equation 4.1 by Eθ maxj NMB(j, θ).
However, I am interested in the value of perfect information on two specific
parameters in the model: 1) the initial efficacy of the vaccine, 2) the waning speed
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of the vaccine. Therefore, this analysis will focus on the expected value of partially
perfect information (EVPPI) to determine the value of those parameters rather than
the EVPI which evaluates the value of perfect information for every parameter in the
model. EVPPI analysis uses Equation 4.2.
EV PPIϕ = Eϕ
[
max
j
Eψ|ϕ[NMB(j, ϕ, ψ)]
]
−max
j
Eθ[NMB(j, θ)] (4.2)
Equation 4.2 shares one maximization term with Equation 4.1: maxj EθNMB(j, θ).
This again shows that the optimal age of vaccination, j, given all the unknown pa-
rameters, θ, is the expectation of all simulated outcomes of θ. In Equation 4.2,
the two parameters of interest (initial efficacy and waning speed) are represented
by ϕ. Assuming perfect information about these parameters, it would be possible
to make a decision about the optimal age of vaccination j by averaging over all
remaining unknown variables in the model (ψ, where ψ ( θ). This is shown by:
maxj Eψ|ϕ[NMB(j, ϕ, ψ)] in Equation 4.2. However, similar to EVPI, the values of
ϕ are not known and therefore must be averaged over their simulated values of ϕ
(where ϕ ( θ, ϕ∪ ψ = θ and ϕ⊥⊥ ψ). The EVPPI analysis will always be positive or
0, but never negative. In the case of vaccination, if the optimal age j under perfect
information is the same as the optimal age without information (i.e., under current
information), then the value of information is zero as the decision does not change.
If, under perfect information, j is different than the recommendation under current
information, the NMB under perfect information will be greater than the NMB under
current information, thus the EVPPI will always be ≥ 0.
Three separate EVPPI analyses were conducted. Each of these analyses used
a different probabilistic modeling approach to estimate the EVPPI. The method
used for each analysis will be discussed in turn below. In brief, EVPPI analysis was
conducted using the MDP model structure from Chapter 3. EVPPI analysis was then
completed using a forward simulation state-transition model. Finally, EVPPI analysis
was completed using a non-parametric regression technique for efficient computation.
Of note, in a standard EVPPI analysis, it would be important to consider the
EVPPI for every age group that could be affected by the results (e.g., people age: 50,
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51, ..., 100). However, for the following analyses, I assume the perspective of a people
age 64. This decision was made given the projected lifetime over which the information
would be valuable. There is currently a new vaccine in development. Early trial data
suggests that the new vaccine will be more efficacious than the current vaccine [136].
Because of this increase in efficacy I assume the new vaccine will be more highly
utilized than the current vaccine when it is released to market. However, the new
vaccine is not likely to be available to the public for 24 – 48 months. Therefore,
I assume the lifetime of the information generated by this analysis of the current
vaccine is approximately 3 years (36 months). Given the projections of the MDP in
Chapter 3 (with 66 being the optimal age of vaccination in the base case analysis),
assuming the perspective of a cohort at age 64 would allow for the information to
be valuable for the next 2 – 4 years. Therefore, the decision to vaccinate can be
optimized from ages 64 – 68 when it is most likely optimal to vaccinate people. If,
for example, the analysis took the perspective of a 50 year old and it was optimal to
vaccinate between 64 – 68, the information would have to be valuable for the next 14
– 18 years, which is unlikely given the circumstances.
MDP Structure Analysis
DF-2
HZ
D
DF DF-2
HZ
D
Figure 4.1: State-transition model. DF: Disease-free. HZ: Herpes zoster. DF-2: Disease
free 2. D: Death.
The first EVPPI analysis was conducted using the MDP model structure from
the one dose analysis in Chapter 3. Probabilistic state-transition models (STMs)
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were needed to generate the data for the MDP structure. The STMs shared the same
structure as the STMs used to inform the MDP analysis in Chapter 3. These models
were created using R (v.3.2.3), and are shown by Figure 4.1. In the vaccination STM
the cohort starts in the disease free state and each cycle has the chance to transition
to the HZ state or the death state. If a transition to HZ occurs, the cohort will stay
in HZ for one cycle and then either transition to disease free 2 or death, if death
occurs. HZ is an all-inclusive health state that provides a cumulative estimate of the
QALYs and costs with a case of HZ, which may include PHN or ocular complications.
If disease free 2 is reached, the cohort will remain in this state until death occurs.
The vaccination model calculates the lifetime costs and QALYs for someone who has
been vaccinated at some age. The HZ natural history model starts a cohort in the
HZ state at some age. Like the vaccination model, HZ is a transient state and the
cohort will only spend one cycle with HZ. This model calculates the lifetime costs
and QALYs for for developing HZ at some age. The probability of HZ related death
was set to 0 for this analysis, and the probability of death was set to 100% at age
100. The cycle time for these state-transition models was set to 1 year. The model
takes the lifetime perspective and assumes a 3% discounting per year (0.97).
Once the STMs were constructed, a sampling algorithm was implemented to
generate the data needed. This sampling algorithm uses two nested levels of Monte
Carlo sampling over the plausible ranges for both the parameters of interest and
the remaining uncertain parameters. First, values for the initial vaccine efficacy and
waning speed (ϕ) were drawn from their respective distributions and fixed. This was
the outer loop of the sampling algorithm. Once outer values were fixed, one set of the
remaining unknown variables (ψ) were drawn from there respective distributions and
one probabilistic model was run; this was the inner loop of the sampling algorithm.
A total of 1000 inner loops were run for each outer loop; 1000 outer loops were run
creating a 1000×1000 sampling simulation.
Because the MDP structure requires data for all ages of vaccination tested, the
two-level Monte Carlo simulation was required for every age from 64 (the start age of
the analysis) to 100. This lead to a total of 1000×1000×37×2 simulations to generate
the data needed for men and women. Because the HZ STM has no vaccination
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component a first order Monte Carlo simulation was run to generate the data needed
to estimate the lifetime costs and QALYs for those who developed HZ at some age
(i.e., 1000×37×2 HZ PSA simulations). Seeding of the distributions was used to
ensure continuity across all STMs.
Once all data was generated from the STMs it was implemented into the MDP
structure – which was an adaptation of the model built in Chapter 3 for the one dose
optimization problem. A WTP of $100,000 was used to convert all STM data to NMB
for use in the MDP structure. The goal of this structure was to determine which
of the possible ages of vaccination produced the highest net monetary benefit using
the same backwards induction method as in Chapter 3. Models were run that fixed
vaccination between the ages of 64 – 72; a no vaccination policy was also included.
Note that this is MDP structure is not a true MDP as the decision is being fixed
at different ages rather than the model selecting the best ages to vaccinate. The
structure of the model is the same, but the decision process is fixed. The models
were run using parallel processing.
After all MDP structures had been simulated, all data were averaged by age of
vaccination j over all inner and outer loops to determine the optimal age of vaccination
under current information jc. Then, results for each outer loop were averaged by age
of vaccination j over all inner loops. This provided the optimal age of vaccination jp
under the perfect information provided by each outer loop. The NMBs for each outer
loop iteration o were evaluated by comparing jp to jc.
Forward Simulation Analysis
The second EVPPI analysis used forward simulation STMs to determine which age
of vaccination j would produce the highest NMB. The forward simulation models
were built as an adaptation of the vaccination STM presented in Figure 4.1. In the
forward simulation models, a cohort started in the disease free state and had the
chance to transition to the HZ state or the death state at every cycle. HZ was a
one cycle transient health state, from which the cohort would either transition to
disease free 2 or death, if death occurred. If disease free 2 was reached, the cohort
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would remain in the disease free 2 state until death occurs. The probability of disease
related death was set to 0 for this analysis, and the probability of death was set to
100% at age 100. The cycle time for this state-transition model was set to 1 year.
The model takes the lifetime perspective and assumes a 3% discounting per year.
In these forward simulation models, the cohort started at age 64 and was vaccinated
at age j. When vaccinated, the transition probability from disease free to HZ is
reduced by the age when the vaccine was received and was adjusted by the waning
function for subsequent cycles. This model fixes the time when the vaccine was given
to evaluate multiple vaccination possibilities. Vaccination was fixed from ages 64 –
72, and independent forward simulations were run for each fixed age of vaccination.
A never vaccinate option was also included. The forward simulation models provided
the lifetime costs and QALYs for a cohort of 64 year olds who were either never
vaccinated (j = ⊗) vaccinated at some point in the future (j ≥ 64). Once the model
structure had been set up, the same methods from the EVPPI analysis using the MDP
structure were used to apply the two-level Monte Carlo simulation to the forward
simulation models. One 1000×1000 simulation was run for each age of vaccination
between 64 and 72. Simulations were run for men and women leading to a total of
1000×1000×9×2 simulations. Once all simulations were complete, the lifetime costs
and QALYs associated with each age of vaccination were converted to NMB using
the following formula: NMB(joi) = λQALY(joi) − Cost(joi), where λ is the WTP, j is
the age of vaccination, o is the outer loop iteration, and i is the inner loop iteration.
All NMBs were averaged by j over all iterations of o and i to determine the optimal
age of vaccination under current information jc. The NMBs were then averaged by j
over all values of i to determine the optimal age of vaccination the given perfection
information in the outer loop jp. Once finished, jp was compared to jc for each outer
loop iteration to determine the EVPPI for each outer loop, EV PPIo. All values of
EV PPIo were averaged to determine EV PPIϕ. This procedure was done for varying
WTP values from $0 to $1,000,000 to determine how the EVPPI changes with WTP.
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Strong’s Regression Analysis
One of the main issues with the two-level Monte Carlo simulation required for
EVPPI is computational burden. For example, using the two-level method for this
analysis requires 1000×1000×9×2 simulations using forward simulation. When the
MDP was used to evaluate the same set of decisions from age 64, it would required
1000×1000×37×2 simulations to simulate the required data, plus an additional
1000×1000×9×2 simulations in the MDP to determine the same information. Using
parallel processing or high performance computing (HPC) can significantly decrease
computation time, however, this also assumes that the modeler has access to those
technologies, and knowledge of how to best utilize them. As a result of these
limitations, newer and more efficient EVPPI methods have emerged [144–148]. Strong
et al have developed methods using non-parametric regression techniques to provide
an efficient method to estimate the EVPPI [145–147]. This section will discuss these
methods and their application to this problem.
Strong’s method works by using generalized additive model (GAM) regression.
Regression analysis is a useful statistical technique for estimating relationships between
variables. Linear regression is perhaps the most commonly used method, however,
many relationships do not follow a linear form [149]. GAM regression is a flexible
method that can be used for estimating non-linear relationships. This method
alters the typical regression equation by replacing coefficients with functions. These
functions are then predicted based on the data available. A benefit of GAM models
is that no prior assumption is required about the distributional form of the function,
which is what makes these models flexible and ‘non-parametric’. Functions are
predicted using an algorithm that smooths the relationship between the data [149].
In order to utilize this method, steps need to be taken to alter the EVPPI equation
(Equation 4.2). First, as shown in Equation 4.3, the right maximization term is
changed using the the Law of Total Expectation and the independence between ϕ
and ψ.
EV PPIϕ = Eϕ
[
max
j
Eψ|ϕ[NMB(j, ϕ, ψ)]
]
−max
j
Eϕ
[
Eψ|ϕ[NMB(j, ϕ, ψ)]
]
(4.3)
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Once this change has been made, the inner expectation, Eψ|ϕ[NMB(j, ϕ, ψ)], can
be manipulated. This expectation will be reframed as a regression problem. This
is done in three steps. First, results from a probabilistic sensitivity analysis (PSA)
of N samples, indexed by n = 1, ..., N , are needed. Given these N PSA samples,
it is possible to express the net monetary benefit for the age of vaccination j using
PSA sample n as a conditional expectation plus an error term; shown by Equation
4.4 [147].
NMB(j, θ(n)) = Eψ|ϕ(n) [NMB(j, ϕ
(n), ψ)] + (n) (4.4)
Once the inner expectation is reframed, it can be seen that Equation 4.4 changes
for each value of ϕ(n). This implies that NMB can be written as some unknown
function f(j, ϕ). This is then used to determine the net monetary benefit for each of
the N PSA simulations. This is shown by Equation 4.5 [147].
NMB(j, θ(n)) = f(j, ϕ(n)) + (n) (4.5)
The final step is to make the following assumption. For each age of vaccination
j (j ∈ {⊗, 64, 65, ..., J}), we assume that the net benefits produced by the different
values of the PSA {NMB(j, θ(1)), ..., NMB(j, θ(N))} represent the data that can be
regressed to learn about the target function: f(j, ϕ(n)). This can be thought of as solv-
ing J total regression problems. Once a GAM model was fit for each of the J options,
the fitted values were extracted. These are denoted by: {fˆ(j, ϕ(1)), ..., fˆ(j, ϕ(N))}.
Once these values were extracted, the estimated EVPI is given by Equation 4.6 [147].
̂EV PPI(ϕ) =
1
N
N∑
n=1
max
j
fˆ(j, ϕ(n))−max
j
1
N
N∑
n=1
fˆ(j, ϕ(n)) (4.6)
R was used to accomplish Strong’s method for EVPPI. First, second order Monte
Carlo PSA was performed on the forward simulation models described in the previous
section. To run the PSA models, the two-loop algorithm was replaced with a single
loop and 1000 samples from the same distributions used for the MDP structure and
the forward simulations. Once the PSA was completed, I utilized the R code that had
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been previously published online by Strong et al as part of the Sheffield Accelerated
Value of Information (SAVI) tool to perform the EVPPI [150]. Mark Strong’s GitHub
repository provided the R code to perform regressions and EVPPI calculations (using
Equations 4.4 – 4.6) with PSA output from any model. Upon deconstructing his code,
I was able to modify it to determine the age of vaccination that provided the highest
NMB. Using this information I was able to generate policy plots to determine what the
optimal age of vaccination would be given perfect information on vaccine parameters.
Given the computational efficiency of this method, I tested several starting ages from
62 – 68, with each analysis fixing vaccination at every age between the starting age –
72 (e.g., 62 – 72,..., 68 – 72). A scenario analysis was conducted which shortened the
time horizon of the model from lifetime to three years for completeness.
Population EVPPI
Once all simulations had been completed, the population EVPPI was calculated.
Population EVPPI is the EVPPI scaled up to the population level to determine
the upper bound for the value of the information. For both the MDP and forward
simulation models, the number of 64 year old men and women in the United States [8]
was multiplied by the EVPPI for men and women, respectively. For results using
Strong’s method, multiple starting ages were tested. The EVPPI for men and women
was multiplied by their respective population sizes to give the population EVPPI for
different age groups.
Model Inputs
Table 4.1 provides the distributions for the EVPPI analysis. These distributions were
used in both two-level Monte Carlo simulations for EVPPI and the GAM regression
models.
Variable Distribution Category
Vaccine – Initial Efficacy** N (0, 0.035) ϕ
Vaccine – Waning Rate* N (1, 0.12) ϕ
Probability – HZ* – asymp lnN (0, 0.099) ψ
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Variable Distribution Category
Probability – PHN* – b1 lnN (0, 0.295) ψ
Probability – Ocular Complications** N (0, 0.01) ψ
Cost – HZ Γ(106.143, 1/18.021) ψ
Cost – PHN See page 218 ψ
Cost – Ocular Complications Γ(41.961, 1/99.201) ψ
Cost – Vaccine Γ(23.33, 1/7.5) ψ
Cost – Vaccine Administration Γ(2196.6, 70) ψ
Cost – Vaccine Severe Reactions Γ(18, 100) ψ
Disutility – HZ β(24.39, 804.59) ψ
Disutility – PHN See page 218 ψ
Disutility – Ocular Complications β(16.4, 254.81) ψ
Disutility – Common Vaccine Complications β(6, 6000)× (30/365) ψ
Disutility – Severe Vaccine Complications β(2.13, 100000)× (30/365) ψ
Table 4.1: Parameter distributions for EVPPI. * – A parameter was sampled and added
to base case parameter value. ** – A scaling factor for the parameter was sampled and
multiplied by the base value for that parameter.
4.3 Results
Results from the three EVPPI analyses will be presented in order. A comparison of
the computation times of the methods will be shown at the end of the results section.
MDP Model
The EVPPI for women starting at age 64 and a WTP of $100,000 is $0.68. For men,
the EVPPI is projected to be $1.52. For the cohort of all 64 year old women and men
in the US the population EVPPIs are estimated to be $1,248,843 and $2,523,492,
respectively. The total EVPPI is $3,772,335. Figure 4.2 shows the recommended
policy for vaccination given perfect information on the vaccine, for women assuming
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a WTP of $100,000. If the base case values for vaccine efficacy and waning were the
“true” values (i.e., 0.00, 1.00, respectively), Figure 4.2 shows that it would be optimal
to vaccinate at age 66. Only if the vaccine waning speed was very slow, approximately
30% slower than the base case, would it be optimal to vaccinate as early as 64. The
figure also shows that if the vaccine was fast waning and had a lower initial efficacy,
there are circumstances when it would not be optimal to vaccinate women. Under
current information, for women and men, the policy would recommend vaccination at
age 66.
Forward Simulation
Figures 4.4 – 4.5 show the EVPPI for 64 year old women and men at varying WTPs
between $0, and $300,000, respectively. For women the highest EVPPI is at a WTP of
$50,000. Here EVPPI equals $9.42. For men, EVPPI is greatest at a WTP of $70,000.
At this WTP, EVPPI equals $11.19. Figure 4.6 shows the population EVPPI for men
and women. At the WTP corresponding to the highest EVPPI values for women
and men, the population EVPPI equals $17,070,360 and $18,504,254, respectively.
For men and women, at a WTP of $100,000 the EVPPI was equivalent to the MDP
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Figure 4.6: Population EVPPI – forward simulation
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structure simulation at $0.68 and $1.52 for women and men, respectively.
Figure 4.7 shows the policy results of the optimal vaccination policy given perfect
information for women at varying levels of WTP. It also shows the optimal policy
under current information. At a WTP of $50,000/QALY for women under current
information, it would be optimal to never vaccinate. Conversely, with perfect informa-
tion, it would be optimal to vaccinate people as early as age 65. For vaccination to be
optimal for women given a WTP of $50,000/QALY, the vaccine must have a higher
initial efficacy, a slower waning rate or a combination of both. Figure 4.8 shows the
policy results for men. At a WTP of $70,000/QALY it would be optimal to vaccinate
at age 66 under current information. Under perfect information, if the vaccine has
faster waning or lower initial efficacy, it would be optimal to never vaccinate.
Assuming a WTP of $100,000, it would be optimal to vaccinate a cohort of 64 year
olds at age 66 assuming that the base case assumptions about the vaccine efficacy
and waning were the “true” values. However, the policy plot also shows that a
slight increase in vaccine efficacy or a slight decrease in waning speed would shift the
recommendation to vaccination at age 65. Under current information, assuming a
WTP of $100,000 we would recommend vaccination at age 66. The policy plots help
to interpret the why the EVPPI may be higher at certain WTPs than others.
Strong’s Regression Method
Individual and population EVPPI results are presented in Figures 4.9 – 4.12. Figures
4.9 – 4.10 show the individual EVPPI results for women and men at varying WTPs,
respectively. The highest EVPPI for women is at a WTP of $50,000 with a value of
$9.88 (vs. $9.42). For men, the highest EVPPI is $11.62 (vs. $11.19) at a WTP of
$70,000. Scaled to the population level, the EVPPI is $17,910,454 and $19,216,874 for
women and men, respectively. At a WTP of $100,000/QALY the EVPPI is $2.04 and
$0.91 for men and women, respectively. The EVPPI results from Strong’s method
are marginally greater at every WTP compared to forward simulation and the MDP
model.
Figure 4.11 shows the population EVPPI results for starting ages between 63 – 67
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Figure 4.12: Population EVPPI – all ages combined – Strong’s method
at varying levels of WTP. Results suggest information may be more valuable to men
than women, and more valuable to younger ages than older ages. When combining
all possible starting ages together, as shown by Figure 4.12, the highest values of
population EVPPI for men and women between the ages of 63 – 67 are $99,542,341
and $93,967,997, respectively. At a WTP of $100,000 the population EVPPIs for the
same groups of men and women are $15,516,265 and $6,177,378, respectively. The
total population of men and women between 63 – 67 is 17,191,928, which equates to
an average EVPPI of $1.26 / person at a WTP of $100,000.
Policy results for a cohort of 64 year old women are presented in Figure 4.13.
Policy results for women and men starting between ages 62 – 68 can be found in
Figures 4.15 – 4.27 on pages 155 – 167 in the end of chapter appendix. For a cohort
of 64 year women, this figure shows nearly the same results as the Figure 4.7 from
the forward simulation. The policy results indicate that under a WTP of $100,000
and assuming that the base case assumptions about the vaccine’s efficacy and waning
were the “true” values, that 66 would be the optimal age for vaccination. If the
vaccine was more efficacious or the vaccine had a slightly slower waning rate then it
would be optimal to vaccinate at age 65. Under current information, age 66 would
be the optimal age for vaccination. As WTP increases, the age of vaccination under
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current information decreases. Under perfect information the younger ages for optimal
vaccination increase in presence on the plots, moving in from the left side. This trend
can be seen on all policy plots (see Figures 4.7 and 4.15 – 4.27).
In examining Figures 4.15 – 4.27, for women, the earliest age where vaccination
is recommended under current information is 63, for a cohort starting at age 62
assuming a WTP of $500,000. Under perfect information, WTP needs to be at least
$500,000 for vaccination at age 62 to be included as an option. For men, vaccination
at age 62 is considered optimal under current information at a WTP of $500,000. At
ages 67 – 68, the current policy has nearly the same recommendation as the policy
under perfect information for WTPs above $100,000.
Comparison of Method Efficiency
This section outlines the differences between the methods in terms of computation
time. As mentioned previously, two-level EVPPI can be computationally and time
intensive. Table 4.2 shows the computation time that was required to generate the
data for each of the possible methods for this chapter. This table only presents the
data generation times, not data analysis times. All computation was done on the
same computer and parallel processing was used when possible (not used for Strong’s
methods). For parallel processing, eight CPU cores were used for each simulation on
an Intel Core i7-2600 3.4GHz processor with 8.00GB of ram. Profiling methods used
during the analysis, showed the processor working at 100% capacity; RAM was not
highly utilized during computations. This indicates that the run times were limited
by processor capability, not memory capability. Table 4.3 shows the computation
time that would be required to process the data generated in Table 4.2.
Data generation for using a MDP model structure requires both more data
generation and processing time. An important distinction about this method is that
the processing times listed in Table 4.3 are for only one value of WTP. This is due to
the nature of the MDP structure, where costs and QALYs must be first converted
into NMB before they can be analyzed in the model; thus the MDP must be run
again for each new WTP. Conversely with forward simulation, the costs and QALYs
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Figure 4.13: Policy Plot – Women, age: 64 – Strong’s Method. Waning speed: relative
change. Initial vaccine efficacy: additive change.
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generated by the model reflect the lifetime costs and QALYs of cohort starting at 64
and being vaccinated at some age j. These costs and QALYs can be converted to
NMBs easily. Analysis time results show that generating a 1,000 sample PSA and
calculating the EVPPI using Strong’s methods was more than 4 times faster than
just processing the data for the 1000×1000 forward simulation (3.66 min vs. 15 min).
Method Model Iterations CPU time
MDP 1000×1000×37×2 52 hours
Forward simulation 1000×1000×13×2 31 hours
Strong’s method 1000×13×2 3 min
Table 4.2: Computation times for data generation for EVPPI analysis
Method ‘Outer loops’ for ϕ CPU time
MDP* 1000 7 hours
Forward simulation** 1000 15 min
Strong’s method** 1000 20 seconds
Table 4.3: Computation times for data processing for EVPPI analysis. For one gender
only. * – For one value of WTP ($100,000) only. ** – For 31 values of WTP ($0 – $300,000,
by $10,000)
.
Scenario Analysis
Figures 4.28 – 4.29 in the end of chapter appendix provide the results of the scenario
analysis where the time horizon of the model was shortened to three years. In this
scenario the cohort started at age 64 but only decisions to vaccinate at ⊗, 64, 65,
and 66 were allowed (given the truncated time horizon). Results indicate that with a
truncate time line, the value of information is $0 for all WTP less than $200,000 for
women and $260,000 for men. Once a high enough WTP was reached ($210,000 for
women, $270,000 for men) some of the simulation results suggest that there would
be circumstances where it would be optimal to vaccinate at age 64. Similar to all
previous results, the EVPPI was highest when the distribution of simulation results
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was approximately equivalent between no vaccination and vaccination at age 64; this
can be seen by examining the policy plots in Figures 4.30 and 4.31. Vaccination at
65 or 66 was never recommended under the truncated time horizon model.
4.4 Discussion
The objective of this chapter was to determine the value of additional research for
two of the key parameters from both of the previous chapter analyses. Results from
the cost-effectiveness and from the MDP indicated that the initial efficacy of the
vaccine and its waning speed could have a substantial impact on the results. These
parameters were considered to be the most important for determining the value of
perfect information. In this chapter I used three different modeling techniques to
assess the value of information for these parameters. The results from the analyses
provide some useful insight.
The EVPPI was greatest when the simulation results were approximately equally
distributed between never vaccinate or vaccinate at some age under perfect information.
This can be seen by comparing the policy plot figures to the EVPPI figures. For
women, the highest value of information came at a WTP of $50,000. In this situation,
under current information, the recommended policy would be to not vaccinate,
and under perfect information, approximately half of the points in the policy plot
recommended vaccination. For men, the highest EVPPI was at a WTP of $70,000.
At this WTP, the optimal vaccination strategy for (every cohort younger than age 68)
was vaccination at age 67. Under perfect information, approximately half of points in
the policy plot recommend no vaccination.
As WTP increases, results shift to include more simulation results in favor of
vaccination vs. no vaccination. As this happens the value of information decreases.
As WTP increased younger ages move in from the left hand side, “pushing” the older
ages to the right. This observation has a logic to it. If the policy plots were divided
into quadrants (an example is shown in Figure 4.14) the NW quadrant would be the
best possible quadrant for the vaccine. Here, the vaccine is waning slowest, and has a
higher initial efficacy. It is in this quadrant that younger ages for vaccination appear
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Figure 4.14: Quadrant plot – Women – Age: 64 – Strong’s Method – WTP: $100,000
first. If we knew with certainty the vaccine would wane more slowly and would have
a higher initial efficacy it would seem reasonable to recommend vaccination at earlier
ages as the vaccine would confer more benefit for longer.
Conversely, the SE quadrant would be the worst for the vaccine. Here, the
vaccine would be waning quickest and have the least initial efficacy. It is in this
quadrant where the oldest ages or do not vaccinate are the most common. Given these
characteristics, it would be logical to postpone vaccination until a time where the
vaccine could be administered to those at higher risk. The NE and the SW quadrants
assume that there fast waning with higher initial efficacy, or slower waning with lower
initial efficacy, respectively. Compared to the SW, the NE quadrant has more older
ages were vaccination is recommended. For example, for 64 year old women, under
WTPs from $50,000 – $70,000, age 68 is recommended as an optimal policy in only
the NE quadrant. This suggests that even under fast waning conditions, a higher
initial efficacy could make vaccination optimal at older ages. Based only on a visual
comparison of these plots it appears that the vaccines waning speed has more of an
impact on recommending lower ages of vaccination than does the vaccines efficacy, as
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younger ages are more frequent in the SW quadrant compared to the NE.
Analyses suggest that there is a high value in determining the uncertain information
at WTPs associated with the greatest decision uncertainty. At lower WTPs under
perfect information no vaccination would be recommended approximately 50% of the
time (assuming vaccine characteristics in the SE quadrant). However, assuming a
WTP of $100,000 or more, which is not unreasonable for the US [75,151], the value of
information about these parameters declines. Therefore, the most value occurs with
the decision to vaccinate or not, not in the ability to optimize when the vaccine would
be given. That is there may only be a marginal value in determining the perfect
information to change the optimal recommendation by one or two years. Further, as
one moves to older starting ages (e.g., 67 – 68), the VOI at higher WTP drops to near
zero or zero. This is because there is not as much “room” to optimize the decision.
For example at a WTP of $200,000 for women starting at age 62 there are four
optimal decisions under perfect information (vaccinate between 63 – 67, depending on
information). Comparatively, for women at age 67 there is only one optimal decision
given perfect information (vaccinate at 67). At 67 the perfect information matches
the current information, thus the information is not valuable.
Despite the value of information on an individual basis being low, the population
EVPPI for this analysis was high. This is due to the population at risk for disease;
with an estimated 90% or greater of the US population being at risk for HZ. For a
group of 64 year olds the population EVPPI was still greater than $3.5 million at a
WTP of $100,000. If we assume that the WTP in the US is at least $100,000 and
decision makers were only interested in 64 year olds, the additional research would
need to cost less than $3.5 million to be recommended. The type of research needed
would likely be a clinical trial with several years follow-up. The price of clinical
trials varies considerably, with an approximate range of $1million – $100million or
more [152]. It could be possible to use observational data to answer this question.
However, that could also be costly unless data collection infrastructure was already in
place. Given the new vaccine on the horizon [136], there are fewer age groups where
the information would be valuable. Figure 4.12 does indicate that if more ages could
be affected the value of information could be quite high. Overall, while there may a
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lower value of information about determining the optimal age, it does not mean this
information is value-less. However, given the constraints with a new vaccine coming
to market and the higher WTP in the US [75, 151], the additional research needed to
be able to optimize the delivery from current information over the small 1 – 2 year
window would not likely be worth the investment.
A potential limitation to these conclusions is the data used for the models. VOI
assumes that perfect information would be known and indeed could be known to the
decision maker. The data used here encompasses a wide range or possible options
and based on our understanding of the disease and the vaccine I have confidence
that the ‘true’ value of the parameters tested would be within the distributions
used. Further, the results of the policy ploys show that there are ranges within the
results under perfect information, so while it may never be possible to gain perfect
information, narrowing the range on what the ‘true’ value is would still allow for
further optimization. However, narrowing the range would not provide as much
value as determining perfect information and we have shown that obtaining perfect
information is not likely to be worth the investment at this time.
Model Comparisons
One unique feature about this analysis was the use of three different methods to
compare the EVPPI. The first method utilized was the MDP where the decisions were
fixed to determine which age would produce the best age. This MDP structure did use
backward induction, but it did not use the same maximization function implemented
in Chapter 3, rather the model was using a fixed policy. This fixed policy was then
used to determine the NMB at every age which could then be used to determine the
optimal age of vaccination.
Because the MDP structure was using a fixed policy rather than an optimization
policy, it was able to be replicated as a forward simulation. Turning the backward
induction model into a forward simulation had several advantages. First, no additional
data was needed to run the model. A MDP structure requires a large amount of data.
Generating this data was the biggest time constraint in using the MDP structure as
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shown by Table 4.2. To run the MDP structure for one gender required 37 vaccine
STMs, each run for a two-level 1000×1000 Monte Carlo (i.e., 37,000,000 STMs). PSA
was also required for the lifetime costs and QALYs of developing HZ. Once all the
data was generated, it was run through the MDP structure. Therefore 1,000,000
MDPs were run for each fixed age of vaccination. Conversely, the forward simulation
started a cohort of people at age 64 and then fixed the vaccination policy at some
age in the future. Because this model included the chance of HZ and the benefit of
vaccination, no additional data was needed. Therefore, each age of vaccination tested
only required a 1000×1000 two-level Monte Carlo implementation. This drastically
decreased simulation and analysis time. Another benefit of the forward simulation
is that the model provided the lifetime costs and QALYs associated with the fixed
vaccination policy for the cohort starting at age 64. The STM data needed for the
MDP model only provided the lifetime costs and QALYs for being vaccinated at
some age but did not include the prior risk of disease – that is the goal of the MDP
structure to determine. Therefore, to determine the NMB for each of these are
very different tasks. For the MDP structure, all input data must be converted into
NMBs using a predefined threshold of WTP/QALY and then run through the MDP
structure to determine the value of the fixed policy. This takes approximately 7 hours.
Conversely, the forward simulation already provides the lifetime costs and QALYs of
each possible policy assuming prior risks. To convert to NMB, a WTP can be applied
directly to the QALYs and costs are then subtracted. This process takes less than
two seconds even with a large amount of data. Because in the forward simulation this
conversion is a simple multiplication and subtraction problem, many more WTPs
can be tested much faster compared the MDP structure. Therefore, in comparing
forward simulation the MDP structure for the purposes of EVPPI, it is evident that
the forward simulation is a faster method for this problem; this is shown in Tables
4.2 – 4.3.
In comparing the forward simulation method to Strong’s regression method it is
obvious there is another large advantage in computation time. Strong’s method is
also simpler as all that is required is a second order Monte Carlo PSA; this method
does not require a complicated two-level sampling algorithm. The pattern in the
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results is nearly the same under the same WTP, Figures 4.7 and 4.13 are nearly
identical. When comparing the results of the EVPPI analysis in terms of magnitude,
Strong’s method does produce a EVPPI that is higher than the EVPPI produced by
the gold standard two-level Monte Carlo methods. Indeed, Strong recognizes that
his method does add an upward bias to the results [145–147]. This upward bias is
a limitation of this method. In this research, the maximum impact of this bias was
seen at the from a WTP range of $50,000 – $70,000/QALY which were the WTPs
that produced the largest EVPPIs. The bias resulted in population EVPPI estimates
of $700,000 and $800,000 more than the forward simulation estimates for men and
women, respectively. This difference was lower at higher WTPs. While Strong’s
method does introduce an upward bias into the results, it does work well for a first
step in estimating the EVPPI. Given the dramatic savings in computation time, this
method provides a check of the value of information and can hopefully provide fast
insight into if additional research would be valuable. If the value of information is
near the expected cost of the research design that would be needed to acquire that
information, then the traditional two-level algorithm methods could be used, along
with techniques like expected value of sample information (EVSI) to better predict
the value. However if the EVPPI is very high or very low then two-level methods
may not be needed. Therefore, despite the bias, I would still recommend Strong’s
methods as a first approach to determine the ceiling for the EVPPI.
Conclusion
In conclusion, this chapter sought to determine the value of perfect information
on two key parameters in the models from the previous chapters. This research
showed the benefit, in terms of time, on using efficient estimation techniques to
determine the EVPPI. While these techniques may not be as accurate as the gold
standard two-level Monte Carlo simulation methods, they do provide very similar
results at a fraction of the computation time. For this problem, methodologically,
Strong’s method provided useful information and given the results could have likely
been sufficient without further analysis. There has been a call for using EVPPI in
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situations that involve multiple interventions or multiple decisions [153]. While this
research only investigated one intervention, multiple options for vaccination timing
were considered. Based on a cursory scan of the literature, EVPPI analysis has not
been widely applied to the issue of treatment timing. This work also presents policy
plots to assist in the interpretation of the EVPPI plots. I have not seen these types
of plots used in the literature but I do feel that they add value to the analysis and
provide insight to why EVPPI may be higher at certain WTP thresholds compared
to others. Results suggest that there is value to this information, but that most of
the value comes at WTPs that are less than the typical WTP assumed for health
technologies in the US. I found that there was more value in deciding whether to use
the vaccine at all rather than optimizing the age of administration. Therefore, while
there would be some value in determining more about this vaccine in an effort to
optimize the age of administration, it is unlikely that the research required would be
worth the investment. Further, with a new vaccine on the horizon [136], the time
that this information could be valuable is diminished. However, this research does
lay ground work for further value of information studies on the new HZ vaccine or
for other vaccines where optimal timing is important. Given the impact that the
vaccines efficacy and waning make on the outcomes of the cost-effectiveness and the
optimal timing of the vaccine it will be important for new studies on the new vaccine
to pay close attention to these parameters.
154
4.A Additional Figures and Tables
Current Information Perfect Information
-0.2
-0.1
0.0
0.1
0.2
-0.2
-0.1
0.0
0.1
0.2
-0.2
-0.1
0.0
0.1
0.2
-0.2
-0.1
0.0
0.1
0.2
-0.2
-0.1
0.0
0.1
0.2
-0.2
-0.1
0.0
0.1
0.2
-0.2
-0.1
0.0
0.1
0.2
-0.2
-0.1
0.0
0.1
0.2
-0.2
-0.1
0.0
0.1
0.2
-0.2
-0.1
0.0
0.1
0.2
-0.2
-0.1
0.0
0.1
0.2
-0.2
-0.1
0.0
0.1
0.2
-0.2
-0.1
0.0
0.1
0.2
0
50000
60000
70000
80000
90000
1e+05
110000
150000
2e+05
3e+05
5e+05
1e+06
0.7 0.9 1.1 1.3 0.7 0.9 1.1 1.3
Vaccine Waning 'Speed'
In
itia
l V
ac
cin
e 
Ef
fic
ac
y Policy
Do Not Vaccinate
Vaccinate at 62
Vaccinate at 63
Vaccinate at 64
Vaccinate at 65
Vaccinate at 66
Vaccinate at 67
Vaccinate at 68
Policy, Starting Age: 62
Figure 4.15: Policy Plot – Women, age: 62 – Strong’s Method. Waning speed: relative
change. Initial vaccine efficacy: additive change.
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Figure 4.16: Policy Plot – Women, age: 63 – Strong’s Method. Waning speed: relative
change. Initial vaccine efficacy: additive change.
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Figure 4.17: Policy Plot – Women, age: 65 – Strong’s Method. Waning speed: relative
change. Initial vaccine efficacy: additive change.
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Figure 4.18: Policy Plot – Women, age: 66 – Strong’s Method. Waning speed: relative
change. Initial vaccine efficacy: additive change.
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Figure 4.19: Policy Plot – Women, age: 67 – Strong’s Method. Waning speed: relative
change. Initial vaccine efficacy: additive change.
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Figure 4.20: Policy Plot – Women, age: 68 – Strong’s Method. Waning speed: relative
change. Initial vaccine efficacy: additive change.
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Figure 4.21: Policy Plot – Men, age: 62 – Strong’s Method. Waning speed: relative
change. Initial vaccine efficacy: additive change.
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Figure 4.22: Policy Plot – Men, age: 63 – Strong’s Method. Waning speed: relative
change. Initial vaccine efficacy: additive change.
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Figure 4.23: Policy Plot – Men, age: 64 – Strong’s Method. Waning speed: relative
change. Initial vaccine efficacy: additive change.
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Figure 4.24: Policy Plot – Men, age: 65 – Strong’s Method. Waning speed: relative
change. Initial vaccine efficacy: additive change.
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Figure 4.25: Policy Plot – Men, age: 66 – Strong’s Method. Waning speed: relative
change. Initial vaccine efficacy: additive change.
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Figure 4.26: Policy Plot – Men, age: 67 – Strong’s Method. Waning speed: relative
change. Initial vaccine efficacy: additive change.
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Figure 4.27: Policy Plot – Men, age: 68 – Strong’s Method. Waning speed: relative
change. Initial vaccine efficacy: additive change.
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Figure 4.28: EVPPI – Women, age: 64 – Strong’s Method – Scenario analysis (truncated
timeline)
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Figure 4.29: EVPPI – Men, age: 64 – Strong’s Method – Scenario analysis (truncated
timeline)
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Figure 4.30: Policy Plot – Women, age: 64 – Strong’s Method – Scenario analysis
(truncated time line). Waning speed: relative change. Initial vaccine efficacy: additive
change.
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Figure 4.31: Policy Plot – Men, age: 64 – Strong’s Method – Scenario analysis (truncated
time line). Waning speed: relative change. Initial vaccine efficacy: additive change.
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Chapter 5
Discussion & Conclusion
The aim of this dissertation was to use techniques in decision science and operations
research to better determine the benefit and policies for administering the HZ vaccine.
Herpes zoster is a disease that most people are at risk for [2]; it can have deleterious
effects on quality of life and a high economic impact. The current vaccine is the best
tool available to combat this disease. However, because the vaccine does not have a
lifetime durability, it is important to make good decisions on when to use the vaccine
so that we can maximize its benefits. The ACIP recommends vaccination for people
ages 60 and older.
Cost-Effectiveness Analysis & Markov Decision Processes
The cost-effectiveness analysis shows the vaccine is more cost-effective for women than
men at every age. The most cost-effective age to vaccinate using this model was 67
for men and women. Likewise, the MDP suggests the vaccine is likely more optimal
for women than men. The MDP optimization model suggests that vaccination for
both men and women should not begin until age 66, assuming only one dose will
be given. The results from these models are very similar. The modeling structures
were slightly different, which could explain the one year difference in the optimal
recommendations. The MDP used a collapsed HZ health state that included the
costs and disutilities associated with HZ and its complications, whereas the CEA
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model used a more complicated structure. The MDP used annual epochs which may
have slightly overestimated the benefit of the vaccine, compared to the CEA which
was run in monthly cycles. While the results of the models are similar, the MDP
does not recommend vaccination earlier than 66 in the base case. Comparatively,
using a WTP of $100,000 in the CEA, ages younger than 67 still had ICERs less
than $100,000. An important distinction between the CEA and the MDP is that
the MDP tries to optimize the time when the person should get the vaccine rather
than evaluate the cost-effectiveness. Therefore, it does assess the benefits of getting
vaccinated at ages earlier than 66, but the model suggests that vaccinating at those
earlier ages is not optimal, even if in an ICER would be less than $100,000.
Comparatively, one benefit of the MDP model is the ability to evaluate many
different options quickly. Theoretically, there 250 different policy options evaluated
by the one dose MDP (50 epochs, 2 action options per epoch) compared to the 50
decisions that were required to be evaluated independently in the CEA model. To
replicate the results of the MDP with a CEA model would have taken much more
computation time. Adding the second dose option further increases the policy options,
making the problem a huge computational burden through if only using standard
STMs. When two doses were available, it would be optimal to vaccinate women with
two doses in the base case, whereas it would never be optimal to vaccinate men with
two doses in the base case. Future studies on disease modeling should consider the
two dose question about when would be the optimal time to receive the new vaccine,
given that a person has received the current vaccine at some time in the past.
Value of Information
Both the CEA and the MDP models showed that the results were sensitive to the
waning speed and the initial efficacy of the vaccine. These two parameters had
the biggest impact on the results of both models. This lead to the decision to
focus on the value of additional research for these parameters. The analysis showed
that the value of information was highest at lower WTPs when the decision under
perfect information would be mostly split between vaccination at some age and no
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vaccination at all. However, under WTPs that are more commonly used in the US
(e.g., ≥ $100,000) [75, 151], the value of information decreased. When converting
the EVPPI to a population level estimate, the population EVPPI was high (e.g. >
$3.5million). However, the cost of the research to gain this information would also
likely cost several million dollars. Therefore, while there is some benefit to being
able to select the optimal age with perfect information, the benefit may be marginal,
especially as there is a new vaccine that will soon be coming to market. Given the
impact these parameters had on my models, these will be important parameters to
focus on for research and models on the new vaccine.
Limitations
This research does have limitations. All work done is specific to the US. The disutilities
used for health states were from direct elicitation time trade off study on herpes
zoster. All costs for the models are from US studies. Therefore, translating the
recommendations to other countries without further research on health utilities or
costs for a specific country should not be done. Modeling studies are only as good
as the data used. All data used in these models was collected using systematic
review procedures to ensure collection of the highest quality data. However, some
assumptions were made – which have been outlined in their respective chapters –
when data was not available. To account for uncertainty in the data many sensitivity
and scenario analyses were performed. While the sensitivity analyses do show
that the models were robust to certain changes, it does highlight the impact that
certain parameters can make. Like all modeling studies, the results of this research
are subject to change, and indeed should be updated as new information becomes
available [48]. It should also be noted that results for these analyses are only applicable
to immunocompetent patients. Immunocompromised patients are known to be at
a higher risk for both HZ and its complications [154]. However, event probabilities
do change between different types of immunocompromised patients, which adds a
further layer of complication to any analysis done for immunocompromised patients.
There is also minimal data on costs and health utilities for immunocompromised
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patients who experience HZ or its complications. If further epidemiology, health
utility, and cost studies were done, the methods used in this dissertation could be
applied to sub-groups of immunocompromised patients to determine how cost-effective
the vaccine may be and when it would be best to administer it.
Future Work
Coming from this work there are several research opportunities moving forward. First,
as there is a new vaccine in development [136], there will be the opportunity to repeat
the cost-effectiveness analysis and the MDP analysis for the new vaccine. There
will also be the opportunity to include the current vaccine in those analysis to do
comparative work. One interesting question which I have already started working
on in this dissertation is the question of multiple doses with both the current and
upcoming vaccine. The two dose scenario analysis in Chapter 3 on the new vaccine
showed that it would be optimal to administer that vaccine at age 69 and older under
several assumed conditions (same cost, same safety profile, same waning, better initial
efficacy). Because of the high efficacy of this vaccine, it appears that it is optimal to
further delay the administration of this vaccine such that it provides the most benefit
to people later in life when they are most at risk. However, it is also possible that the
new vaccine will be priced higher than the current vaccine given that it is likely to be
more efficacious. Therefore, once the new data is available on the new vaccine and it
has been priced, future work examining a two dose question should be examined. In
this work, I hope to investigate the question of it would be optimal to receive two
doses of the new vaccine, or if it would be optimal to receive two doses (one current,
one new) given that the current vaccine is does provide good protection at younger
ages and may be priced cheaper than the new vaccine.
Data Visualization
One part of this dissertation that I would like to continue is my work with data
visualization. In each chapter I have tried to think of unique ways to display data
that I have not seen used in other papers. In the CEA I created the cost-effectiveness
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acceptability contour (a way of displaying several cost-effectiveness acceptability
curves on one plot), and the contour plots for the two-way sensitivity analysis. In the
MDP analysis, I created optimal policy plots and optimal policy heat maps for the
PSA. In the VOI analysis, I made policy plots to help visualize why the EVPPI may
be higher at certain WTPs. These policy plots also showed all available decisions
on one plot. Health economic evaluation models typically produce a large amount
of data, are very complex, and often (in my anecdotal experience) are not easily
understood by a general audience. I think that data visualization is a technique that
helps bridge the gap between us as researchers and people with limited understanding
of what we do. In my future work I plan to continue to think of new ways to display
data to make results clear and easily accessible.
Conclusion
This dissertation has used advance decision modeling techniques to show that the
vaccine is cost-effective for men and women at several ages. However, when accounting
for risk of disease when deferring vaccination, it is likely that a policy to vaccinate
people under 65 years of age is sub-optimal. While there is uncertainty about the
vaccine parameters, in the US our WTP is typically great enough where there would
only be a marginal benefit to gaining the information required to make optimize the
decision beyond the our capabilities with current information. Vaccination is the
best option available to combat this disease. It is my hope that the results of this
dissertation can and will be used to make good decisions about the application of the
HZ vaccine in the attempt to maximize the benefit to society while maximizing our
available resources.
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Appendices
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Appendix A
Model Data for Dissertation
A.1 Epidemiology Data
Incidence of HZ
Data from three papers [101–103] were used to create the age-specifc incidence of
HZ for men and women. These papers were selected as each provided the incidence
rates for men and women separately. First, incidence rates from these selected papers
were checked against other papers and systematic reviews for face validity and were
deemed appropriate. To create an estimate of incidence, midpoints of the age ranges
provided were plotted against reported incidence. This data was then fit using a
logistic function (see Equation A.1) in R.
Incidence =
(
asymp
1 + e(
xmid−age
scale )
)
/1000 (A.1)
The logistic shape was selected a priori; data from a recent systematic review [13]
suggests that incidence follows a logistic growth pattern. To determine the confidence
interval, the asymptote parameter (asymp) of the logistic function was manually
altered to cover the range of data extracted from the literature reviews. Figure A.1
shows the fit and the confidence interval for HZ incidence. Note, data was fit from
ages 18 – 100, but only incidence data beyond age 50 was used.
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Figure A.1: Risk of HZ. Females: Data ∗, Purple fit and 95% CI region. Males: Data •,
Green fit and 95% CI region. Ages under 50 used for fitting. Data left of dashed line not
used in model.
Risk of PHN
To calculate the risk of PHN given HZ, six papers from a recent systematic review [13]
and one additional study from Italy were used [42,79, 104–108]. All papers from the
systematic review [13] were also found during the literature review for model inputs.
Papers were selected as each provided data on at least three age groups and used a
similar diagnosis strategy for PHN (risk at 90 days after infection). When available,
data was preferentially used from the systematic review [13] as age categories had all
been converted to the same range. Similar to HZ incidence methods, midpoints of the
age ranges were plotted against the corresponding risk of PHN; shown in Figure A.2.
Different functions were fit to the data using Microsoft Excel (v.2013). The power
function (see Equation A.2) was selected as it provided the highest R2. Data when
then transferred to R, and parameters from the Excel power function were used as
starting values for non-linear regression. Similar to HZ incidence, data for ages 18 –
100 were used to create the fits, but only data from age 50 and above was used in the
model. There is no distinction made between the risk of PHN for men and women.
178
0.0
0.1
0.2
0.3
20 30 40 50 60 70 80 90 100
Age
R
is
k 
of
 P
HN
Figure A.2: Risk of PHN. Data: ∗. Solid line: Base case fit. Shaded region indicates
regions used for sensitivity analysis. Upper risk limited at 35%. Ages under 50 used for
fitting. Data left of dashed line not used in model.
Once the equation was fit, the b1 parameter was altered to provide a range for the
possible risk. The risk of PHN was limited to 35% at the upper bound. This limit
was used as without it, the risk of PHN risk would have been outside the value of
any of the literature used.
PHN Risk = b1 × ageb2 (A.2)
PHN Time and Severity
One paper provides data for the chance of developing moderate or severe PHN as well
as the duration of specific PHN health states (i.e., mild, moderate, severe) [79]. This
data was used to construct probabilities for transitioning into and between different
PHN health states. Data on PHN severity were extracted from the paper and fit
using a linear model using the midpoints of the age ranges provided. There were no
confidence estimates for these data so a range of ± 10% was used. Data on PHN
time are provided in Table A.1. To use this data, it is assumed that people starting
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PHN Severity Duration Lower CI Upper CI SE
Mild 6.7 6.1 7.4 0.325
Moderate 10 9.4 10.7 0.325
Severe 12.5 11.1 14.1 0.75
Table A.1: Time in PHN data. All durations in months.
in more severe PHN states must transition through all subsequent mild PHN states
before reaching the disease free state. To convert the duration data into probabilities
Equation A.3 was used.
1
DPHNj −DPHNi
(A.3)
j: Worse state of PHN i: Better state of PHN
A.2 Cost Data
Disease Costs
Medical expenditures related to HZ and its complications were calculated using data
from one paper [14]. This paper was selected as it provided two time periods of
information and the most specific data of any of the papers found in the literature.
Costs were converted into 2015 US dollars using the medical care component of the
consumer price index (CPI) [155]. As recommended by Briggs et al (2006) [139]
costs were assumed to fit a gamma distribution. The α and β parameters were
calculated using Equations A.4 – A.7 and data from Table A.2. After fitting the data
to a distribution, each corresponding distribution was used to generate a confidence
interval for one-way sensitivity analysis.
180
Parameter Mean SE CI Distribution
HZ 957 47 (867, 1,051) Γ(414.598, 2.308)
PHN 5,831 990 (4,055, 7,963) Γ(34.691, 168.084)
Ocular Complications 4,163 652 (2,986, 5,543) Γ(40.767, 102.114)
Neurologic Complications 9,872 2,979 (5,520, 15,253)∗ Γ(10.981, 898.950)
Cosmetic Complications 9,873 5,285 (3,036, 19,883)∗ Γ(3.489, 2829.051)
Table A.2: Direct medical expenditures. SE: Standard Error of the mean. CI: 95%
Confidence Intervals ( ∗ 90% Confidence Intervals used due to heavy tails). All costs in
2015 US dollars ($)
E[Costs] = µ¯ = αβ (A.4)
V ar[Costs] = s2 = αβ2 (A.5)
α =
µ¯2
s2
(A.6)
β =
s2
µ¯
(A.7)
Lost Productivity
Productivity losses for the model were calculated using data from three papers
[63, 116, 117] as well as data from the U.S. Bureau of Labor Statistics (BLS) [118].
Table A.3 provides an overview of the data. Mean hours lost were extracted for each
pain condition along with the percentage of the population that takes time away from
work given disease. These numbers were combined to give an estimate of the mean
number of working hours lost due to HZ or PHN. BLS data was used to determine
mean weekly earnings for the US population. Weekly earnings were converted into
hourly earnings assuming an average of 40 hours per week worked. The mean weekly
earnings for the US population in 2015 was $1007.00, which equals a mean hourly
earning rate of $25.20. This earning rate was multiplied by the mean number of
working hours lost given disease to give an estimate of the productivity lost due to
disease.
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Disease Pain State Hours1 Patients(%) Hours2 Cost($) Reference
HZ None 17.4 43 7.4 147.96 [116]
Mild 17.4 43 7.4 147.96
Moderate 41.9 69 28.9 571.72
Severe 51.6 67 34.5 683.66
HZ None – – – – [117]
Mild 3.8 100 3.8 75.10
Moderate 18.4 100 18.4 363.86
Severe 74.2 100 74.2 1467.31
HZ None 48.0 4 2.1 41.57 [63]
Mild 50.6 13 6.3 125.18
Moderate 50.6 39 19.9 394.35
Severe 93.6 78 73.0 1443.73
PHN Mild 49.3 9 4.5 89.51 [63]
Moderate 91.2 33 30.4 601.10
Severe 153.4 53 80.7 1595.42
Table A.3: Productivity lost data. Patients(%): proportion of patients who take time
away from work. Hours1: Hours lost not accounting for proportion of patients who take
time from work. Hours2: Hours lost accounting for proportion of patients who take time
from work. Costs presented in 2014 US Dollars.
Vaccine Costs
Costs for the vaccine were taken from the 2015 CDC adult vaccine price list [109].
Administration costs for the vaccine were taken from three papers [110–112]. These
data sources provided data on labor, supplies, and overhead costs. All data was
converted in to 2015 US dollars and then averaged to provide an estimate of the
administration costs for the vaccine. The main severe adverse event for the vaccine
was an allergic reaction that may or may not have lead to anaphylaxis [115]. In a large
cohort study (n = 193083) there were 71 cases of vaccination that required further
medical care due to an allergic reaction and 9 cases that resulted in anaphylaxis [115].
Costs were sourced from one study that examined the costs associated with allergic
reactions in adults [114]. Costs were converted to 2015 US dollars and then multiplied
by the probability of a general allergic reaction or anaphylaxis and then summed to
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estimate the costs of severe adverse reactions of the vaccine. It was assumed that the
there was no costs for common adverse reactions. The vaccine is not related with
increased risk of any other severe outcome [115].
A.3 QALY Data
Disease Disutilities
Data from Lieu et al (2008) [88] were selected to create the disutilities for the disease
states in the model. This data was selected as it provides the only US estimate of
health state disutilities using a direct elicitation time-trade off (TTO) method and
includes a large sample size including community members, HZ patients, and PHN
patients. Data from the paper was in a similar format to Table A.4 below. Each
condition is defined by a pain score (valued from 0 – 10) and a time duration in
months. The model assumes cut points in the pain scores to be: 1 – 3: Mild Pain; 4 –
6: Moderate Pain; and 7 – 10: Severe pain. Therefore, the condition 3×1 month is
considered 1 month of mild pain. Any condition with 1 month period is assumed to
be an HZ health state; any condition with > 1 month time period is assumed to be a
PHN health state.
Group Cmty HZ PHN
Condition T.Mean L.CI U.CI T.Mean L.CI U.CI T.Mean L.CI U.CI
3 × 1m 15 10 21 6 4 8 18 11 27
8 × 12m 76 58 96 100 81 120 301 181 443
Table A.4: Example TTO table. Cmty: Community Members. HZ: HZ Patients. PHN:
PHN Patients. T.Mean: Trimmed Mean – removal of the highest and lowest 2.5% values of
the mean distribution. L.CI: Lower 95% confidence interval of the trimmed mean. U.CI:
Upper 95% confidence interval of the trimmed mean.
To generate the disutilities the trimmed mean, upper, and lower confidence limits
were divided by the number of days in corresponding condition (1 month = 30
days). If there was more than condition for a health state (e.g., two severe PHN
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states), the utility generated from each was averaged. In the model, I elected to use
the disutilities generated from the corresponding patient group. For example, the
disutilities calculated from the HZ group were used to represent the disutilities for
the HZ health states in the model. All disutility values were limited at a maximum
value of 1.0. Lieu et al [88] also provide an estimate of the health state disutility
of herpes zoster ophthalmicus (HZO); this was used to generate the health state
disutility for ocular complications. For this estimate I used the estimates provided
by the community members. Each of the health state disutilities were entered into
the model as a decrement from a baseline QOL that corresponded with a persons
age. That is, if the disutility of the health state = 0.50, it was assumed that a person
would lose 0.50 utility from whatever his/her baseline health utility was at the time.
The QALY Calculation Examples box provides an example of how the health state
utilities were generated.
• 3 × 1 Month = Mild HZ for 30 days
• Mean Community Member Disutility = 15/30 = 0.50
• 8 × 12 Month = Severe PHN for 365 Days
• Mean PHN Patient Disutility = 301/365 = 0.825
• Upper CI PHN Patient Disutility = 443/365 = 1.21 Rounded to 1.0
QALY Calculation Examples
Vaccine Disutilities
The main severe adverse event for the vaccine was an allergic reaction that may or
may not have lead to anaphylaxis [115]. In a large cohort study (n = 193083) there
were 71 cases of vaccination that required further medical care due to an allergic
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reaction and 9 cases that resulted in anaphylaxis [115]. Disutility values for allergic
reactions were sourced from another cost-effectiveness analysis that examined allergic
reactions as an outcome of treatment [119]. Values from this study were in the form
of quality adjusted life days lost due to a reaction. These values were divided by 30
to estimate quality adjusted life months. The quality adjusted life month disutility
was then multiplied by the probability of event to provide an estimate of the average
disutility associated with receiving the vaccine. Common vaccine reactions occur
approximately 30% of the time with the main symptom being bruising at the injection
site [115]. It was assumed that all common reactions would not require any additional
medical treatment and would resolve within 2 – 5 days.
Background Utility
Data on the background quality of life was sourced from one study [120]. Data was
extracted from this study and fit using a linear regression to determine the background
QOL by age. The mean value using the EQ-5D US scoring algorithm was used as
the outcome variable. The predictors variables were the midpoint of the age ranges
provided and gender.
A.4 Vaccine – HZ Risk Reduction
This section examines the protection benefit against HZ given vaccination. Four
papers, an FDA statistical report, and a conference presentation were used to create
the estimates of protection [15,20–22,51,78]. Protection against HZ is the combination
of two components:
1. Waning Efficacy: The vaccines protection over time against HZ. This is
defined as the period of protection from t = [0, X], where t is measured in
years and X is some number of years in the future when the vaccine reaches
0% efficacy.
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2. Initial Efficacy: The vaccines initial protection against HZ. This is defined as
the as the period of protection from t = [0, 1), where t is measured in years.
For this model, the components (initial efficacy and waning) are combined using
the form of a linear equation (y = mt+ b). That is, the initial efficacy was assumed
to be the intercept (b), the waning efficacy was assumed to be the slope (m), t was
the number of years vaccinated from [0, X], and y was the protection of the vaccine
against HZ. Note, this does not assume that the components (initial efficacy and
waning) are strictly linear; rather these components were estimated separately and
then combined using this form. The minimum value for vaccine efficacy was 0%; that
is, the vaccine can not have a negative effect.
Waning Efficacy
The first step to determining the protection benefit of the vaccine was to determine the
waning efficacy of the vaccine. Data for this step came from four sources [20–22,78].
Data from the clinical trail and its follow-up [20–22] are given in Table A.5. Data
from the large cohort study [78] is given in Table A.6. First, these data were used to
generate synthetic observational data. This data was then combined and fit using
statistical methods. The process of creating each of the syntheitc observational
datasets will be discussed in turn.
Synthetic Data Generation – Zoster Clinical Trials
To generate the synthetic data using the clinical trial data, count data from Table
A.5 were used. First, it was that these data were Poisson distributed (see Equation
A.8). Twenty Poisson distributions (see Equation A.8) were created to reflect all
Trial Group and Years VX combinations from Table A.5. The corresponding λ
for each distribution was assumed to be the number of cases divided by the follow-up
time. To create one set of data points, Y random observations (person-years) were
sampled from each distribution to create 20 datasets, each corresponding to its
distribution. Because of further uncertainty with this data, the number of sampled
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Trial Group Years VX Cases Follow-up Time Reference
Vaccine 0–1 76 19132 [22]
1–2 103 18827 [22]
2–3 98 14505 [22]
3–4 49 6264 [21,22]
4–5 26 3180 [21,22]
5–6 48 4850 [21]
6–7 13 2243 [21]
7–8 50 6564 [20]
8–9 50 6280 [20]
9–10 50 5005 [20]
Placebo 0–1 201 19081 [22]
1–2 194 18679 [22]
2–3 171 14327 [22]
3–4 87 6158 [21,22]
4–5 42 2921 [21,22]
5–6 47 3295 [21]
6–7 11 896 [21]
7–8 66 6564 [20]
8–9 54 6280 [20]
9–10 57 5005 [20]
Table A.5: Data on vaccine efficacy over time – RCTs. Years VX: Years Vaccinated
observations, (person-years, Y ), varied for each distribution. The number of samples
was the average of the follow-up times (Vaccine and Placebo Trial Groups) for
the specific years vaccinated group. After these observations were collected the sum
of each dataset was taken. Equation A.9 was used to create one set of data points for
efficacy over time.
P (X = x) = e−λ
λx
x!
(A.8)
The data set was split into two pieces: years 0 – 6 and years 7 – 10. For years 0
– 6, 2250 data points were generated. Each newly generated data points using the
above procedure were assigned an integer value between [0,6] that corresponded with
its Years VX group. To determine the proportion of the 2250 data points that each
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year would contribute, the total person-years for each year of follow-up was divided
by the total person-years follow-up for years 0 – 6 (131,219) to create the proportion.
Example Box 1 provides an example of this process.
1−
∑
HZ CasesyHZ∑
HZ CasesyPL
(A.9)
y: year
V X: Vaccine group
PL: Placebo group
A similar procedure was followed for years 7 – 10 with two modifications. First,
only 250 data points were generated for years 7 – 10. This was due to uncertainty in
the data presented by Morrison et al [20] due to the study design and lack of control
group. Second, because no control group was present, the number of cases for the
Vaccine and Placebo group had to be estimated by holding the number of vaccine
cases constant and altering the number of placebo cases to correspond with the
vaccine efficacies presented in the paper; shown in Table A.5. Further, as there was
no control group, the number of person-years follow-up for each group was assumed
be the same. This 90:10 (years 0–6: years 7–10) weighting of the synthetic data was
done to weight the statistical fits more toward the first six years of data where more
certainty existed. This weighting decision was based on conversations with zoster
vaccine experts at the CDC.
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Years VX PY ≈ Proportion (%)
0–1 38213 29.12
1–2 37506 28.58
2–3 28832 21.97
3–4 12422 9.46
4–5 6101 4.65
5–6 8145 6.20
6–7 2243 10.40
7–8 6564 30.44
8–9 6280 29.12
9–10 5005 23.21
Repetitions, Years 0–1: 29.12% × 2500 ≈ 655
Repetitions, Years 8–9: 29.12% × 250 ≈ 72
Example 1
Synthetic Data Generation – Kaiser Observational Study
To generate the synthetic data using observational data, efficacy data from Table A.6
were used. The means were reported and the SD were estimated from the figures
provided by Tseng et al [78] (see Figure A.3). It was assumed that these data were
Normally distributed, due to the approximate symmetry of the confidence intervals
(exceptions occur at years 6–7 and 7–8). Eight total distributions were created
to correspond to reflect all Years VX groups from Table A.6. Each distribution
randomly sampled X number of times to create X data points per Years VX group.
In total 2500 data points were generate across all groups. To determine the number
of data points per Years VX group (X), weighting was used. Tseng et al [78]
provided the number of person-years follow-up for each year of data collection. These
person-years were summed for years 0–1 through 7–8. The person-years follow-up
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Figure A.3: Kaiser data
for the year group was divided by this sum to provide the weight (shown in Table
A.6). This weight was multiplied by 2500 to determine X, the number of data points
sampled for each Years VX group.
Years VX Mean SD Weight Follow-up Time Reference
0–1 0.700 0.010 0.240 180620 [78]
1–2 0.498 0.022 0.208 156444 [78]
2–3 0.418 0.027 0.165 124325 [78]
3–4 0.390 0.035 0.123 92789 [78]
4–5 0.347 0.037 0.094 71092 [78]
5–6 0.294 0.050 0.078 59006 [78]
6–7 0.102 0.070 0.058 43618 [78]
7–8 0.243 0.125 0.038 29224 [78]
Table A.6: Data on vaccine efficacy over time – Kaiser. Years VX: Years Vaccinated
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Synthetic Data – Statistical Fitting
Once the synthetic data was generated from both studies, it was treated as observa-
tional and combined. Each data set contained 2500 observations, so the data was
assumed to be equally weighted. The decision to equally weight this data was based
on a discussion with zoster vaccine experts at the CDC.
The combined data was then fit to estimate the efficacy of the vaccine over time
(V Ei, where i is number of years vaccinated (0–1, 1–2, etc.)). Linear, second order
polynomial, third order polynomial and restricted cubic spline (RCS) regression
models were used. Based on AIC score, the RCS and third order polynomial linear
regression models were selected. These models were also preferential due to the
observation that there is a visibly steep decline in efficacy over the first year [20, 78];
this decline is not accounted for when using linear or second order polynomials. The
form of the RCS and third order polynomial are shown by Equations A.10 and A.11,
respectively. Output from the models is shown in Table A.7.
V Ei = β0 + β1i+ β2 max(i, 0)
3
+ β3 max(i− 1, 0)3
+ β4 max(i− 2, 0)3
+ β5 max(i− 7, 0)3
(A.10)
V Ei = β0 + β1i+ β2i
2 + β3i
3 (A.11)
Model β0 β1 β2 β3 β4 β5 AIC adj.R
2
RCS 0.6574 -0.2083 0.0317 -0.0657 0.0344 -0.0004 -9923 0.772
Polynomial 0.6425 -0.1554 0.0273 -0.0019 – – -9576 0.701
Table A.7: V Ei regression output
Initial Efficacy
Data from the literature was used to estimate the initial protection of the vaccine
[15, 22, 51]. Two HZ vaccine clinical trails provided this data. The initial clinical
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Figure A.4: Vaccine efficacy by time since vaccination. Yellow fit – RCS model. Blue fit –
third order polynomial model. Grey data – synthetic RCT data. Green data – synthetic
Kaiser data
trial for the HZ vaccine includes only people over age 60 [15,22]. A subsequent trial
includes people from ages 50 – 59 [51]. Data from these trials were combined to
create the initial efficacy of the vaccine. To combine the data, a synthetic data set
was generated, adjusted, and then fit using statistical models.
Synthetic Data Generation
First, data (shown in Table A.8) was assumed to be Poisson distributed. In total,
16 poisson distributions (see Equation A.8) were created to account for each Trial
Group and Age Group combination from Table A.8. The λ for each distribution
was assumed to be the number of cases divided by follow-up time. To create an
estimate of the initial efficacy, 100,000 random observations (person-years) were
sampled from each distribution and 16 datasets were created using these observations
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Trial Group Age Group Cases Follow-up Time Reference
Vaccine 50 – 59 26 14124 [51]
59 – 64 54 15693 [15,22]
65 – 69 68 15630 [15,22]
70 – 74 89 13830 [15,22]
75 – 79 67 9329 [15,22]
80 – 84 31 3172 [15,22]
85 – 89 5 498 [15,22]
≥ 90 1 51 [15,22]
Placebo 50 – 59 94 14091 [51]
59 – 64 153 15384 [15,22]
65 – 69 181 15569 [15,22]
70 – 74 158 13814 [15,22]
75 – 79 103 9105 [15,22]
80 – 84 39 3189 [15,22]
85 – 89 7 605 [15,22]
≥ 90 1 70 [15,22]
Table A.8: Data on initial vaccine efficacy
(one dataset per distribution). The sum of each dataset was taken and efficacy was
determined by using Equation A.12. This created one estimate of initial vaccine
efficacy for each of the eight Age Groups in Table A.8. Random ages were then
drawn for each age group and assigned to the newly created estimate of initial vaccine
protection. The total number of person years from both trials were used to determine
how many estimates of initial protection should be generated. Across both trials
there were a total of 144,217 person-years follow-up. The sum the person-years for
vaccine and placebo patients for each age group was divided by the number of total
person-years to give a proportion of data points that were generated for each age
group; Example 2 provides an example of this process. In total 2,500 data points
were generated.
1−
∑
HZ CasesaVX∑
HZ CasesaPL
(A.12)
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a: Age group
V X: Vaccine group
PL: Placebo group
Age Group PY ≈ Proportion (%)
50 – 59 28215 19.56
59 – 64 31077 21.54
65 – 59 31262 21.67
70 – 74 27644 19.16
75 – 79 18434 12.78
80 – 84 6361 4.44
85 – 89 1103 0.076
90 – 95 121 0.008
PY: Person-years
Repetitions, Ages 59 – 64: 21.54% × 2500 ≈ 539
Repetitions, Ages 85 – 89: 0.076% × 2500 ≈ 19
Example 2
Synthetic Data – Adjustment
The synthetic data generated for estimating initial efficacy provides the vaccines
efficacy (V Ej) conditional upon being vaccinated at some age j. However, this data
needed to be adjusted to account only for the time period of interest. Data used
for people ages 60 and over was from a trial that reported three years of follow-up.
Data from people ages 50 – 59 was from a trial that reported two years of follow-up.
Therefore, the synthetic estimates were not specific to the time period from t = [0, 1),
the time period of interest. I used published methods [19] to adjust the data before
fitting. This adjustment was used to determine V Eij, where i is the number of years
vaccinated (i.e., 0–1, 1–2, etc.), and j is the age at vaccination.
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In order to make this adjustment, I made the following assumptions. First, the
initial efficacy declines with age. Second, the vaccine does wane at the same rate
for people of all ages. Third, the vaccine can not have less than 0% efficacy. Forth,
the synthetic estimate of vaccine efficacy (V Ej) is the weighted average of waning
vaccine efficacy; weights are determined by the person-years follow-up (from [19]; see
Equation A.13).
V Ej =
py0× V Eij(i = 0) + py1× V Eij(i = 1) + py2× V Eij(i = 2)
py0 + py1 + py2
(A.13)
To determine the age specific initial efficacy, a modification is first made the
waning function (V Ei, where i is the number of years vaccinated). For the remainder
of this section I will show equations assuming the vaccine wanes using the RCS
function, this same procedure was repeated for the third order polynomial function.
The initial waning function is shown in Equation A.14. In Equation A.14, β0 provides
the initial efficacy for the waning function (t = [0, 1)). Changing β0 to β0j, as shown
in Equation A.15, changes V Ei to V Eij as β0j provides the age specific initial efficacy
of the vaccine, where j is the age at vaccination. For simplicity, I will use βREM
(REM : Remainder; shown in Equation A.16) for the remaining the calculations.
V Ei = β0 + β1i+ β2 max(i, 0)
3
+ β3 max(i− 1, 0)3
+ β4 max(i− 2, 0)3
+ β5 max(i− 7, 0)3
(A.14)
V Eij = β0j + β1i+ β2 max(i, 0)
3
+ β3 max(i− 1, 0)3
+ β4 max(i− 2, 0)3
+ β5 max(i− 7, 0)3
(A.15)
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βREM = β1i+ β2 max(i, 0)
3
+ β3 max(i− 1, 0)3
+ β4 max(i− 2, 0)3
+ β5 max(i− 7, 0)3
(A.16)
First, each synthetic data point for initial efficacy is assumed to represent one
estimate of V Ej and must be adjusted to determine β0j before the data can be fit
and combined. Substituting Equation A.15 into Equation A.13 yields Equation A.17,
where β0j is the only unknown. Substituting and solving for β0j adjusts the previous
synthetic data to provide an age-specific estimate of the initial vaccine efficacy. These
new estimates replace the estimates of initial vaccine efficacy V Ej produced by the
synthetic data, to create an adjusted synthetic data set of β0js.
V Ej × (py0 + py1 + py2) = py0× (β0j + βREM(i = 0))
+ py1× (β0j + βREM(i = 1))
+ py2× (β0j + βREM(i = 2))
(A.17)
To solve Equation A.17 person-years were taken from the clinical trial data [22,51].
As noted, the trial for 50 – 59 year olds only included 2 years of follow-up and the trial
for people ≥ 60 included 3 years of follow-up on average. Person-years follow-up data
are presented in Table A.9. For people ≥ 60, pyX was calculated from data in [22]
as the person-years follow-up for specific age groups was not reported. First, total
person years for years 0 - 2 were summed (19132 + 18827 + 14505 = 52464). Next
the person years for each year was made a fraction by dividing the total follow-up for
that year by the grand total (e.g., 19312/52464). Finally, these fractions were applied
to the total person-years follow-up for each age group. Figures A.5 and A.6 show the
synthetic dataset pre- and post-adjustment, respectively.
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Age Group Total py py0 py1 py2 Reference
50 – 59 15040 10956 4084 0 [51]
60 – 64 15384 5610 5521 4253 [22]
65 – 69 15569 5678 5587 4304 [22]
70 – 74 13814 5038 4957 3819 [22]
75 – 79 9105 3320 3267 2517 [22]
80 – 84 3189 1163 1144 882 [22]
≥ 85 605 221 217 167 [22]
Table A.9: Person Year Inputs. pyX: person-years for year x – x+1 of trial
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Figure A.5: Vaccine efficacy by age –
pre-adjustment
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Figure A.6: Vaccine efficacy by age –
post-adjustment
Synthetic Data – Statistical Fitting
Once the synthetic data on initial efficacy was adjusted it was fit using statistical
methods. This fit provided the adjusted age-specific initial efficacy of the vaccine (β0j ,
where j is the age vaccinated). Second order polynomial, and RCS linear regression
models were used based on the shape of the data (see Figure A.6). The initial fits of
the models are shown in Figure A.7. Based on AIC score, the RCS model was selected
over the polynomial model. The form of the RCS and second order polynomial are
shown by Equations A.18 and A.19, respectively. Output from the models is shown
in Table A.10. Both models showed a slight increase (approximately 1 percentage
point) in the age specific initial efficacy (β0j) from ages 50 – 58. This is because of the
adjustment and using two different data sets. This increase was manually changed so
that the vaccine had the same initial efficacy from age 50 – 58.
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Figure A.7: Age-specific initial efficacy fits – piecewise waning. Yellow fit – Piecewise
model. Blue fit – second order polynomial model.
β0j = α0 + α1j + α2 max(j − 54, 0)3
+ α3 max(j − 66, 0)3
+ α4 max(j − 77.4, 0)3
(A.18)
β0j = α0 + α1j + α2j
2 (A.19)
Model α0 α1 α2 α3 α4 AIC adj.R
2
RCS 0.6900 0.0016 -3.63e-05 7.45e-05 -3.823e-05 -8228 0.894
Polynomial -1.351 0.0766 -0.0007 – – -7922 0.880
Table A.10: β0j Regression Output
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Synthetic Data – Combining
Once the age-specific initial efficacy was generated it was combined with the waning
function to create estimates of the age-specific efficacy and waning (shown in Equation
A.15). The final for the combination assuming a RCS waning and polynomial waning
model are shown by Equations A.20 and A.21, respectively. Simulating these equations
for values of age at vaccination, j, between 50 and 100, and different values of years
vaccinated, i, plots of the age-specific waning of the vaccine were created. These are
shown in Figures A.8 – A.13.
V Eij = β0j + β1i
+ β2 max(i, 0)
3
+ β3 max(i− 1, 0)3
+ β4 max(i− 2, 0)3
+ β5 max(i− 7, 0)3
(A.20)
V Eij = β0j + β1i
+ β2i
2
+ β3i
3
(A.21)
A.5 PHN Risk Reduction
This section examines the potential additional benefit of protection against PHN given
HZ vaccination. The FDA statistical report [22] provides the only data available to
examine if the HZ vaccine provides an additional protection benefit against PHN (i.e.,
the incidence of PHN is further reduced beyond the reduction in HZ incidence). The
report provides the number of cases of HZ and PHN as well as the follow-up time for
the both vaccine and placebo groups; data from the statistical report [22] is presented
in Table A.11. Using Equation A.22, data in Table A.11 suggest that approximately
96% of the reduction in PHN cases in the 60 – 69 age group is attributable to the
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Figure A.8: RCS age-specific waning –
side. Top line – Vaccination age 50. Bot-
tom line – Vaccination age 94.
0.00
0.25
0.50
0.75
1.00
0 1 2 3 4 5 6 7 8 9 10 11 12
 Years Vaccinated
Va
cc
in
e 
Ef
fic
ac
y
Figure A.9: Polynomial age-specific
waning – side. Top line – Vaccination
age 50. Bottom line – Vaccination age
94.
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Figure A.10: RCS age-specific waning –
contour.
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Figure A.11: Polynomial age-specific
waning – contour.
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Figure A.12: RCS age-specific waning –
3D.
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reduction in HZ incidence (i.e., a 4% additional protection benefit). Conversely, in
the ≥ 70 group, approximately 51% of the reduction in PHN cases is attributable to
reduction in HZ incidence (i.e., a 49% additional protection benefit). Thus data from
Table A.11 suggests a discontinuity in additional protection benefit of the vaccine.
Trial Group Age Group Disease Category Cases Follow-up Time
Vaccine 60 – 69 HZ 122 31323
PHN 8 31323
≥ 70 HZ 193 26881
PHN 19 26881
Placebo 60 – 69 HZ 334 30953
PHN 23 30953
≥ 70 HZ 308 26783
PHN 57 26783
Table A.11: Data from FDA statistical report
As no additional data exists, simulation methods were used to create a synthetic
data set to examine possible trends. To create the synthetic data, count data in
Table A.11 were assumed to be Poisson distributed. Eight Poisson distributions (see
Equation A.8) were created to reflect all Trial Group, Age Group, and Disease
Category combinations from Table A.11. The corresponding λ for each distribution
was assumed to be the number of cases divided by the follow-up time. To create
one data point, 100,000 random observations (person-years) were sampled from each
distribution to create eight datasets, (one per distribution). After these observations
were collected the sum of each dataset was taken. Equation A.22 was used to create
one estimate of the additional protection benefit.
1−
(∑
PHN CasesaVX/
∑
HZ CasesaVX∑
PHN CasesaPL/
∑
HZ CasesaPL
)
(A.22)
a: Age group
V X: Vaccine group
PL: Placebo group
A newly generated estimate of additional protection was then randomly assigned
an age within its corresponding age group (e.g., 60 – 69, ≥ 70). The FDA statistical
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report [22] provides data on number of patients enrolled by five-year age categories
(e.g., 59 – 64, 65 – 69, ...). This data was used to determine how many people from
each five year age cohort were sampled and randomly assigned to the estimates for
additional protection. In total this process of generating one estimate of additional
protection and assigning an age to that estimate was repeated 2500 times. This
ensured a large enough sample to include people in order age groups (e.g., ≥ 85).
Example 3 demonstrates the process of determining how many of the 2500 repetitions
(estimates) were assigned to each age group. Figure A.14 shows the final set of
synthetic data.
Data in Figure A.14 shows a discontinuity in the additional protection from age
69 – 70. Based on discussions with collaborators at the CDC, this is likely due
to the way in which the data from Table A.11 is categorized, rather than some
biological mechanism. In addition, the Poisson arrival process suggests that the
additional impact could be negative from the ages of 60 – 69. This finding is also not
supported by the understanding of how the vaccine works. Therefore, I made the
following assumptions. First, the vaccine can not have an additional protection benefit
below 0%. At 0% protection benefit, the reduction in PHN cases due to vaccination
would be entirely attributable to the number of HZ cases reduced. Second, there is
some function that represents the additional protection benefit. This assumption
suggests that the discontinuity presented by Table A.11 and Figure A.14 generated
by simulation of that data is an artifact of the way the data was grouped in the FDA
report.
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Figure A.14: Initial additional protection against PHN given vaccination – synthetic data
Age Group n Proportion (%)
59 – 64 5216 50.30
65 – 59 5154 49.70
70 – 74 4545 51.16
75 – 79 3076 34.62
80 – 84 1063 11.97
85 – 89 181 2.04
90 – 95 19 0.21
59 – 69 10370 53.8
≥ 70 8884 46.2
Repetitions, Ages 59 – 64: 53.8% × 50.30% × 2500 ≈ 677
Repetitions, Ages 85 – 89: 46.2% × 2.04% × 2500 ≈ 22
Example 3
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Synthetic Data – Approximation Methods
Because of the discontinuity in the synthetic data shown in Figure A.14, statistical
methods were found to produce models with clinically unlikely anomalies. Therefore,
approximation methods methods were used to estimate linear segments at different
breakpoints. Seven total approximations were generated; these are shown in Figure
A.15. Data on the breakpoints and assumed additional efficacies are given in Table
A.12. This method was selected as there is no further data on this additional
protection. Therefore, these approximation methods provide a best guess of the
additional protection without assuming some prior mathematical relationship. Based
on conversations with zoster vaccine experts at the CDC, model A was chosen as
the base case model to estimate the initial additional protection (β0jPHN ). There
is unfortunately no data on how the additional protection against PHN wanes with
time. Therefore, it was assumed that the additional protection against PHN would
wane at the same rate as the vaccines protection against HZ. This was accomplished
using Equation A.23.
V EijPHN =
β0jPHN ×
V EijHZ
β0jHZ
if β0jHZ > 0
0 if β0jHZ = 0
(A.23)
Model bp1 Efficacy bp1 bp2 Efficacy bp2 Color
A 75.4 0.4653 – – Grey
B 70 0.4653 – – Pink
C 64.2 0.0425 75.4 0.4653 Blue
D 59 0.0425 70 0.4653 Green
E 69 0.0425 81 0.4653 Red
F 64.2 0.0000 75.4 0.0000 Black
G 64.2 0.4653 75.4 0.4653 Orange
Table A.12: Additional PHN protection – approximation fits. bp: breakpoint. Ages 50
and 100, with efficacies 0.04 and Efficacy bp2, respectively, were the initial and final points
for approximations in all models.
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Figure A.15: Additional protection against PHN given vaccination. Model letter corre-
sponds to Table A.12.
A.6 Literature Review
The following section presents the information and on the systematic review to
collect model inputs. Systematic literature reviews were conducted to assess the
published data relating to costs, health utilities, and epidemiology of herpes zoster
and its complications. The search terms for each review are presented in Table A.13.
Search terms were selected based on their use in similar systematic reviews. Searches
were conducted by combining a Main Term along with a Epidemiology, Cost, or
QALY Term using the “AND” search operator.
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Main Term
Epidemiology
Term
Cost Term QALY Term
Herpes Zoster OR
Shingles
Epidemiology Cost QALYs
PHN OR Posther-
petic neuralgia
Incidence Cost of Illness
Quality Adjusted Life
Years
(HZ OR Shingles)
neurological
Incidence of Hos-
pitalization
Economic Quality Adjusted
(HZ OR Shingles)
(eye OR ocular OR
ophthalmic)
Morbidity Economic Burden
Quality Adjusted Cost
Per Life Year
(HZ OR Shingles)
complications
Mortality Economic Impact Cost(-)Effectiveness
(HZ OR Shingles)
secondary
Societal Cost Cost(-)Utility
(HZ OR Shingles)
vaccine
Direct Cost Utility
Indirect Cost
Presenteeism
Absenteeism
Productivity
Productivity Loss
Healthcare Utiliza-
tion
Health Expenditure
Table A.13: Search terms from systematic review
Literature reviews focused on peer-reviewed published literature relating to herpes
zoster in the US. Peer-reviewed articles relating to herpes zoster outside the US
were considered (depending on data quality and transferability). Search results from
the literature reviews were compiled and all duplicate articles were removed. The
remaining unique entries were subjected to a title and abstract review. Results were
excluded using pre-defined criteria. Any paper that was not a full scientific study, such
as letters to the editor, commentaries, or conference abstracts were excluded due to a
potential for selective reporting bias. A running list of all excluded studies was kept
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for reference. The remaining papers were subject to a full review. Exclusion criteria
for this step was also pre-defined. References for full review papers were inspected to
check for any record that may have been missed during the initial searches. Each
additional record was subject to the same title, abstract, and full review criteria.
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Appendix B
Models and Input Data for MDPs
B.1 State Transition Models for MDP
Main STM – One Dose MDP
Data for the one dose MDP was generated from a state-transition model (STM)
built in R. This model was designed to emulate the MDP (also built in R). A model
overview is shown in B.1. This model was used to generate the lifetime costs and
QALYs for people who were either vaccinated, or who developed a case of zoster
without vaccination. Those who were vaccinated started the model in the disease
free health state. After each cycle, the cohort had the chance to develop HZ, die, or
remain disease free. The cycle-time for the model was set to one year with a 3% (0.97)
discount rate for costs and QALYs. At age 100, the probability of death was set to
100%. If HZ occurs, the cohort spends one cycle with disease. Within that cycle,
there is the opportunity to develop further complications (HZ with PHN, or HZ with
ocular complications), however, these complications occur within the cycle only (as
shown by Figure B.2). The costs and QALYs for the intra-HZ states were determined
by sub-models that will be presented in the following sections of this appendix. This
model structure assumption was based on HZ without complications typically lasting
for one month and the majority of complications resolving within one year. At the
end of the HZ cycle, the cohort can transfer to disease free 2 health state, a transient
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Figure B.2: Intra-HZ transition model
state where the cohort remains until death, or to death should death occur. The
lifetime costs and QALYs for HZ without vaccination was determined by using the
same STM but starting the cohort in the HZ state at some age.
The results from this STM, and its sub-models (described further in the following
sections), were used to generate data for the base case analysis, the one-way sensitivity
analysis, and the probabilistic sensitivity analysis. All data for this STM and its
sub-models comes from data used in the Chapter 2 cost-effectiveness models, which
can be found in Tables 2.2 – 2.4 on pages 27 – 28.
HZ Sub-model
To determine the costs and disutility due to a case of HZ a decision tree model
was constructed in TreeAge. The model is shown in Figure B.3. In this model it is
assumed that every person starts with HZ. HZ is first differentiated as producing
pain or not. If the HZ does produce pain, the model then differentiates between mild,
moderate, or severe pain. The terminal nodes for the model (denoted by triangles in
Figure B.3) give both cost and disutility rewards. The result of this model produces
the average costs and disutility due of a case of HZ. The cycle time for this model is
assumed to be 1 month; therefore, the disutility due to HZ is divided by 12 before
being implemented into the main STM.
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Figure B.3: HZ sub-model
PHN Sub-model
To determine the costs and disutility due to a case of PHN a Markov-like model
was constructed in TreeAge, the model is shown in Figure B.4. In this model it is
assumed that the cohort starts with PHN. PHN is initially characterized as mild,
moderate, or severe; the likelihood of starting in any of these three states is age
dependent (as PHN severity increases with age). The data for these states are given
in Table 2.2 on page 27. This model contains the same type of laddering structure as
the cost-effectiveness model from Chapter 2, where a person must move through all
better states of PHN before eventually reaching the disease free state. At each cycle,
a person collects some disutility due to their PHN. There is no background QOL in
this model. Simulating this model produces the average disutility and cost due of
a case of PHN. The cycle time for this model is assumed to be 1 month; therefore,
the disutility due to PHN was divided by 12 before being implemented into the main
STM.
Ocular Complications Sub-model
To determine the disutility lost due to ocular complications given HZ, a Markov-like
model was constructed in TreeAge, shown in Figure B.5. In this models it is assumed
that every person starts with a complication, and has a chance of moving to disease
free after each model cycle. Unlike PHN, there is no stratification for severity. That
is, I assume that one complication is as bad/good as the next. While this is unlikely,
210
Figure B.4: PHN sub-model
Figure B.5: Ocular complications sub-model
there is limited data on the epidemiology, costs, and disutility for differing levels of
severity with ocular complications. At each cycle, the cohort collects some disutility
due to their complication. There is no background QOL in this model. Simulating
this model produces the average costs and disutility due an ocular complication. The
cycle time for this model is assumed to be 1 month; therefore, the disutility lost due
to a complication are divided by 12 before being implemented into the main STM.
211
Main STM Model – Two Dose MDP
Data for the two dose MDP was generated by creating a one additional STM in R.
The model follows the same structure as the HZ model presented in Figure B.1. This
model was used to generate the lifetime costs and QALYs for people who received
a vaccine at some age j and developed HZ at some age Y . Determining when HZ
occurs given the age of vaccination is important as the probability of developing PHN
increases with age as does the probability of more severe PHN. The probability of
developing PHN given HZ (as occurs in the intra-HZ model, see Figure B.2), was
adjusted by the age when the vaccine was originally received j and the number of
years the person had been vaccinated i. HZ was still a transient state so the initial
transition occurred within the cycle. At the end of the cycle, the cohort can transfer
to disease free 2, a transient state where the cohort remains until death, or to death
should death occur.
B.2 Sensitivity Analysis
One-way Sensitivity Analysis
To perform the one-way sensitivity analysis, first all sub-model inputs were converted
to distributions. The distributions used for each sub-model were the same distributions
for the cost-effectiveness analysis (available in Table 2.5). Once all sub-model inputs
had been replaced with distributions, PSAs were run on each sub-model. For PHN, a
PSA was run for every age between 50 – 100. The data from the PSAs was exported
from TreeAge and imported into R. The raw data was used to determine the mean
and confidence intervals for each of the sub-models. These means and confidence
intervals were used as the data for the intra-HZ states as part of the MDP analysis.
Data for PHN is presented in Table B.1, and data for HZ and ocular complications is
given in Table 3.2 in Chapter 3.
PHN Data
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Age Q – M Q – L Q – U $ – M $ – L $ – U
50 0.284 0.209 0.355 6, 235 4, 504 8, 236
51 0.285 0.209 0.356 6, 240 4, 510 8, 241
52 0.286 0.211 0.358 6, 245 4, 515 8, 245
53 0.287 0.211 0.359 6, 250 4, 520 8, 250
54 0.288 0.212 0.360 6, 255 4, 524 8, 255
55 0.289 0.213 0.361 6, 260 4, 529 8, 260
56 0.291 0.214 0.363 6, 264 4, 534 8, 265
57 0.292 0.215 0.363 6, 269 4, 538 8, 270
58 0.293 0.216 0.365 6, 274 4, 543 8, 275
59 0.294 0.217 0.366 6, 279 4, 548 8, 280
60 0.295 0.218 0.367 6, 284 4, 552 8, 285
61 0.296 0.218 0.368 6, 289 4, 557 8, 290
62 0.297 0.219 0.370 6, 294 4, 562 8, 295
63 0.298 0.220 0.371 6, 298 4, 566 8, 299
64 0.299 0.221 0.372 6, 303 4, 571 8, 304
65 0.301 0.222 0.374 6, 308 4, 575 8, 309
66 0.302 0.223 0.375 6, 313 4, 580 8, 314
67 0.303 0.224 0.376 6, 318 4, 585 8, 319
68 0.304 0.225 0.377 6, 323 4, 589 8, 324
69 0.305 0.225 0.378 6, 327 4, 594 8, 329
70 0.306 0.226 0.379 6, 332 4, 599 8, 334
71 0.307 0.227 0.380 6, 337 4, 603 8, 339
72 0.308 0.228 0.381 6, 342 4, 608 8, 344
73 0.309 0.229 0.383 6, 347 4, 613 8, 349
74 0.311 0.230 0.384 6, 352 4, 617 8, 354
75 0.312 0.231 0.385 6, 356 4, 622 8, 358
76 0.313 0.232 0.386 6, 361 4, 627 8, 363
77 0.314 0.232 0.388 6, 366 4, 631 8, 368
78 0.315 0.233 0.389 6, 371 4, 636 8, 373
79 0.316 0.234 0.390 6, 376 4, 641 8, 378
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Age Q – M Q – L Q – U $ – M $ – L $ – U
80 0.317 0.235 0.391 6, 381 4, 645 8, 383
81 0.318 0.236 0.393 6, 386 4, 650 8, 388
82 0.319 0.236 0.394 6, 390 4, 655 8, 393
83 0.321 0.237 0.395 6, 395 4, 659 8, 398
84 0.322 0.238 0.396 6, 400 4, 664 8, 403
85 0.323 0.239 0.398 6, 405 4, 668 8, 408
86 0.324 0.240 0.399 6, 410 4, 673 8, 413
87 0.325 0.241 0.400 6, 415 4, 678 8, 418
88 0.326 0.241 0.402 6, 419 4, 682 8, 423
89 0.327 0.242 0.403 6, 424 4, 687 8, 428
90 0.328 0.243 0.404 6, 429 4, 692 8, 433
91 0.329 0.244 0.405 6, 434 4, 696 8, 438
92 0.331 0.245 0.407 6, 439 4, 701 8, 443
93 0.332 0.246 0.408 6, 444 4, 705 8, 448
94 0.333 0.247 0.409 6, 448 4, 710 8, 453
95 0.334 0.248 0.410 6, 453 4, 714 8, 458
96 0.335 0.249 0.411 6, 458 4, 719 8, 462
97 0.336 0.249 0.412 6, 463 4, 724 8, 467
98 0.337 0.250 0.413 6, 468 4, 728 8, 472
99 0.338 0.251 0.415 6, 473 4, 733 8, 477
100 0.339 0.252 0.416 6, 477 4, 738 8, 482
Table B.1: MDP sensitivity analysis parameters – PHN. Q: QALYs. $: Costs. M: Mean.
L: Lower limit of 95% confidence interval. U: Upper limit of 95% confidence interval.
Probabilistic Sensitivity Analysis
A probabilistic sensitivity analysis was conducted for the one and two dose MDP
models. To conduct this analysis, the distributions created for the one-way sensitivity
analysis sub-models were used. Using R, the STM sub-model PSA output data was
analyzed to define distributions for the costs and QALY inputs for the STM. Following
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recommendations [139], gamma distributions ∼ Γ(α, β) were fit for cost data, and
beta distributions ∼ β(α, β) were fit for QALY data. Once all parameters had been
converted to distributions a first order Monte Carlo PSA was run for each STM (1000
iterations). To ensure continuity between the STMs, a priori seeded distributions
were used. To do this, distributions for the PSA analysis were created in a separate
R file; the distributions were drawn, saved, and loaded into each of the R files for the
STMs. Each saved distribution contained 1000 values. I coded the PSA STMs to
load variables into the model by position. Therefore, PSA STM 1 would load one
set of parameter values from position 1 of the distributions loaded into the file. This
allowed all STMs use one set of distributions across all models; this also guaranteed
that values that needed to be consistent across all models would be.
For the one dose model PSA was conducted for each age between 50 and 100
independently. Variables in the analysis were saved to check the continuity between
the models. Each age between 50 and 100 had 1000 data points, therefore there was an
opportunity to run 1000 different one dose MDP iterations, each with a complete set
of input data. Data was structured so that each MDP iteration sampled the complete
set of outcome data for ages 50 – 100, from each PSA sample (e.g., MDP iteration 1
used data from PSA iteration 1 for ages 50 – 100). A visualization of the methods is
shown by Figure B.6. Each of the 1000 MDP iterations produced a optimal policy
over the time horizon. Each policy was converted into a binary formatted vector (1
= vaccinate, 0 = wait), where each place in the vector corresponded to an age (e.g.,
vector place 1 = age 100). The sum of across each vector location age was taken and
divided by the total number of iterations to produce the probability that a particular
age would be part of the optimal policy given a certain WTP. The two dose PSA
followed the exact same procedure, I just also included the use of the two dose STM
that predicted the lifetime costs and QALYs for an individual who was vaccinated at
age j and developed HZ at some age Y . Age-dependent PHN distribution data is
given in Table B.2, and the remaining distributions used for the PSA analysis are
given in Chapter 3 in Table 3.3.
215
Figure B.6: MDP PSA methods diagram
PHN Data
Age β – α Term β – β Term Γ – α Term Γ – β Term
50 39.600 102.180 42.773 145.800
51 39.800 102.210 42.835 145.705
52 39.970 102.080 42.896 145.609
53 40.030 101.690 42.957 145.514
54 40.070 101.240 43.019 145.419
55 40.280 101.290 43.080 145.324
56 40.060 100.180 43.141 145.230
57 40.400 100.550 43.202 145.136
58 40.330 99.840 43.264 145.043
59 40.270 99.170 43.325 144.949
60 40.420 99.000 43.386 144.856
61 40.500 98.730 43.447 144.764
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Age β – α Term β – β Term Γ – α Term Γ – β Term
62 40.480 98.160 43.509 144.671
63 40.410 97.460 43.570 144.579
64 40.460 97.120 43.631 144.487
65 40.410 96.490 43.692 144.396
66 40.460 96.100 43.753 144.305
67 40.650 96.110 43.814 144.214
68 40.760 95.910 43.876 144.123
69 40.930 95.870 43.937 144.033
70 41.170 95.990 43.998 143.943
71 41.370 95.950 44.059 143.853
72 41.380 95.480 44.120 143.764
73 41.170 94.490 44.181 143.675
74 41.320 94.410 44.242 143.586
75 41.290 93.910 44.303 143.497
76 41.260 93.350 44.364 143.409
77 41.210 92.760 44.425 143.321
78 41.290 92.560 44.486 143.233
79 41.360 92.240 44.547 143.146
80 41.260 91.490 44.608 143.059
81 41.190 90.920 44.669 142.972
82 41.000 90.040 44.730 142.886
83 41.090 89.850 44.791 142.800
84 41.120 89.490 44.851 142.714
85 41.220 89.270 44.912 142.628
86 41.110 88.630 44.973 142.543
87 41.060 88.070 45.034 142.458
88 40.990 87.480 45.095 142.373
89 41.050 87.150 45.155 142.289
90 41.010 86.690 45.216 142.205
91 41.010 86.250 45.277 142.121
217
Age β – α Term β – β Term Γ – α Term Γ – β Term
92 41.050 85.890 45.338 142.037
93 41.230 85.880 45.398 141.954
94 41.320 85.700 45.459 141.871
95 41.380 85.440 45.520 141.788
96 41.550 85.370 45.580 141.706
97 41.490 84.870 45.641 141.624
98 41.460 84.370 45.702 141.542
99 41.470 84.030 45.762 141.460
100 41.520 83.700 45.823 141.379
Table B.2: MDP probabilistic sensitivity analysis parameters – PHN. β distribution for
QALYs. Γ distribution used for costs.
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